

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**





848

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :		(11) International Publication Number:	WO 94/04492
C07C 311/29, C07D 213/30, C07K 5/06 C07C 317/44, 311/05, 311/18, C07D 213/89 C07D 215/48, C07C 317/14, C07D 239/26 C07D 213/81, 213/82, C07C 323/67, 311/41 C07D 209/08, A61K 31/18, 37/02, 31/44 A61K 31/27		A1	
		(43) International Publication Date:	3 March 1994 (03.03.94)
(21) International Application Number: PCT/US93/07814 (22) International Filing Date: 24 August 1993 (24.08.93) (30) Priority data: 07/934,984 25 August 1992 (25.08.92) US (60) Parent Application or Grant (63) Related by Continuation US 07/934,984 (CIP) Filed on 25 August 1992 (25.08.92) (71) Applicants (for all designated States except US): G. D. SEARLE & CO. [US/US]; Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US). THE MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63166 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): VAZQUEZ, Michael, L. [US/US]; 233 Saratoga Court, Gurnee, IL 60031 (US). MUELLER, Richard, A. [US/US]; 562 Stonegate Terrace, Glencoe, IL 60022 (US). TALLEY, John, J. [US/US]; 1510 Amisk Court, Chesterfield, MO 63017		(US). GETMAN, Daniel [US/US]; 66 Sunnyhill Court, Chesterfield, MO 63017 (US). DECRESCENZO, Gary, A. [US/US]; 536 Schrader Farm Drive, St. Peters, MO 63376 (US). FRESKOS, John, N. [US/US]; 7572 York, Clayton, MO 63105 (US). (74) Agents: UNGEMACH, Frank, S. et al.; G.D. Searle & Co., Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS



(57) Abstract

Hydroxyethylamino sulfonamide compounds of formulae (I, II) wherein R, R', R¹, R^{1'}, R^{1''}, R², R³, R⁴, R⁶, x, t, Y, P¹ and P² are as defined in Claims 1 and 171, are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

HYDROXYETHYLAMINO SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS

RELATED APPLICATION

5 This application is a continuation in part in U.S.
Application Serial No. 076/934,984 filed August 25, 1992.

BACKGROUND OF THE INVENTION10 1. Field of the Invention

The present invention relates to retroviral protease inhibitors and, more particularly, relates to novel compounds and a composition and method for inhibiting retroviral proteases. This invention, in
15 particular, relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, a composition and method for inhibiting retroviral proteases such as human immunodeficiency virus (HIV) protease and for treating a retroviral infection, e.g.,
20 an HIV infection. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

2. Related Art

25 During the replication cycle of retroviruses, gag and gag-pol gene products are translated as proteins. These proteins are subsequently processed by a virally encoded protease (or proteinase) to yield viral enzymes and structural proteins of the virus core. Most
30 commonly, the gag precursor proteins are processed into the core proteins and the pol precursor proteins are processed into the viral enzymes, e.g., reverse transcriptase and retroviral protease. It has been shown that correct processing of the precursor proteins by the
35 retroviral protease is necessary for assembly of infectious virions. For example, it has been shown that frameshift mutations in the protease region of the pol

gene of HIV prevents processing of the gag precursor protein. It has also been shown through site-directed mutagenesis of an aspartic acid residue in the HIV protease that processing of the gag precursor protein is prevented. Thus, attempts have been made to inhibit viral replication by inhibiting the action of retroviral proteases.

Retroviral protease inhibition may involve a transition-state mimetic whereby the retroviral protease is exposed to a mimetic compound which binds to the enzyme in competition with the gag and gag-pol proteins to thereby inhibit replication of structural proteins and, more importantly, the retroviral protease itself. In this manner, retroviral replication proteases can be effectively inhibited.

Several classes of compounds have been proposed, particularly for inhibition of proteases, such as for inhibition of HIV protease. Such compounds include hydroxyethylamine isosteres and reduced amide isosteres. See, for example, EP O 346 847; EP O 342,541; Roberts et al, "Rational Design of Peptide-Based Proteinase Inhibitors, "Science, 248, 358 (1990); and Erickson et al, "Design Activity, and 2.8Å Crystal Structure of a C₂ Symmetric Inhibitor Complexed to HIV-1 Protease," Science, 249, 527 (1990).

Several classes of compounds are known to be useful as inhibitors of the proteolytic enzyme renin. See, for example, U.S. No. 4,599,198; U.K. 2,184,730; G.B. 2,209,752; EP O 264 795; G.B. 2,200,115 and U.S. SIR H725. Of these, G.B. 2,200,115, GB 2,209,752, EP O 264,795, U.S. SIR H725 and U.S. 4,599,198 disclose urea-containing hydroxyethylamine renin inhibitors. G.B. 2,200,115 also discloses sulfamoyl-containing hydroxyethylamine renin inhibitors, and EP 0264 795 discloses certain sulfonamide-containing


hydroxyethylamine renin inhibitors. However, it is known that, although renin and HIV proteases are both classified as aspartyl proteases, compounds which are effective renin inhibitors generally cannot be predicted to be effective HIV protease inhibitors.

BRIEF DESCRIPTION OF THE INVENTION

The present invention is directed to virus inhibiting compounds and compositions. More particularly, the present invention is directed to retroviral protease inhibiting compounds and compositions, to a method of inhibiting retroviral proteases, to processes for preparing the compounds and to intermediates useful in such processes. The subject compounds are characterized as sulfonamide-containing hydroxyethylamine inhibitor compounds.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there is provided a retroviral protease inhibiting compound of the formula:



or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl,

aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl,
 aryloxyalkanoyl, heterocyclylcarbonyl,
 heterocyclyloxycarbonyl, heterocyclylalkanoyl,
 heterocyclylalkoxycarbonyl, heteroaralkanoyl,
 5 heteroaralkoxycarbonyl, heteroaryloxycarbonyl,
 heteroaroyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl,
 aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
 aminocarbonyl and mono- and disubstituted aminoalkanoyl
 10 radicals wherein the substituents are selected from
 alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
 heteroaryl, heteroaralkyl, heterocycloalkyl,
 heterocycloalkylalkyl radicals, or where said
 aminocarbonyl and aminoalkanoyl radicals are
 15 disubstituted, said substituents along with the nitrogen
 atom to which they are attached form a heterocycloalkyl
 or heteroaryl radical;

R' represents hydrogen, radicals as defined for R³ or
 20 R"SO₂- wherein R" represents radicals as defined for R³;
 or R and R' together with the nitrogen to which they are
 attached represent heterocycloalkyl and heteroaryl
 radicals;

25 R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃,
 -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),
 -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl,
 alkenyl, alkynyl and cycloalkyl radicals, and amino acid
 side chains selected from asparagine, S-methyl cysteine
 30 and the sulfoxide (SO) and sulfone (SO₂) derivatives
 thereof, isoleucine, allo-isoleucine, alanine, leucine,
 tert-leucine, phenylalanine, ornithine, histidine,
 norleucine, glutamine, threonine, glycine, allo-
 threonine, serine, O-alkyl serine, aspartic acid, beta-
 35 cyano alanine and valine side chains;

R¹' and R¹" independently represent hydrogen and radicals
 as defined for R¹, or one of R¹' and R¹", together with

R¹ and the carbon atoms to which R¹, R^{1'} and R^{1''} are attached, represent a cycloalkyl radical;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -CN, -CF₃, -OR⁹ and -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals, and halogen radicals;

10

R³ represents hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical;

R⁴ represents radicals as defined by R³ except for hydrogen;

25

R⁶ represents hydrogen and alkyl radicals;

x represents 0, 1 or 2;

30


t represents either 0 or 1; and

Y represents O, S and NR¹⁵ wherein R¹⁵ represents hydrogen and radicals as defined for R³.

35

A family of compounds of particular interest within Formula I are compounds embraced by Formula II:

6



wherein:

- 5 R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbonyl, aryloxy carbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,
- 10 heterocyclyloxy carbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl,
- 15 aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,
- 20 heterocycloalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
- 25 R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;
- 30 R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine

and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-
5 threonine, serine, O-methyl serine, aspartic acid, beta-cyano alanine and valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally
10 substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl,
15 hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl,
20 cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl
25 radical; and

R⁴ represents radicals as defined by R³.

A more preferred family of compounds within
30 Formula II consists of compounds wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl,
35 aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl,

- heterocyclalalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl,
heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl,
aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl,
5 aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
aminocarbonyl and mono- and disubstituted aminoalkanoyl
radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl,
10 heterocycloalkylalkyl radicals, or where said
aminoalkanoyl radical is disubstituted, said substituents
along with the nitrogen atom to which they are attached
form a heterocycloalkyl or heteroaryl radical;
- 15 R' represents hydrogen and radicals as defined for R³ or
R and R' together with the nitrogen to which they are
attached represent heterocycloalkyl and heteroaryl
radical;
- 20 R¹ represents CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃),
C(CH₃)₂(S[O]CH₃), C(CH₃)₂(S[O]₂CH₃), alkyl, alkenyl and
alkynyl radicals, and amino acid side chains selected
from the group consisting of asparagine, valine,
threonine, allo-threonine, isoleucine, tert-leucine,
25 S-methyl cysteine and the sulfone and sulfoxide
derivatives thereof, alanine, and allo-isoleucine;
- R² represents alkyl, cycloalkylalkyl and aralkyl
radicals, which radicals are optionally substituted with
30 halogen radicals and radicals represented by the formula
-OR⁹ and -SR⁹ wherein R⁹ represents alkyl radicals; and
- R³ and R⁴ independently represent alkyl, alkenyl,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
35 heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl
and heteroaralkyl radicals.

Of highest interest are compounds within
Formula II wherein

R represents alkoxycarbonyl, aralkoxycarbonyl,
5 alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl,
aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl,
aryloxyalkanoyl, heterocyclylcarbonyl,
heterocyclylloxycarbonyl, heterocyclylalkanoyl,
10 heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl,
heteroaroyl, aminocarbonyl, aminoalkanoyl, and mono- and
disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are
15 selected from alkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroaralkyl,
heterocycloalkyl, heterocycloalkyl radicals, or where
said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they
20 are attached form a heterocycloalkyl or heteroaryl
radical;

R' represents hydrogen and radicals as defined for R³ or
R and R' together with the nitrogen to which they are
25 attached represent heterocycloalkyl and heteroaryl
radical;


R¹ represents CH₂C(O)NHCH₃, C(CH₃)₂(SCH₃),
C(CH₃)₂(S[O]CH₃), C(CH₃)₂(S[O]₂CH₃), methyl, propargyl,
30 t-butyl, isopropyl and sec-butyl radicals, and amino acid
side chains selected from the group consisting of
asparagine, valine, S-methyl cysteine, allo-iso-leucine,
iso-leucine, and beta-cyano alanine side chains;

35 R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl,
4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl
radicals;

R³ represents isoamyl, n-butyl, isobutyl and cyclohexyl radicals; and

R⁴ represents phenyl, substituted phenyl and methyl radicals.

Another family of compounds of particular interest within Formula I are compounds embraced by Formula III:



wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbonyl, aryloxy carbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxy carbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;

R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are

attached represent heterocycloalkyl and heteroaryl radical;

5 R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃,
-CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),
-C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl,
alkenyl, alkynyl and cycloalkyl radicals, and amino acid
side chains selected from asparagine, S-methyl cysteine
and the sulfoxide (SO) and sulfone (SO₂) derivatives
10 thereof, isoleucine, allo-isoleucine, alanine, leucine,
tert-leucine, phenylalanine, ornithine, histidine,
norleucine, glutamine, threonine, glycine, allo-
threonine, serine, aspartic acid, beta-cyano alanine and
valine side chains;

15

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
and aralkyl radicals, which radicals are optionally
substituted with a group selected from alkyl and halogen
radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹

20 represents hydrogen and alkyl;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl,
hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, heteroaryl, heterocycloalkylalkyl,
25 aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and
disubstituted aminoalkyl radicals, wherein said
substituents are selected from alkyl, aryl, aralkyl,
cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl,
heterocycloalkyl, and heterocycloalkylalkyl radicals, or
30 in the case of a disubstituted aminoalkyl radical, said
substituents along with the nitrogen atom to which they
are attached, form a heterocycloalkyl or a heteroaryl
radical; and

35 R⁴ represents radicals as defined by R³.

A more preferred family of compounds within Formula III consists of compounds wherein

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,
5 alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl,
aralkanoyl, aroyl, aryloxy carbonyl, aryloxy carbonylalkyl,
aryloxyalkanoyl, heterocyclylcarbonyl,
heterocyclyloxy carbonyl, heterocyclylalkanoyl,
10 heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl,
heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl,
aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl,
aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
15 aminocarbonyl and mono- and disubstituted aminoalkanoyl
radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl,
heterocycloalkyl radicals, or where said
20 aminoalkanoyl radical is disubstituted, said substituents
along with the nitrogen atom to which they are attached
form a heterocycloalkyl or heteroaryl radical;

R' represents hydrogen and radicals as defined for R³ or
25 R and R' together with the nitrogen to which they are
attached represent heterocycloalkyl and heteroaryl
radical;

R¹ represents hydrogen, alkyl and alkenyl radicals, and
30 amino acid side chains selected from the group consisting
of asparagine, valine, threonine, allo-threonine,
isoleucine, tert-leucine, S-methyl cysteine and the
sulfone and sulfoxide derivatives thereof, alanine, and
allo-isoleucine;

35 R² represents alkyl, cycloalkylalkyl and aralkyl
radicals, which radicals are optionally substituted with
halogen radicals and radicals represented by the formula

-OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl and halogen radicals; and

R³ and R⁴ independently represent alkyl, alkenyl,
5 alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl,
heteroaryl and heteroaralkyl radicals.

Of highest interest are compounds within
10 Formula III wherein

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,
alkylcarbonyl, cycloalkylcarbonyl,
cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl,
15 aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl,
aryloxyalkanoyl, heterocyclylcarbonyl,
heterocyclyloxycarbonyl, heterocyclylalkanoyl,
heterocyclylalkoxycarbonyl, heteroaralkanoyl,
heteroaralkoxycarbonyl, heteroaryloxy-carbonyl,
20 heteroaroyl, aminocarbonyl, aminoalkanoyl, and mono- and
disubstituted aminocarbonyl and mono- and disubstituted
aminoalkanoyl radicals wherein the substituents are
selected from alkyl, aryl, aralkyl, cycloalkyl,
cycloalkylalkyl, heteroaryl, heteroaralkyl,
25 heterocycloalkyl, heterocycloalkylalkyl radicals, or where
said aminoalkanoyl radical is disubstituted, said
substituents along with the nitrogen atom to which they
are attached form a heterocycloalkyl or heteroaryl
radical;

30 R' represents hydrogen and radicals as defined for R³ or
R and R' together with the nitrogen to which they are
attached represent heterocycloalkyl and heteroaryl
radical;

35 R¹ represents hydrogen, methyl, propargyl, t-butyl,
isopropyl and sec-butyl radicals, and amino acid side
chains selected from the group consisting of asparagine,

valine, S-methyl cysteine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine, and allo-threonine side chains;


5 R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals; and

10 R³ represents alkyl, cyclohexyl, isobutyl, isoamyl, and n-butyl radicals; and

R⁴ represents methyl, phenyl and substituted phenyl radicals wherein the substituents are selected from halo, alkoxy, hydroxy, nitro and amino substituents.

15

Another family of compounds of particular interest within Formula I are compounds embraced by Formula IV:



20

wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclylalkoxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from

25

30

35

alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl,
heterocycloalkyl radicals, or where said
aminoalkanoyl radical is disubstituted, said substituents
5 along with the nitrogen atom to which they are attached
form a heterocycloalkyl or heteroaryl radical;

R' represents hydrogen and radicals as defined for R³ or
R and R' together with the nitrogen to which they are
10 attached represent heterocycloalkyl and heteroaryl
radical;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃,
-CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),
15 -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl,
alkenyl, alkynyl and cycloalkyl radicals, and amino acid
side chains selected from asparagine, S-methyl cysteine
and the sulfoxide (SO) and sulfone (SO₂) derivatives
thereof, isoleucine, allo-isoleucine, alanine, leucine,
20 tert-leucine, phenylalanine, ornithine, histidine,
norleucine, glutamine, threonine, glycine, allo-
threonine, serine, aspartic acid, beta-cyano alanine and
valine side chains;

25 R^{1'} and R^{1''} independently represent hydrogen and radicals
as defined for R¹, or one of R^{1'} and R^{1''}, together with
R¹ and the carbon atoms to which R¹, R^{1'} and R^{1''} are
attached, represent a cycloalkyl radical;

30 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
and aralkyl radicals, which radicals are optionally
substituted with a group selected from alkyl and halogen
radicals, -NO₂, -C≡N, CF₃, -OR⁹ and -SR⁹, wherein R⁹
represents hydrogen and alkyl radicals;

35 R³ represents alkyl, haloalkyl, alkenyl, alkynyl,
hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, heteroaryl, heterocycloalkylalkyl,

aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; and

10

R⁴ represents radicals as defined by R³.

15

A more preferred family of compounds within Formula IV consists of compounds wherein

15

R represents an arylalkanoyl, heteroaroyl, aryloxyalkanoyl, aryloxycarbonyl, alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, or disubstituted aminoalkanoyl, or mono-or dialkylaminocarbonyl radical;

20

R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are attached represent a heterocycloalkyl or heteroaryl radical;

25

R¹, R^{1'} and R^{1''} independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms, alkenyl, alkynyl, aralkyl radicals, and radicals represented by the formula -CH₂C(O)R^{*} or -C(O)R^{*} wherein R^{*} represents R³⁸, -NR³⁸R³⁹ and OR³⁸ wherein R³⁸ and R³⁹ independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms;

30

R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula

35

-OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl radicals; and

5 R³ and R⁴ independently represent alkyl, alkenyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl, heteroaryl and heteroaralkyl radicals.

10 Of highest interest are compounds of Formula IV wherein:

R represents an arylalkanoyl, aryloxycarbonyl, aryloxyalkanoyl, alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, or disubstituted
15 aminoalkanoyl, or mono-or dialkylaminocarbonyl radical;

R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are attached represent a heterocycloalkyl or heteroaryl
20 radical;

R¹, R^{1'} and R^{1''} independently represent hydrogen, methyl, ethyl, benzyl, phenylpropyl and propargyl radicals;

25 R² represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals;

30 R³ represents alkyl, cyclohexyl, isobutyl, isoamyl and n-butyl radicals; and

R⁴ represents methyl, phenyl and substituted phenyl radicals wherein the substituents are selected from halo, alkoxy, amino and nitro substituents.
35

As utilized herein, the term "alkyl", alone or in combination, means a straight-chain or branched-chain alkyl radical containing from 1 to about 10, preferably

from 1 to about 8, carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl and the like. The term "alkenyl",
5 alone or in combination, means a straight-chain or branched-chain hydrocarbon radical having one or more double bonds and containing from 2 to about 18 carbon atoms preferably from 2 to about 8 carbon atoms. Examples of suitable alkenyl radicals include ethenyl,
10 propenyl, alkyl, 1,4-butadienyl and the like. The term "alkynyl", alone or in combination, means a straight-chain hydrocarbon radical having one or more triple bonds and containing from 2 to about 10 carbon atoms. Examples of alkynyl radicals include ethynyl, propynyl,
15 (propargyl), butynyl and the like. The term "alkoxy", alone or in combination, means an alkyl ether radical wherein the term alkyl is as defined above. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy,
20 tert-butoxy and the like. The term "cycloalkyl", alone or in combination, means a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl radical wherein each cyclic moiety contains from about 3 to about 8 carbon atoms and is cyclic. The term "cycloalkylalkyl"
25 means an alkyl radical as defined above which is substituted by a cycloalkyl radical containing from about 3 to about 8, preferably from about 3 to about 6, carbon atoms. Examples of such cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the
30 like. The term "aryl", alone or in combination, means a phenyl or naphthyl radical which optionally carries one or more substituents selected from alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, haloalkyl and the like, such as phenyl, p-tolyl, 4-methoxyphenyl, 4-(tert-
35 butoxy)phenyl, 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 1-naphthyl, 2-naphthyl, and the like. The term "aralkyl", alone or in combination, means an alkyl radical as defined above in which one hydrogen atom

is replaced by an aryl radical as defined above, such as benzyl, 2-phenylethyl and the like. The term "aralkoxy carbonyl", alone or in combination, means a radical of the formula $-C(O)-O-$ aralkyl in which the term "aralkyl" has the significance given above. An example of an aralkoxycarbonyl radical is benzyloxycarbonyl. The term "aryloxy" means a radical of the formula aryl-O- in which the term aryl has the significance given above. The term "alkanoyl", alone or in combination, means an acyl radical derived from an alkanecarboxylic acid, examples of which include acetyl, propionyl, butyryl, valeryl, 4-methylvaleryl, and the like. The term "cycloalkylcarbonyl" means an acyl group derived from a monocyclic or bridged cycloalkanecarboxylic acid such as cyclopropanecarbonyl, cyclohexanecarbonyl, adamantanecarbonyl, and the like, or from a benz-fused monocyclic cycloalkanecarboxylic acid which is optionally substituted by, for example, alkanoylamino, such as 1,2,3,4-tetrahydro-2-naphthoyl, 2-acetamido-1,2,3,4-tetrahydro-2-naphthoyl. The term "aralkanoyl" means an acyl radical derived from an aryl-substituted alkanecarboxylic acid such as phenylacetyl, 3-phenylpropionyl (hydrocinnamoyl), 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, 4-aminohydrocinnamoyl, 4-methoxyhydrocinnamoyl, and the like. The term "aroyl" means an acyl radical derived from an aromatic carboxylic acid. Examples of such radicals include aromatic carboxylic acids, an optionally substituted benzoic or naphthoic acid such as benzoyl, 4-chlorobenzoyl, 4-carboxybenzoyl, 4-(benzyloxycarbonyl)benzoyl, 1-naphthoyl, 2-naphthoyl, 6-carboxy-2 naphthoyl, 6-(benzyloxycarbonyl)-2-naphthoyl, 3-benzyloxy-2-naphthoyl, 3-hydroxy-2-naphthoyl, 3-(benzyloxyformamido)-2-naphthoyl, and the like. The heterocyclyl or heterocycloalkyl portion of a heterocyclylcarbonyl, heterocyclylloxycarbonyl, heterocyclylalkoxycarbonyl, or heterocyclylalkyl group or the like is a saturated or partially unsaturated


monocyclic, bicyclic or tricyclic heterocycle which contains one or more hetero atoms selected from nitrogen, oxygen and sulphur, which is optionally substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo, and the like, and/or on a secondary nitrogen atom (i.e., -NH-) by alkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. = N-) by oxido and which is attached via a carbon atom. The heteroaryl portion of a heteroaroyl, heteroaryloxycarbonyl, or a heteroaralkoxy carbonyl group or the like is an aromatic monocyclic, bicyclic, or tricyclic heterocycle which contains the hetero atoms and is optionally substituted as defined above with respect to the definition of heterocyclyl. Examples of such heterocyclyl and heteroaryl groups are pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiamorpholinyl, pyrrolyl, imidazolyl (e.g., imidazol 4-yl, 1-benzyloxycarbonylimidazol-4-yl, etc.), pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, furyl, thienyl, triazolyl, oxazolyl, thiazolyl, indolyl (e.g., 2-indolyl, etc.), quinolinyl, (e.g., 2-quinolinyl, 3-quinolinyl, 1-oxido-2-quinolinyl, etc.), isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, etc.), tetrahydroquinolinyl (e.g., 1,2,3,4-tetrahydro-2-quinolyl, etc.), 1,2,3,4-tetrahydroisoquinolinyl (e.g., 1,2,3,4-tetrahydro-1-oxo-isoquinolinyl, etc.), quinoxalinyl, β -carbolinyl, 2-benzofurancarbonyl, 1-, 2-, 4- or 5-benzimidazolyl, and the like. The term "cycloalkylalkoxycarbonyl" means an acyl group derived from a cycloalkylalkoxycarboxylic acid of the formula cycloalkylalkyl-O-COOH wherein cycloalkylalkyl has the significance given above. The term "aryloxyalkanoyl" means an acyl radical of the formula aryl-O-alkanoyl wherein aryl and alkanoyl have the significance given above. The term "heterocyclylloxycarbonyl" means an acyl group derived from heterocyclyl-O-COOH wherein heterocyclyl is as defined above. The term "heterocyclylalkanoyl" is an acyl radical derived from a

heterocyclyl-substituted alkane carboxylic acid wherein heterocyclyl has the significance given above. The term "heterocyclylalkoxycarbonyl" means an acyl radical derived from a heterocyclyl-substituted alkane-O-COOH wherein heterocyclyl has the significance given above. The term "heteroaryloxycarbonyl" means an acyl radical derived from a carboxylic acid represented by heteroaryl-O-COOH wherein heteroaryl has the significance given above. The term "aminocarbonyl" alone or in combination, means an amino-substituted carbonyl (carbamoyl) group derived from an amino-substituted carboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term "aminoalkanoyl" means an acyl group derived from an amino-substituted alkanecarboxylic acid wherein the amino group can be a primary, secondary or tertiary amino group containing substituents selected from hydrogen, and alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl radicals and the like. The term "halogen" means fluorine, chlorine, bromine or iodine. The term "haloalkyl" means an alkyl radical having the significance as defined above wherein one or more hydrogens are replaced with a halogen. Examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl and the like. The term "leaving group" generally refers to groups readily displaceable by a nucleophile, such as an amine, a thiol or an alcohol nucleophile. Such leaving groups are well known in the art. Examples of such leaving groups include, but are not limited to, N-hydroxysuccinimide, N-hydroxybenzotriazole, halides, triflates, tosylates and the like. Preferred leaving groups are indicated herein where appropriate.

Procedures for preparing the compounds of Formula I are set forth below. It should be noted that the general procedure is shown as it relates to preparation of compounds having the specified stereochemistry, for example, wherein the absolute stereochemistry about the hydroxyl group is designated as (R). However, such procedures are generally applicable to those compounds of opposite configuration, e.g., where the stereochemistry about the hydroxyl group is (S). In addition, the compounds having the (R) stereochemistry can be utilized to produce those having the (S) stereochemistry. For example, a compound having the (R) stereochemistry can be inverted to the (S) stereochemistry using well-known methods.


Preparation of Compounds of Formula I

The compounds of the present invention represented by Formula I above can be prepared utilizing the following general procedure. This procedure is schematically shown in the following Schemes I and II:

SCHEME I


a) amine b) sulfonyl chloride R^4SO_2Cl (or anhydride) + acid scavenger c) deprotection d) coupling e) coupling.

SCHEME II



a) amine b) sulfonyl chloride R^4SO_2Cl (or anhydride) + acid scavenger c) deprotection d) coupling e) coupling.

An N-protected chloroketone derivative of an amino acid having the formula:




5

wherein P represents an amino protecting group, and R² is as defined above, is reduced to the corresponding alcohol utilizing an appropriate reducing agent. Suitable amino protecting groups are well known in the art and include carbobenzoxy, t-butoxycarbonyl, and the like. A preferred amino protecting group is carbobenzoxy. A preferred N-protected chloroketone is N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone. A preferred reducing agent is sodium borohydride. The reduction reaction is conducted at a temperature of from -10°C to about 25°C, preferably at about 0°C, in a suitable solvent system such as, for example, tetrahydrofuran, and the like. The N-protected chloroketones are commercially available, e.g., such as from Bachem, Inc., Torrance, California. Alternatively, the chloroketones can be prepared by the procedure set forth in S. J. Fittkau, J. Prakt. Chem., 315, 1037 (1973), and subsequently N-protected utilizing procedures which are well known in the art.

25


The halo alcohol can be utilized directly, as described below, or, preferably, is then reacted, preferably at room temperature, with a suitable base in a suitable solvent system to produce an N-protected amino epoxide of the formula:

30



wherein P and R² are as defined above. Suitable solvent systems for preparing the amino epoxide include ethanol, methanol, isopropanol, tetrahydrofuran, dioxane, and the like including mixtures thereof. Suitable bases for producing the epoxide from the reduced chloroketone include potassium hydroxide, sodium hydroxide, potassium t-butoxide, DBU and the like. A preferred base is potassium hydroxide.

Alternatively, a protected amino epoxide can be prepared, such as in co-owned and co-pending PCT Patent Application Serial No. PCT/US93/04804 which is incorporated herein by reference, starting with an L-amino acid which is reacted with a suitable amino-protecting group in a suitable solvent to produce an amino-protected L-amino acid ester of the formula:



wherein P³ represents carboxyl-protecting group, e.g., methyl, ethyl, benzyl, tertiary-butyl and the like; R² is as defined above; and P¹ and P² independently are selected from amine protecting groups, including but not limited to, arylalkyl, substituted arylalkyl, cycloalkenylalkyl and substituted cycloalkenylalkyl, allyl, substituted allyl, acyl, alkoxycarbonyl, aralkoxycarbonyl and silyl. Examples of arylalkyl include, but are not limited to benzyl, ortho-methylbenzyl, trityl and benzhydryl, which can be optionally

substituted with halogen, alkyl of C₁-C₈, alkoxy, hydroxy, nitro, alkylene, amino, alkylamino, acylamino and acyl, or their salts, such as phosphonium and ammonium salts. Examples of aryl groups include phenyl, naphthalenyl, indanyl, anthracenyl, durenyl, 9-(9-phenylfluorenyl) and phenanthrenyl, cycloalkenylalkyl or substituted cycloalkylenylalkyl radicals containing cycloalkyls of C₆-C₁₀. Suitable acyl groups include carbobenzoxy, t-butoxycarbonyl, iso-butoxycarbonyl, benzoyl, substituted benzoyl, butyryl, acetyl, tri-fluoroacetyl, tri-chloroacetyl, phthaloyl and the like.


Additionally, the P¹ and/or P² protecting groups can form a heterocyclic ring with the nitrogen to which they are attached, for example, 1,2-bis(methylene)benzene, phthalimidyl, succinimidyl, maleimidyl and the like and where these heterocyclic groups can further include adjoining aryl and cycloalkyl rings. In addition, the heterocyclic groups can be mono-, di- or tri-substituted, e.g., nitrophthalimidyl. The term silyl refers to a silicon atom optionally substituted by one or more alkyl, aryl and aralkyl groups.

Suitable silyl protecting groups include, but are not limited to, trimethylsilyl, triethylsilyl, tri-isopropylsilyl, tert-butyldimethylsilyl, dimethylphenylsilyl, 1,2-bis(dimethylsilyl)benzene, 1,2-bis(dimethylsilyl)ethane and diphenylmethylsilyl. Silylation of the amine functions to provide mono- or bis-disilylamine can provide derivatives of the aminoalcohol, amino acid, amino acid esters and amino acid amide. In the case of amino acids, amino acid esters and amino acid amides, reduction of the carbonyl function provides the required mono- or bis-silyl aminoalcohol. Silylation of the aminoalcohol can lead to the N,N,O-tri-silyl derivative. Removal of the silyl function from the silyl ether function is readily accomplished by treatment with, for example, a

metal hydroxide or ammonium fluoride reagent, either as a discrete reaction step or in situ during the preparation of the amino aldehyde reagent. Suitable silylating agents are, for example, trimethylsilyl chloride, tert-butyl-
5 dimethylsilyl chloride, phenyldimethylsilyl chloride, diphenylmethylsilyl chloride or their combination products with imidazole or DMF. Methods for silylation of amines and removal of silyl protecting groups are well known to those skilled in the art. Methods of preparation of these amine
10 derivatives from corresponding amino acids, amino acid amides or amino acid esters are also well known to those skilled in the art of organic chemistry including amino acid/amino acid ester or aminoalcohol chemistry.

15 Preferably P^1 and P^2 are independently selected from aralkyl and substituted aralkyl. More preferably, each of P^1 and P^2 is benzyl.

The amino-protected L-amino acid ester is then
20 reduced, to the corresponding alcohol. For example, the amino-protected L-amino acid ester can be reduced with diisobutylaluminum hydride at -78°C in a suitable solvent such as toluene. Preferred reducing agents include lithium aluminium hydride, lithium borohydride,
25 sodium borohydride, borane, lithium tri-tert-butoxyaluminum hydride, borane/THF complex. Most preferably, the reducing agent is diisobutylaluminum hydride (DiBAL-H) in toluene. The resulting alcohol is then converted, for example, by way of a Swern oxidation,
30 to the corresponding aldehyde of the formula:



wherein p1, p2 and R² are as defined above. Thus, a dichloromethane solution of the alcohol is added to a cooled (-75 to -68° C) solution of oxalyl chloride in dichloromethane and DMSO in dichloromethane and stirred
5 for 35 minutes.

Acceptable oxidizing reagents include, for example, sulfur trioxide-pyridine complex and DMSO, oxalyl chloride and DMSO, acetyl chloride or anhydride
10 and DMSO, trifluoroacetyl chloride or anhydride and DMSO, methanesulfonyl chloride and DMSO or tetrahydrothiaphene-S-oxide, toluenesulfonyl bromide and DMSO, trifluoromethanesulfonyl anhydride (triflic anhydride) and DMSO, phosphorus pentachloride and
15 DMSO, dimethylphosphoryl chloride and DMSO and isobutylchloroformate and DMSO. The oxidation conditions reported by Reetz et al [Angew Chem., 99, p. 1186, (1987)], Angew Chem. Int. Ed. Engl., 26, p. 1141, 1987) employed oxalyl chloride and DMSO at
20 -78°C.

The preferred oxidation method described in this invention is sulfur trioxide pyridine complex, triethylamine and DMSO at room temperature. This
25 system provides excellent yields of the desired chiral protected amino aldehyde usable without the need for purification i.e., the need to purify kilograms of intermediates by chromatography is eliminated and large scale operations are made less hazardous.
30 Reaction at room temperature also eliminated the need for the use of low temperature reactor which makes the process more suitable for commercial production.

The reaction may be carried out under and
35 inert atmosphere such as nitrogen or argon, or normal or dry air, under atmospheric pressure or in a sealed reaction vessel under positive pressure. Preferred is

a nitrogen atmosphere. Alternative amine bases include, for example, tri-butyl amine, tri-isopropyl amine, N-methylpiperidine, N-methyl morpholine, azabicyclononane, diisopropylethylamine, 2,2,6,6-
5 tetramethylpiperidine, N,N-dimethylaminopyridine, or mixtures of these bases. Triethylamine is a preferred base. Alternatives to pure DMSO as solvent include mixtures of DMSO with non-protic or halogenated solvents such as tetrahydrofuran, ethyl acetate,
10 toluene, xylene, dichloromethane, ethylene dichloride and the like. Dipolar aprotic co-solvents include acetonitrile, dimethylformamide, dimethylacetamide, acetamide, tetramethyl urea and its cyclic analog, N-methylpyrrolidone, sulfolane and the like. Rather
15 than N,N-dibenzylphenylalaninol as the aldehyde precursor, the phenylalaninol derivatives discussed above can be used to provide the corresponding N-monosubstituted [either P^1 or $P^2 = H$] or N,N-disubstituted aldehyde.

20

In addition, hydride reduction of an amide or ester derivative of the corresponding alkyl, benzyl or cycloalkenyl nitrogen protected phenylalanine, substituted phenylalanine or cycloalkyl analog of
25 phenylalanine derivative can be carried out to provide the aldehydes. Hydride transfer is an additional method of aldehyde synthesis under conditions where aldehyde condensations are avoided, cf, Oppenauer Oxidation.


30

The aldehydes of this process can also be prepared by methods of reducing protected phenylalanine and phenylalanine analogs or their amide or ester derivatives by, e.g., sodium amalgam with HCl in ethanol or lithium or
35 sodium or potassium or calcium in ammonia. The reaction temperature may be from about -20°C to about 45°C , and preferably from about 5°C to about 25°C . Two additional methods of obtaining the nitrogen protected aldehyde include

oxidation of the corresponding alcohol with bleach in the presence of a catalytic amount of 2,2,6,6-tetramethyl-1-pyridyloxy free radical. In a second method, oxidation of the alcohol to the aldehyde is accomplished by a catalytic amount of tetrapropylammonium perruthenate in the presence of N-methylmorpholine-N-oxide.

Alternatively, an acid chloride derivative of a protected phenylalanine or phenylalanine derivative as disclosed above can be reduced with hydrogen and a catalyst such as Pd on barium carbonate or barium sulphate, with or without an additional catalyst moderating agent such as sulfur or a thiol (Rosenmund Reduction).

The aldehyde resulting from the Swern oxidation is then reacted with a halomethyl lithium reagent, which reagent is generated in situ by reacting an alkyl lithium or aryl lithium compound with a dihalomethane represented by the formula $X^1CH_2X^2$ wherein X^1 and X^2 independently represent I, Br or Cl. For example, a solution of the aldehyde and chloriodomethane in THF is cooled to $-78^\circ C$ and a solution of n-butyllithium in hexane is added. The resulting product is a mixture of diastereomers of the corresponding amino-protected epoxides of the formulas:



The diastereomers can be separated e.g., by chromatography, or, alternatively, once reacted in subsequent steps the diastereomeric products can be separated. For compounds having the (S) stereochemistry, a D-amino acid can be utilized in place of the L-amino acid.

The addition of chloromethylithium or bromomethylithium to a chiral amino aldehyde is highly diastereoselective. Preferably, the chloromethylithium or bromomethylithium is generated in-situ from the reaction of the dihalomethane and n-butyllithium. Acceptable methyleneating halomethanes include chloriodomethane, bromochloromethane, dibromomethane, diiodomethane, bromofluoromethane and the like. The sulfonate ester of the addition product of, for example, hydrogen bromide to formaldehyde is also a methyleneating agent. Tetrahydrofuran is the preferred solvent, however alternative solvents such as toluene, dimethoxyethane, ethylene dichloride, methylene chloride can be used as pure solvents or as a mixture. Dipolar aprotic solvents such as acetonitrile, DMF, N-methylpyrrolidone are useful as solvents or as part of a solvent mixture. The reaction can be carried out under an inert atmosphere such as nitrogen or argon. For n-butyl lithium can be substituted other organometallic reagents reagents such as methylithium, tert-butyl lithium, sec-butyl lithium, phenyllithium, phenyl sodium and the like. The reaction can be carried out at temperatures of between about -80°C to 0°C but preferably between about -80°C to -20°C. The most preferred reaction temperatures are between -40°C to -15°C. Reagents can be added singly but multiple additions are preferred in certain conditions. The preferred pressure of the reaction is atmospheric however a positive pressure is valuable under certain conditions such as a high humidity environment.

Alternative methods of conversion to the epoxides of this invention include substitution of other charged methylenation precursor species followed by their treatment with base to form the analogous anion. Examples of these species include trimethylsulfoxonium tosylate or triflate, tetramethylammonium halide, methyldiphenylsulfoxonium halide wherein halide is chloride, bromide or iodide.

The conversion of the aldehydes of this invention into their epoxide derivative can also be carried out in multiple steps. For example, the addition of the anion of thioanisole prepared from, for example, a butyl or aryl lithium reagent, to the protected aminoaldehyde, oxidation of the resulting protected aminosulfide alcohol with well known oxidizing agents such as hydrogen peroxide, tert-butyl hypochlorite, bleach or sodium periodate to give a sulfoxide. Alkylation of the sulfoxide with, for example, methyl iodide or bromide, methyl tosylate, methyl mesylate, methyl triflate, ethyl bromide, isopropyl bromide, benzyl chloride or the like, in the presence of an organic or inorganic base. Alternatively, the protected aminosulfide alcohol can be alkylated with, for example, the alkylating agents above, to provide a sulfonium salts that are subsequently converted into the subject epoxides with tert-amine or mineral bases.


The desired epoxides formed, using most preferred conditions, diastereoselectively in ratio amounts of at least about an 85:15 ratio (S:R). The product can be purified by chromatography to give the diastereomerically and enantiomerically pure product but it is more conveniently used directly without purification to prepare retroviral protease inhibitors. The foregoing process is applicable to mixtures of optical isomers as well as resolved compounds. If a particular optical isomer is desired, it can be selected by the choice of starting material, e.g., L-phenylalanine, D-phenylalanine, L-phenylalaninol, D-phenylalaninol, D-hexahydrophenylalaninol and the like, or resolution can occur at intermediate or final steps. Chiral auxiliaries such as one or two equivalents of camphor sulfonic acid, citric acid, camphoric acid, 2-methoxyphenylacetic acid and the like can be used to form salts, esters or amides of the compounds of this invention. These compounds or derivatives can be crystallized or separated chromatographically using either a

chiral or achiral column as is well known to those skilled in the art.

The amino epoxide is then reacted, in a
 5 suitable solvent system, with an equal amount, or preferably an excess of, a desired amine of the formula:




10 wherein R^3 is hydrogen or is as defined above. The reaction can be conducted over a wide range of temperatures, e.g., from about 10°C to about 100°C, but is preferably, but not necessarily, conducted at a temperature at which the solvent begins to reflux.
 15 Suitable solvent systems include protic, non-protic and dipolar aprotic organic solvents such as, for example, those wherein the solvent is an alcohol, such as methanol, ethanol, isopropanol, and the like, ethers such as tetrahydrofuran, dioxane and the like, and toluene,
 20 N,N-dimethylformamide, dimethyl sulfoxide, and mixtures thereof. A preferred solvent is isopropanol. Exemplary amines corresponding to the formula R^3NH_2 include benzyl amine, isobutylamine, n-butyl amine, isopentyl amine, isoamylamine, cyclohexanemethyl amine, naphthylene methyl
 25 amine and the like. The resulting product is a 3-(N-protected amino)-3-(R^2)-1-(NHR^3)-propan-2-ol derivative (hereinafter referred to as an amino alcohol) can be represented by the formulas:



wherein P, P^1 , P^2 , R^2 and R^3 are as described above. Alternatively, a haloalcohol can be utilized in place of the amino epoxide.


The amino alcohol defined above is then reacted in a suitable solvent with a sulfonyl chloride (R^4SO_2Cl) or sulfonyl anhydride in the presence of an acid scavenger. Suitable solvents in which the reaction can be conducted include methylene chloride, tetrahydrofuran. Suitable acid scavengers include triethylamine, pyridine. Preferred sulfonyl chlorides are methanesulfonyl chloride and benzenesulfonyl chloride. The resulting sulfonamide derivative can be represented, depending on the epoxide utilized by the formulas



wherein P, P¹, P², R², R³ and R⁴ are as defined above. These intermediates are useful for preparing inhibitor compounds of the present invention and are also active inhibitors of retroviral proteases.

The sulfonyl halides of the formula R^4SO_2X can be prepared by the reaction of a suitable Grignard or alkyl lithium reagent with sulfuryl chloride, or sulfur dioxide followed by oxidation with a halogen, preferably chlorine. Also, thiols may be oxidized to sulfonyl chlorides using chlorine in the presence of water under carefully controlled conditions. Additionally, sulfonic acids may be converted to sulfonyl halides using reagents such as PCl_5 , and also to anhydrides using suitable dehydrating reagents. The sulfonic acids may in turn be prepared using procedures well known in the art. Such sulfonic acids are also commercially available. In place of the sulfonyl halides, sulfinyl halides (R^4SOX) or sulfenyl halides (R^4SX) can be utilized to prepare compounds wherein the $-SO_2-$ moiety is replaced by an $-SO-$ or $-S-$ moiety, respectively.

Following preparation of the sulfonamide derivative, the amino protecting group P or P¹ and P² amino protecting groups are removed under conditions which will not affect the remaining portion of the molecule. These methods are well known in the art and include acid hydrolysis, hydrogenolysis and the like. A preferred method involves removal of the protecting group, e.g., removal of a carbobenzoxy group, by hydrogenolysis utilizing palladium on carbon in a suitable solvent system such as an alcohol, acetic acid, and the like or mixtures thereof. Where the protecting group is a t-butoxycarbonyl group, it can be removed utilizing an inorganic or organic acid, e.g., HCl or trifluoroacetic acid, in a suitable solvent system, e.g., dioxane or methylene chloride. The resulting product is the amine salt derivative. Following neutralization of the salt, the amine is then reacted with an amino acid or corresponding derivative thereof represented by the formula (PN[CR^{1'} R^{1''}]_t CH(R¹)COOH) wherein t, R¹, R^{1'} and R^{1''} are as defined above, to produce the antiviral compounds of the present invention having the formula:



wherein t, P, R¹, R^{1'}, R^{1''}, R², R³ and R⁴ are as defined above. Preferred protecting groups in this instance are a benzyloxycarbonyl group or a t-butoxycarbonyl group. Where the amine is reacted with a derivative of an amino acid, e.g., when t=1 and R^{1'} and R^{1''} are both H, so that the amino acid is a β-amino acid, such β-amino acids can be prepared according to the procedure set forth in a copending application, U. S. Serial No. 07/345,808. Where t is 1, one of R^{1'} and R^{1''} is H and R¹ is hydrogen

so that the amino acid is a homo- β -amino acid, such homo- β -amino acids can be prepared by the procedure set forth in a copending application, U.S. Serial No. 07/853,561.

Where t is 0 and R¹ is alkyl, alkenyl, alkynyl,


5 cycloalkyl, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂,
-CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),

-C(CH₃)₂[S(O)CH₃], -C(CH₃)₂[S(O₂)CH₃], or an amino acid side chain, such materials are well known and many are commercially available from Sigma-Aldrich.

10

The N-protecting group can be subsequently removed, if desired, utilizing the procedures described above, and then reacted with a carboxylate represented by the formula:

15




wherein R is as defined above and L is an appropriate leaving group such as a halide. Preferably, where R¹ is a side chain of a naturally occurring α -amino acid, R is a 2-quinoline carbonyl group derived from N-hydroxysuccinimide-2-quinoline carboxylate, i.e., L is hydroxy succinimide. A solution of the free amine (or amine acetate salt) and about 1.0 equivalent of the carboxylate are mixed in an appropriate solvent system and optionally treated with up to five equivalents of a base such as, for example, N-methylmorpholine, at about room temperature. Appropriate solvent systems include tetrahydrofuran, methylene chloride or N,N-dimethylformamide, and the like, including mixtures thereof.

20
25
30

Alternatively, the protected amino alcohol from the epoxide opening can be further protected at the newly introduced amino group with a protecting group P' which is not removed when the first protecting P is removed. One


35

skilled in the art can choose appropriate combinations of P and P'. One suitable choice is when P is Cbz and P' is Boc. The resulting compound represented by the formula:



5

can be carried through the remainder of the synthesis to provide a compound of the formula:



10

and the new protecting group P' is selectively removed, and following deprotection, the resulting amine reacted to form the sulfonamide derivative as described above.

15 This selective deprotection and conversion to the sulfonamide can be accomplished at either the end of the synthesis or at any appropriate intermediate step if desired.

20 In place of the sulfonyl halides, sulfinyl halides (RSOCl) and sulfenyl halides (RSCl) can be utilized to prepare compounds wherein the -SO₂- moiety is replaced by -SO- or -S-, respectively.

25 It is contemplated that for preparing compounds of the Formulas having R⁶, the compounds can be prepared following the procedure set forth above and, prior to coupling the sulfonamide derivative or analog thereof, e.g. coupling to the amino acid PNH(CH₂)_tCH(R¹)COOH,

30 carried through a procedure referred to in the art as reductive amination. Thus, a sodium cyanoborohydride and an appropriate aldehyde or ketone can be reacted with the

sulfonamide derivative compound or appropriate analog at room temperature in order to reductively aminate any of the compounds of Formulas I-IV. It is also contemplated that where R^3 of the amino alcohol intermediate is

5 hydrogen, the inhibitor compounds of the present invention wherein R^3 is alkyl, or other substituents wherein the α -C contains at least one hydrogen, can be prepared through reductive amination of the final product of the reaction between the amino alcohol and the amine

10 or at any other stage of the synthesis for preparing the inhibitor compounds.

Contemplated equivalents of the general formulas set forth above for the antiviral compounds and derivatives as well as the intermediates are compounds

15 otherwise corresponding thereto and having the same general properties, such as tautomers thereof as well as compounds, wherein one or more of the various R groups are simple variations of the substituents as defined therein, e.g., wherein R is a higher alkyl group than

20 that indicated. In addition, where a substituent is designated as, or can be, a hydrogen, the exact chemical nature of a substituent which is other than hydrogen at that position, e.g., a hydrocarbyl radical or a halogen,

25 hydroxy, amino and the like functional group, is not critical so long as it does not adversely affect the overall activity and/or synthesis procedure.

The chemical reactions described above are

30 generally disclosed in terms of their broadest application to the preparation of the compounds of this invention. Occasionally, the reactions may not be applicable as described to each compound included within the disclosed scope. The compounds for which this occurs

35 will be readily recognized by those skilled in the art. In all such cases, either the reactions can be successfully performed by conventional modifications known to those skilled in the art, e.g., by appropriate

protection of interfering groups, by changing to alternative conventional reagents, by routine modification of reaction conditions, and the like, or other reactions disclosed herein or otherwise conventional, will be applicable to the preparation of the corresponding compounds of this invention. In all preparative methods, all starting materials are known or readily preparable from known starting materials.


Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

All reagents were used as received without purification. All proton and carbon NMR spectra were obtained on either a Varian VXR-300 or VXR-400 nuclear magnetic resonance spectrometer.

The following Examples 1 through 9 illustrate preparation of intermediates. These intermediates are useful in preparing the inhibitor compounds of the present invention as illustrated in Examples 10-16. In addition, the intermediates of Examples 2-6 are also retroviral protease inhibitors and inhibit, in particular, HIV protease.

30

41

Example 1APreparation of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl]-N-isoamylaminePart A:


To a solution of 75.0g (0.226 mol) of N-benzyloxycarbonyl-L-phenylalanine chloromethyl ketone in a mixture of 807 mL of methanol and 807 mL of tetrahydrofuran at -2°C, was added 13.17g (0.348 mol, 1.54 equiv.) of solid sodium borohydride over one hundred minutes. The solvents were removed under reduced pressure at 40°C and the residue dissolved in ethyl acetate (approx. 1L). The solution was washed sequentially with 1M potassium hydrogen sulfate, saturated sodium bicarbonate and then saturated sodium chloride solutions. After drying over anhydrous magnesium sulfate and filtering, the solution was removed under reduced pressure. To the resulting oil was added hexane (approx. 1L) and the mixture warmed to 60°C with swirling. After cooling to room temperature, the solids were collected and washed with 2L of hexane. The resulting solid was recrystallized from hot ethyl acetate and hexane to afford 32.3g (43% yield) of N-benzyloxycarbonyl-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol, mp 150-151°C and $M+Li^+ = 340$.

Part B:

To a solution of 6.52g (0.116 mol, 1.2 equiv.) of potassium hydroxide in 968 mL of absolute ethanol at room temperature, was added 32.3g (0.097 mol) of N-CBZ-3(S)-amino-1-chloro-4-phenyl-2(S)-butanol. After stirring for fifteen minutes, the solvent was removed under reduced pressure and the solids dissolved in methylene chloride. After washing with water, drying over magnesium sulfate, filtering and stripping, one obtains 27.9g of a white solid. Recrystallization from hot ethyl acetate and hexane afforded 22.3g (77% yield) of N-benzyloxycarbonyl-3(S)-amino-1,2(S)-epoxy-4-phenylbutane, mp 102-103°C and MH⁺ 298.

Part C:

A solution of N-benzyloxycarbonyl 3(S)-amino-1,2-(S)-epoxy-4-phenylbutane (1.00g, 3.36 mmol) and isoamylamine (4.90g, 67.2 mmol, 20 equiv.) in 10 mL of isopropyl alcohol was heated to reflux for 1.5 hours. The solution was cooled to room temperature, concentrated in vacuo and then poured into 100 mL of stirring hexane whereupon the product crystallized from solution. The product was isolated by filtration and air dried to give 1.18g, 95% of N=[3(S)-phenylmethylcarbamoyl]amino-2(R)-hydroxy-4-phenylbutyl]N-[(3-methylbutyl)]amine mp 108.0-109.5°C, MH⁺ m/z = 371.

Example 1BPreparation of N,N-dibenzyl-3(S)-amino-1,2-(S)-epoxy-4-phenylbutaneStep A:

A solution of L-phenylalanine (50.0 g, 0.302 mol), sodium hydroxide (24.2 g, 0.605 mol) and potassium carbonate (83.6 g, 0.605 mol) in water (500 ml) was heated to 97°C. Benzyl bromide (108.5 ml, 0.912 mol) was then slowly added (addition time ~25 min). The mixture was then stirred at 97°C for 30 minutes. The solution was cooled to room temperature and extracted with toluene (2 x 250 ml). The combined organic layers were then washed with water, brine, dried over magnesium sulfate, filtered and concentrated to give an oil product. The crude product was then used in the next step without purification.

Step B:

The crude benzylated product of the above step was dissolved in toluene (750 ml) and cooled to -55°C. A 1.5 M solution of DIBAL-H in toluene (443.9 ml, 0.666 mol) was then added at a rate to maintain the temperature between -55° to -50°C (addition time - 1 hour). The mixture was stirred for 20 minutes at -55°C. The reaction was quenched at -55°C by the slow addition of

methanol (37 ml). The cold solution was then poured into cold (5°C) 1.5 N HCl solution (1.8 L). The precipitated solid (approx. 138 g) was filtered off and washed with toluene. The solid material was suspended in a mixture of toluene (400 ml) and water (100 ml). The mixture was cooled to 5°C, treated with 2.5 N NaOH (186 ml) and then stirred at room temperature until the solid was dissolved. The toluene layer was separated from the aqueous phase and washed with water and brine, dried over magnesium sulfate, filtered and concentrated to a volume of 75 ml (89 g). Ethyl acetate (25 ml) and hexane (25 ml) were then added to the residue upon which the alcohol product began to crystallize. After 30 min., an additional 50 ml hexane was added to promote further crystallization. The solid was filtered off and washed with 50 ml hexane to give approximately 35 g of material. A second crop of material could be isolated by refiltering the mother liquor. The solids were combined and recrystallized from ethyl acetate (20 ml) and hexane (30 ml) to give, in 2 crops, approximately 40 g (40% from L-phenylalanine) of analytically pure alcohol product. The mother liquors were combined and concentrated (34 g). The residue was treated with ethyl acetate and hexane which provided an additional 7 g (~7% yield) of slightly impure solid product. Further optimization in the recovery from the mother liquor is probable.

Alternatively, the alcohol was prepared from L-phenylalaninol. L-phenylalaninol (176.6 g, 1.168 mol) was added to a stirred solution of potassium carbonate (484.6 g, 3.506 mol) in 710 mL of water. The mixture was heated to 65°C under a nitrogen atmosphere. A solution of benzyl bromide (400 g, 2.339 mol) in 3A ethanol (305 mL) was added at a rate that maintained the temperature between 60-68°C. The biphasic solution was stirred at 65°C for 55 min and then

allowed to cool to 10°C with vigorous stirring. The oily product solidified into small granules. The product was diluted with 2.0 L of tap water and stirred for 5 minutes to dissolve the inorganic by products. The product was isolated by filtration under reduced pressure and washed with water until the pH is 7. The crude product obtained was air dried overnight to give a semi-dry solid (407 g) which was recrystallized from 1.1 L of ethyl acetate/heptane (1:10 by volume). The product was isolated by filtration (at -8°C), washed with 1.6 L of cold (-10°C) ethyl acetate/heptane (1:10 by volume) and air-dried to give 339 g (88% yield) of BS-2-[Bis(phenylmethyl)amino]benzene-propanol, mp 71.5-73.0°C. More product can be obtained from the mother liquor if necessary. The other analytical characterization was identical to compound prepared as described above.

Step C:

A solution of oxalyl chloride (8.4 ml, 0.096 mol) in dichloromethane (240 ml) was cooled to -74°C. A solution of DMSO (12.0 ml, 0.155 mol) in dichloromethane (50 ml) was then slowly added at a rate to maintain the temperature at -74°C (addition time -1.25 hr). The mixture was stirred for 5 min. followed by addition of a solution of the alcohol (0.074 mol) in 100 ml of dichloromethane (addition time -20 min., temp. -75°C to -68°C). The solution was stirred at -78°C for 35 minutes. Triethylamine (41.2 ml, 0.295 mol) was then added over 10 min. (temp. -78° to -68°C) upon which the ammonium salt precipitated. The cold mixture was stirred for 30 min. and then water (225 ml) was added. The dichloromethane layer was separated from the aqueous phase and washed with water, brine, dried over magnesium sulfate, filtered and concentrated. The residue was

diluted with ethyl acetate and hexane and then filtered to further remove the ammonium salt. The filtrate was concentrated to give the desired aldehyde product. The aldehyde was carried on to the next step without purification.

Temperatures higher than -70°C have been reported in the literature for the Swern oxidation. Other Swern modifications and alternatives to the Swern oxidations are also possible.

Alternatively, the aldehyde was prepared as follows. (200 g, 0.604 mol) was dissolved in triethylamine (300 mL, 2.15 mol). The mixture was cooled to 12°C and a solution of sulfur trioxide/pyridine complex (380 g, 2.39 mol) in DMSO (1.6 L) was added at a rate to maintain the temperature between $8-17^{\circ}\text{C}$ (addition time - 1.0 h). The solution was stirred at ambient temperature under a nitrogen atmosphere for 1.5 hour at which time the reaction was complete by TLC analysis (33% ethyl acetate/hexane, silica gel). The reaction mixture was cooled with ice water and quenched with 1.6 L of cold water ($10-15^{\circ}\text{C}$) over 45 minutes. The resultant solution was extracted with ethyl acetate (2.0 L), washed with 5% citric acid (2.0 L), and brine (2.2 L), dried over MgSO_4 (280 g) and filtered. The solvent was removed on a rotary evaporator at $35-40^{\circ}\text{C}$ and then dried under vacuum to give 198.8 g of α S-[Bis-(phenylmethyl)amino]-benzenepropanaldehyde as a pale yellow oil (99.9%). The crude product obtained was pure enough to be used directly in the next step without purification. The analytical data of the compound were consistent with the published literature. $[\alpha]_{\text{D}25} = -92.9^{\circ}$ (c 1.87, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ , 2.94 and 3.15 (ABX-System, 2H, $J_{\text{AB}} = 13.9$ Hz, $J_{\text{AX}} = 7.3$ Hz and $J_{\text{BX}} = 6.2$ Hz), 3.56 (t, 1H, 7.1 Hz), 3.69 and 3.82 (AB-System, 4H, $J_{\text{AB}} = 13.7$

Hz), 7.25 (m, 15 H) and 9.72 (s, 1H); HRMS calcd for (M+1) C₂₃H₂₄NO 330.450, found: 330.1836. Anal. Calcd. for C₂₃H₂₃ON: C, 83.86; H, 7.04; N, 4.25. Found: C, 83.64; H, 7.42; N, 4.19. HPLC on chiral stationary phase: (S,S) Pirkle-Whelk-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector at 210nm. Retention time of the desired S-isomer: 8.75 min., retention time of the R-enantiomer 10.62 min.

Step D:

A solution of αS-[Bis(phenylmethyl)amino] benzene-propanaldehyde (191.7 g, 0.58 mol) and chloriodomethane (56.4 mL, 0.77 mol) in tetrahydrofuran (1.8 L) was cooled to -30 to -35°C (colder temperature such as -70°C also worked well but warmer temperatures are more readily achieved in large scale operations) in a stainless steel reactor under a nitrogen atmosphere. A solution of n-butyllithium in hexane (1.6 M, 365 mL, 0.58 mol) was then added at a rate that maintained the temperature below -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. More additions of reagents were carried out in the following manner: (1) additional chloriodomethane (17 mL) was added, followed by n-butyllithium (110 mL) at < -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated once. (2) Additional chloriodomethane (8.5 mL, 0.11 mol) was added, followed by n-butyllithium (55 mL, 0.088 mol) at < -25°C. After addition, the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated 5 times. (3) Additional chloriodomethane (8.5 mL, 0.11 mol) was added, followed by n-butyllithium (37 mL, 0.059 mol) at < -25°C. After addition, the mixture was stirred at -30 to -35°C for 10 minutes. This was

repeated once. The external cooling was stopped and the mixture warmed to ambient temp. over 4 to 16 hours when TLC (silica gel, 20% ethyl acetate/hexane) indicated that the reaction was completed. The reaction mixture was cooled to 10°C and quenched with 1452 g of 16% ammonium chloride solution (prepared by dissolving 232 g of ammonium chloride in 1220 mL of water), keeping the temperature below 23°C. The mixture was stirred for 10 minutes and the organic and aqueous layers were separated. The aqueous phase was extracted with ethyl acetate (2x 500 mL). The ethyl acetate layer was combined with the tetrahydrofuran layer. The combined solution was dried over magnesium sulfate (220 g), filtered and concentrated on a rotary evaporator at 65°C. The brown oil residue was dried at 70°C in vacuo (0.8 bar) for 1 h to give 222.8 g of crude material. (The crude product weight was >100%. Due to the relative instability of the product on silica gel, the crude product is usually used directly in the next step without purification). The diastereomeric ratio of the crude mixture was determined by proton NMR: (2S)/(2R): 86:14. The minor and major epoxide diastereomers were characterized in this mixture by tlc analysis (silica gel, 10% ethyl acetate/hexane), R_f = 0.29 & 0.32, respectively. An analytical sample of each of the diastereomers was obtained by purification on silica-gel chromatography (3% ethyl acetate/hexane) and characterized as follows:

N,N, α S-Tris(phenylmethyl)-2S-oxiranemethanamine

^1H NMR (400 MHz, CDCl_3) δ 2.49 and 2.51 (AB-System, 1H, J_{AB} = 2.82), 2.76 and 2.77 (AB-System, 1H, J_{AB} = 4.03), 2.83 (m, 2H), 2.99 & 3.03 (AB-System, 1H, J_{AB} = 10.1 Hz), 3.15 (m, 1H), 3.73 & 3.84 (AB-System, 4H,

JAB = 14.00), 7.21 (m, 15H); ^{13}C NMR (400 MHz, CDCl_3) δ 139.55, 129.45, 128.42, 128.14, 128.09, 126.84, 125.97, 60.32, 54.23, 52.13, 45.99, 33.76; HRMS calcd for $\text{C}_{24}\text{H}_{26}\text{NO}$ (M+1) 344.477, found 344.2003.

N,N, α S-Tris(phenylmethyl)-2R-oxiranemethanamine

^1H NMR (300 MHz, CDCl_3) δ 2.20 (m, 1H), 2.59 (m, 1H), 2.75 (m, 2H), 2.97 (m, 1H), 3.14 (m, 1H), 3.85 (AB-System, 4H), 7.25 (m, 15H). HPLC on chiral stationary phase: Pirkle-Whelk-O 1 column (250 x 4.6 mm I.D.), mobile phase: hexane/isopropanol (99.5:0.5, v/v), flow-rate: 1.5 ml/min, detection with UV detector at 210nm. Retention time of (8): 9.38 min., retention time of enantiomer of (4): 13.75 min.

Alternatively, a solution of the crude aldehyde 0.074 mol and chloriodomethane (7.0 ml, 0.096 mol) in tetrahydrofuran (285 ml) was cooled to -78°C , under a nitrogen atmosphere. A 1.6 M solution of n-butyllithium in hexane (25 ml, 0.040 mol) was then added at a rate to maintain the temperature at -75°C (addition time - 15 min.). After the first addition, additional chloriodomethane (1.6 ml, 0.022 mol) was added again, followed by n-butyllithium (23 ml, 0.037 mol), keeping the temperature at -75°C . The mixture was stirred for 15 min. Each of the reagents, chloriodomethane (0.70 ml, 0.010 mol) and n-butyllithium (5 ml, 0.008 mol) were added 4 more times over 45 min. at -75°C . The cooling bath was then removed and the solution warmed to 22°C over 1.5 hr. The mixture was poured into 300 ml of saturated aq. ammonium chloride solution. The tetrahydrofuran layer was separated. The aqueous phase was extracted with ethyl acetate (1 x 300 ml). The combined organic layers were washed with brine,


dried over magnesium sulfate, filtered and concentrated to give a brown oil (27.4 g). The product could be used in the next step without purification. The desired diastereomer can be purified by recrystallization at a subsequent step. The product could also be purified by chromatography.

Alternatively, a solution of α S-[Bis(phenylmethyl)amino]benzene-propanaldehyde (178.84 g, 0.54 mol) and bromochloromethane (46 mL, 0.71 mol) in tetrahydrofuran (1.8 L) was cooled to -30 to -35°C (colder temperature such as -70°C also worked well but warmer temperatures are more readily achieved in large scale operations) in a stainless steel reactor under a nitrogen atmosphere. A solution of n-butyllithium in hexane (1.6 M, 340 mL, 0.54 mol) was then added at a rate that maintained the temperature below -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. More additions of reagents were carried out in the following manner: (1) additional bromochloromethane (14 mL) was added, followed by n-butyllithium (102 mL) at < -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated once. (2) Additional bromochloromethane (7 mL, 0.11 mol) was added, followed by n-butyllithium (51 mL, 0.082 mol) at < -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated 5 times. (3) Additional bromochloromethane (7 mL, 0.11 mol) was added, followed by n-butyllithium (51 mL, 0.082 mol) at < -25°C. After addition the mixture was stirred at -30 to -35°C for 10 minutes. This was repeated once. The external cooling was stopped and the mixture warmed to ambient temp. over 4 to 16 hours when TLC (silica gel, 20% ethyl acetate/hexane) indicated that the reaction was completed. The reaction mixture was

51

cooled to 10°C and quenched with 1452 g of 16% ammonium chloride solution (prepared by dissolving 232 g of ammonium chloride in 1220 mL of water), keeping the temperature below 23°C. The mixture was stirred for 10 minutes and the organic and aqueous layers were separated. The aqueous phase was extracted with ethyl acetate (2x 500 mL). The ethyl acetate layer was combined with the tetrahydrofuran layer. The combined solution was dried over magnesium sulfate (220 g), filtered and concentrated on a rotary evaporator at 65°C. The brown oil residue was dried at 70°C in vacuo (0.8 bar) for 1 h to give 222.8 g of crude material.

Example 2




Preparation of N-[[3S-(phenylmethylcarbamoyl)amino]-2R-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)amine

To a solution of 7.51g (20.3 mmol) of N-[[3S-(phenylmethylcarbamoyl)amino]-2R-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)amine in 67 mL of anhydrous tetrahydrofuran was added 2.25g (22.3 mmol) of triethylamine. After cooling to 0°C, 4.4g (20.3 mmol) of di-tert-butyl dicarbonate was added and stirring continued at room temperature for 21 hours. The volatiles were removed in vacuo, ethyl acetate added, then washed with


5% citric acid, saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered and concentrated to afford 9.6g of crude product. Chromatography on silica gel using 30% ethyl acetate/hexane afforded 8.2g of pure N-[[3S-(phenylmethylcarbamoyl)amino]-2R-hydroxy-4-phenyl]-1-[(2-methylpropyl)amino-2-(1,1-dimethylethoxyl)carbonyl]butane, mass spectrum m/e = 477 (M+Li).

Example 3A



Preparation of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (methanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate


To a solution of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl] N-isoamylamine (2.0 gm, 5.2 mmol) and triethylamine (723 uL, 5.5 mmol) in dichloromethane (20 mL) was added dropwise methanesulfonyl chloride (400 uL, 5.2 mmol). The reaction mixture was stirred for 2 hours at room temperature, then the dichloromethane solution was concentrated to ca. 5 mL and applied to a silica gel column (100 gm). The column was eluted with chloroform containing 1% ethanol and 1% methanol. The phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (methanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate was obtained as a white solid. Anal. Calcd for C₂₄H₃₄N₂O₅S: C, 62.31; H, 7.41; N, 6.06. Found: C, 62.17; H, 7.55; N, 5.97.

Example 3B

Preparation of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate

From the reaction of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl] N-isoamylamine (1.47 gm, 3.8 mmol), triethylamine (528 uL, 3.8 mmol) and benzenesulfonyl chloride (483 uL, 3.8 mmol) one obtains phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-carbamate. Column chromatography on silica gel eluting with chloroform containing 1% ethanol afforded the pure product. Anal. Calcd for C₂₉H₃₆N₂O₅S: C, 66.39; H, 6.92; N, 5.34. Found: C, 66.37; H, 6.93; N, 5.26.

54


Example 4

Preparation of Phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (n-propanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate

To a solution of N[3(S)-benzyloxycarbonylamino-2(R)-hydroxy-4-phenylbutyl] N-isoamylamine (192 mg , 0.5 mmol) and triethylamine (139 μ L, 1.0 mmol) in dichloromethane (10 mL) was added dropwise trimethylsilyl chloride (63 μ L, 0.5 mmol). The reaction was allowed to stir for 1 hour at room temperature, cooled to 0° C with an ice bath and then n-propanesulfonyl chloride (56 μ L, 0.5 mmol) was added dropwise. The reaction mixture was stirred for 1.5 hours at room temperature, then diluted with ethyl acetate (50 mL) and washed sequentially with 1N HCl, water, saturated sodium bicarbonate solution, and saturated sodium chloride solution (25 mL each). The organic solution was dried over magnesium sulfate, filtered and concentrated to an oil. The oil was stirred with methanol (10 mL) for 16 hours, concentrated and the residue chromatographed on silica gel (50 gm) eluting with 10% ethyl acetate in hexane (450 mL), then with 1:1 ethyl acetate / hexane. The phenylmethyl [2R-hydroxy-3-[(3-methylbutyl) (n-propanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate was recrystallized from ethyl ether / hexane to afford a white solid Anal. Calcd.

for C₂₆H₃₈N₂O₅S: C, 63.64; H, 7.81; N, 5.71. Found: C, 63.09; H, 7.74; N, 5.64.

Example 5




The procedure described in Example 2 was used to prepare phenylmethyl [2S-hydroxy-3-[(3-methylbutyl) (methanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate.

To a solution of N[3(S)-benzyloxycarbonylamino-2(S)-hydroxy-4-phenylbutyl] N-isoamylamine (192 mg, 0.5 mmol) and triethylamine (139 μ L, 0.55 mmol) in dichloromethane (8 mL) was added dropwise methanesulfonyl chloride (39 μ L, 0.55 mmol). The reaction mixture was stirred for 16 hours at room temperature, then the dichloromethane solution was applied to a silica gel column (50 gm). The column was eluted with dichloromethane containing 2.5% methanol. The phenylmethyl [2S-hydroxy-3-[(3-methylbutyl) (methanesulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate was obtained as a white solid Anal. Calcd. for C₂₄H₃₄N₂O₅S \diamond 0.2 H₂O: C, 61.83; H, 7.44; N, 6.01. Found: C, 61.62; H, 7.40; N, 5.99.

Example 6

Following the procedures of the previous Examples 1-5, the intermediate compounds set forth in Tables 1A and 1B were prepared.

TABLE 1A

Entry	R ³	R ⁴
1	isoamyl	p-fluorophenyl
2	isoamyl	p-nitrophenyl
3	isoamyl	o-nitrophenyl
4	isoamyl	β-naphthyl
5	isoamyl	2-thienyl
6	isoamyl	benzyl
7	isobutyl	p-fluorophenyl
8	p-fluorobenzyl	phenyl
9	4-pyridylmethyl	phenyl
10	cyclohexylmethyl	phenyl
11	allyl	phenyl
12	propyl	phenyl
13	cyclopropylmethyl	phenyl
14	methyl	phenyl
15	propargyl	phenyl
16	isoamyl	p-chlorophenyl

TABLE 1A (Cont'd)










Entry	R ³	R ⁴
17	isoamyl	p-methoxyphenyl
18	isoamyl	m-nitrophenyl
19	isoamyl	m-trifluoromethylphenyl
20	isoamyl	o-methoxycarbonylphenyl
21	isoamyl	p-acetamidophenyl
22	isobutyl	phenyl
23	-CH ₂ Ph	-Ph
24	-CH ₂ - 	-Ph
25	-CH ₂ - 	-Ph
26	-CH ₂ - 	-Ph
27	-CH ₂ - 	-Ph
28	-CH ₂ - 	-Ph
29	-CH ₂ CH=CH ₂	-Ph
30	- 	-Ph
31	- 	-Ph
32	-CH ₂ CH ₂ Ph	-Ph
33	-CH ₂ CH ₂ CH ₂ CH ₂ OH	-Ph
34	-CH ₂ CH ₂ N(CH ₃) ₂	-Ph
35	-CH ₂ CH ₂ -N 	-Ph
36	-CH ₃	-Ph
37	-CH ₂ CH ₂ CH ₂ SCH ₃	-Ph
38	-CH ₂ CH ₂ CH ₂ S(O) ₂ CH ₃	-Ph
39	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
40	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₂ CH ₂ CH ₃

TABLE 1A (Cont'd)













Entry	R ³	R ⁴
41	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₃
42	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -F
43	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -CH ₃
44	-CH ₂ CH ₂ CH(CH ₃) ₂	CO ₂ CH ₃ 
45	-CH ₂ CH(CH ₃) ₂	-  -F
46	-CH ₂ CH(CH ₃) ₂	-  -NHAC
47	-CH ₂ CH(CH ₃) ₂	-  -CH ₃
48	-CH ₂ CH ₂ CH ₃	-  -OCH ₃
49	-CH ₂ CH ₂ CH ₂ CH ₃	-  -OCH ₃
50	-CH ₂ CH ₂ CH(CH ₃) ₂	-CF ₃
51	-CH ₂ CH(CH ₃) ₂	-CH ₃
52	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₂ Cl
53	-CH ₂ CH(CH ₃) ₂	-CH ₂ =CH 
54	-CH ₂ CH(CH ₃) ₂	-  -OCH ₃
55	-CH ₂ CH(CH ₃) ₂	-CH=CH ₂
56	-CH ₂ -CH(CH ₃)(CH ₂ CH ₃)	-  -OCH ₃

TABLE 1A (Cont'd)

Entry					
<div></div>					
MASS MEASUREMENT					
	R ³	R ⁴	MOL FORM	CALC FOUND	
1	<div></div>	<div></div>	C ₂₉ H ₃₆ N ₂ O ₅ S	531 (M+Li)	531
2		<div></div>	C ₂₉ H ₃₆ N ₂ O ₆ S	541(M+H)	541
3		<div></div>	C ₃₀ H ₃₆ N ₂ O ₆ S	555.2529 (M+H)	555.2582
4		<div></div>			
5		<div></div>			
6		<div></div>	C ₂₈ H ₃₃ N ₂ O ₅ SF	529.2172 (M+H)	521.2976
7		<div></div>			
8		<div></div>	C ₂₉ H ₃₆ N ₂ O ₅ S ₂	563 (M+Li)	563
9		<div></div>	C ₂₉ H ₃₆ N ₂ O ₆ S ₂	573(M+H)	573
10		<div></div>	C ₂₉ H ₃₆ N ₂ O ₇ S ₂	595 (M+Li)	595

TABLE 1B

Entry	R	R ³
1		-CH ₂ Ph
2		-CH ₂ CH ₂ CH(CH ₃) ₂
3		-CH ₂ CH(CH ₃) ₂
4		-CH ₂ CH(CH ₃) ₂
5		-CH ₂ CH(CH ₃) ₂

61

TABLE 1B (Cont'd)












Entry	R	R ³
6		-CH ₂ CH(CH ₃) ₂
7		-CH ₂ CH(CH ₃) ₂
8		-CH ₂ CH(CH ₃) ₂
9		-CH ₂ CH ₂ (CH ₃) ₂

Table 1C



X	R ⁸	FORMULA	Mass Determination	
			Calc	Found
H		C ₂₇ H ₃₃ N ₃ O ₅ S	512.2219(M+H)	521.2267
OCH ₃		C ₂₈ H ₃₅ N ₃ O ₆ S	548.2407(M+Li)	548.2434
F		C ₂₇ H ₃₂ N ₃ O ₅ SF	530(M+H)	530
Cl		C ₂₇ H ₃₂ N ₃ O ₅ SCl	546(M+H)	546
NO ₂		C ₂₇ H ₃₂ N ₄ O ₇ S	557(M+H)	557
OH		C ₂₇ H ₃₃ N ₃ O ₆ S	528(M+H)	528

TABLE 1C (Cont'd)

X	R ⁸	FORMULA	Mass Determination	
			Calc	Found
OCH ₃		C ₂₈ H ₃₅ N ₃ O ₆ S	542.2325(M+H)	542.2362
OCH ₃		C ₂₈ H ₃₅ N ₃ O ₆ S	548.2407(M+Li)	548.2393
OCH ₃		C ₂₈ H ₃₅ N ₃ O ₆ S	543(M+H)	543
OCH ₃		C ₂₉ H ₃₆ O ₆ N ₂ S	547.2454(M+Li)	547.2475
OCH ₃	tert-Butyl	C ₂₆ H ₃₈ N ₂ O ₆ S	513.2611(M+Li)	513.2593
OCH ₃		C ₂₈ H ₃₅ N ₃ O ₇ S	564(M+Li)	564
OCH ₃		C ₂₈ H ₃₅ N ₃ O ₇ S	564(M+Li)	564


64

The following Examples 7-9 illustrate preparation of β -amino acid intermediates. These intermediates can be coupled to the intermediate compounds of Examples 1-6 to produce inhibitor compounds of the present invention containing β -amino acids.

Example 7

A. Preparation of 4(4-methoxybenzyl)itaconate


10



A 5 L three-necked round bottomed flask equipped with constant pressure addition funnel, reflux condenser, nitrogen inlet, and mechanical stirrer was charged with itaconic anhydride (660.8g, 5.88 mol) and toluene (2300 mL). The solution was warmed to reflux and treated with 4-methoxybenzyl alcohol (812.4g, 5.88 mol) dropwise over a 2.6h period. The solution was maintained at reflux for an additional 1.5h and then the contents were poured into three 2 L erlenmeyer flasks to crystallize. The solution was allowed to cool to room temperature whereupon the desired mono-ester crystallized. The product was isolated by filtration on a Buchner funnel and air dried to give 850.2g, 58% of material with mp 83-85°C, a second crop, 17% was isolated after cooling of the filtrate in an ice bath. ^1H NMR (CDCl_3) 300 MHz 7.32(d, J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 6.49(s, 1H), 5.85(s, 1H), 5.12(s, 2H), 3.83(s, 3H), 3.40(s, 2H).

65

B. Preparation of Methyl 4(4-methoxybenzyl) itaconate




5 A 5 L three-necked round bottomed flask
equipped with reflux condenser, nitrogen inlet, constant
pressure addition funnel and mechanical stirrer was
charged with 4(4-methoxybenzyl) itaconate (453.4g, 1.81
mol) and treated with 1,5-diazabicyclo[4.3.0]non-5-ene
10 (275.6g, 1.81 mol), (DBN), dropwise so that the
temperature did not rise above 15°C. To this stirring
mixture was added a solution of methyl iodide (256.9g,
1.81 mol) in 250 mL of toluene from the dropping funnel
over a 45m period. The solution was allowed to warm to
15 room temperature and stirred for an additional 3.25h.

The precipitated DBN hydroiodide was removed by
filtration, washed with toluene and the filtrate poured
into a separatory funnel. The solution was washed with
20 sat. aq. NaHCO₃ (2 X 500 mL), 0.2N HCl (1 X 500 mL), and
brine (2 X 500 mL), dried over anhyd. MgSO₄, filtered,
and the solvent removed in vacuo. This gave a clear
colorless oil, 450.2g, 94% whose NMR was consistent with
the assigned structure. ¹H NMR (CDCl₃) 300 MHz 7.30(d,
25 J=8.7 Hz, 2H), 6.90(d, J=8.7 Hz, 2H), 6.34(s, 1H),
5.71(s, 1H), 5.09(s, 2H), 3.82(s, 3H), 3.73(s, 3H),
3.38(s, 2H). ¹³C NMR (CDCl₃) 170.46, 166.47, 159.51,
133.55, 129.97, 128.45, 127.72, 113.77, 66.36, 55.12,
51.94, 37.64.

66

C. Preparation of Methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate



5

A 500 mL Fisher-Porter bottle was charged with methyl 4(4-methoxybenzyl) itaconate (71.1g, 0.269 mol), rhodium (R,R) DiPAMP catalyst (204mg, 0.269 mmol, 0.1 mol%) and degassed methanol (215 mL). The bottle was
10 flushed 5 times with nitrogen and 5 times with hydrogen to a final pressure of 40 psig. The hydrogenation commenced immediately and after ca. 1h the uptake began to taper off, after 3h the hydrogen uptake ceased and the bottle was flushed with nitrogen, opened and the contents
15 concentrated on a rotary evaporator to give a brown oil that was taken up in boiling iso-octane (ca. 200 mL, this was repeated twice), filtered through a pad of celite and the filtrate concentrated in vacuo to give 66.6g, 93% of a clear colorless oil, ¹H NMR (CDCl₃ 300 MHz 7.30(d,
20 J=8.7 Hz, 2H), 6.91(d, J=8.7 Hz, 2H), 5.08(s, 2H), 3.82(s, 3H), 3.67(s, 3H), 2.95(ddq, J=5.7, 7.5, 8.7 Hz, 1H), 2.79(dd, J=8.1, 16.5 Hz, 1H), 2.45(dd, J=5.7, 16.5 Hz, 1H), 1.23(d, J=7.5 Hz, 3H).


25 D. Preparation of Methyl 2(R)-methylsuccinate

A 3 L three-necked round-bottomed flask equipped with a nitrogen inlet, mechanical stirrer, reflux condenser and constant pressure addition funnel
30 was charged with methyl 4(4-methoxybenzyl) 2(R)-methylsuccinate (432.6g, 1.65 mol) and toluene (1200 mL). The stirrer was started and the solution treated with

67

trifluoroacetic acid (600 mL) from the dropping funnel over 0.25h. The solution turned a deep purple color and the internal temperature rose to 45°C. After stirring for 2.25h the temperature was 27°C and the solution had acquired a pink color. The solution was concentrated on a rotary evaporator. The residue was diluted with water (2200 mL) and sat. aq. NaHCO₃ (1000 mL). Additional NaHCO₃ was added until the acid had been neutralized. The aqueous phase was extracted with ethyl acetate (2 X 1000 mL) to remove the by-products and the aqueous layer was acidified to pH=1.8 with conc. HCl. This solution was extracted with ethyl acetate (4 X 1000 mL), washed with brine, dried over anhyd. MgSO₄, filtered and concentrated on a rotary evaporator to give a colorless liquid 251g, >100% that was vacuum distilled through a short path apparatus cut 1: bath temperature 120°C @ >1mm, bp 25-29°C; cut 2: bath temperature 140°C @ 0.5mm, bp 95-108°C, 151g, $[\alpha]_D^{25} = +1.38^\circ$ (c=15.475, MeOH), $[\alpha]_D = +8.48^\circ$ (neat); cut 3: bath temperature 140°C, bp 108°C, 36g, $[\alpha]_D^{25} = +1.49^\circ$ (c=15.00, MeOH), $[\alpha]_D = +8.98^\circ$ (neat). Cuts 2 and 3 were combined to give 189g, 78% of product, ¹H NMR (CDCl₃) 300 MHz 11.6(brs, 1H), 3.72(s, 3H), 2.92(ddq, J=5.7, 6.9, 8.0 Hz, 1H), 2.81(dd, J=8.0, 16.8 Hz, 1H), 2.47(dd, J=5.7, 16.8 Hz, 1H), 1.26(d, J=6.9 Hz, 3H).

E. Preparation of Methyl Itaconate




30

A 50 mL round bottomed flask equipped with reflux condenser, nitrogen inlet and magnetic stir bar was charged with methyl 4(4-methoxybenzyl) itaconate

68

(4.00g, 16 mmol), 12 mL of toluene and 6 mL of trifluoroacetic acid. The solution was kept at room temperature for 18 hours and then the volatiles were removed in vacuo. The residue was taken up in ethyl acetate and extracted three times with saturated aqueous sodium bicarbonate solution. The combined aqueous extract was acidified to pH=1 with aqueous potassium bisulfate and then extracted three times with ethyl acetate. The combined ethyl acetate solution was washed with saturated aqueous sodium chloride, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The residue was then vacuum distilled to give 1.23g, 75% of pure product, bp 85-87 @ 0.1 mm. ¹H NMR (CDCl₃) 300 MHz 6.34(s, 1H), 5.73(s, 2H), 3.76(s, 3H), 3.38(s, 2H). ¹³C NMR (CDCl₃) 177.03, 166.65, 129.220, 132.99, 52.27, 37.46.

F. Curtius Rearrangement of Methyl 2(R)-methylsuccinate:
Preparation of Methyl N-Moz- α -methyl β -alanine.




A 5L four necked round bottomed flask equipped with a nitrogen inlet, reflux condenser, mechanical stirrer, constant pressure addition funnel, and thermometer adapter was charged with methyl 2(R)-methylsuccinate (184.1g, 1.26 mol), triethylamine (165.6g, 218 mL, 1.64 mol, 1.3 equivalents), and toluene (1063 mL). The solution was warmed to 85°C and then treated dropwise with a solution of diphenylphosphoryl azide (346.8g, 1.26 mol) over a period of 1.2h. The

69

solution was maintained at that temperature for an additional 1.0h and then the mixture was treated with 4-methoxybenzyl alcohol (174.1g, 1.26 mol) over a 0.33h period from the dropping funnel. The solution was
5 stirred at 88°C for an additional 2.25h and then cooled to room temperature. The contents of the flask were poured into a separatory funnel and washed with sat. aq. NaHCO₃ (2 X 500 mL), 0.2N HCl (2 X 500 mL), brine (1 X 500 mL), dried over anhyd. MgSO₄, filtered, and
10 concentrated in vacuo to give 302.3g, 85% of the desired product as a slightly brown oil. ¹H NMR (CDCl₃) 300 MHz 7.32(d, J=8.4 Hz, 2H), 6.91(d, J=8.4 Hz, 2H), 5.2(brm, 1H), 5.05(s, 2H), 3.83(s, 3H), 3.70(s, 3H), 3.35(m, 2H), 2.70(m, 2H), 1.20(d, J=7.2 Hz, 3H).

15

G. Hydrolysis of Methyl N-Moz- α -methyl β -alanine:
Preparation of α -methyl β -alanine Hydrochloride




20

A 5 L three-necked round bottomed flask equipped with a reflux condenser, nitrogen inlet and mechanical stirrer was charged with methyl N-Moz- α -methyl β -alanine (218.6g, 0.78 mol), glacial acetic acid (975
25 mL) and 12N hydrochloric acid (1960 mL). The solution was then heated to reflux for 3h. After the solution had cooled to room temperature (ca. 1h) the aqueous phase was decanted from organic residue (polymer) and the aqueous phase concentrated on a rotary evaporator. Upon addition
30 of acetone to the concentrated residue a slightly yellow solid formed that was slurried with acetone and the white solid was isolated by filtration on a Buchner funnel. The last traces of acetone were removed by evacuation to

70

give 97.7g, 90% of pure product, mp 128.5-130.5°C $[\alpha]_D$ @ 25°C=9.0°C (c=2.535, Methanol). ^1H NMR (D_2O) 300 MHz 3.29(dd, J=8.6, 13.0 Hz, 1H), 3.16(dd, J=5.0, 13.0m Hz, 1H), 2.94(ddq, J=7.2, 5.0, 8.6 Hz, 1H), 1.30(d, J=7.2 Hz, 3H); ^{13}C NMR (D_2O) 180.84, 44.56, 40.27, 17.49.

H. Preparation of N-Boc α -Methyl β -Alanine



10

A solution of α -methyl β -alanine hydrochloride (97.7g, 0.70 mol) in water (1050 mL) and dioxane (1050 mL) the pH was adjusted to 8.9 with 2.9N NaOH solution. This stirring solution was then treated with di-tert-butyl pyrocarbonate (183.3g, 0.84 mol, 1.2 equivalents) all at once. The pH of the solution was maintained between 8.7 and 9.0 by the periodic addition of 2.5N NaOH solution. After 2.5h the pH had stabilized and the reaction was judged to be complete. The solution was concentrated on a rotary evaporator (the temperature was maintained at <40°C). The excess di-tert-butyl pyrocarbonate was removed by extraction with dichloromethane and then the aqueous solution was acidified with cold 1N HCl and immediately extracted with ethyl acetate (4 X 1000 mL). The combined ethyl acetate extract was washed with brine, dried over anhyd. MgSO_4 , filtered and concentrated on a rotary evaporator to give a thick oil 127.3g, 90% crude yield that was stirred with n-hexane whereupon crystals of pure product formed, 95.65g, 67%, mp 76-78°C, $[\alpha]_D$ @ 25°C=-11.8°C (c=2.4, EtOH). A second crop was obtained by concentration of the filtrate and dilution with hexane, 15.4g, for a combined yield of 111.05g, 78%. ^1H NMR (acetone D_6) 300

7/

MHz 11.7 (brs, 1H), 6.05 (brs 1H), 3.35 (m, 1H), 3.22 (m, 1H), 2.50 (m, 1H), 1.45(s, 9H), 1.19 (d, J=7.3 Hz, 3H); ¹³C NMR (acetone D₆) 177.01, 79.28, 44.44, 40.92, 29.08, 15.50. Elemental analysis calc'd. for C₉H₁₇NO₄: C, 53.19, H, 8.42; N, 6.89. Found: C, 53.36; H, 8.46; N, 6.99.

I. Preparation of N-4-Methoxybenzyloxycarbonyl α -Methyl β -Alanine

10

A solution of N-4-methoxybenzyloxycarbonyl α -methyl β -alanine methyl ester (2.81g, 10.0 mmol) in 30 mL of 25% aqueous methanol was treated with lithium hydroxide (1.3 equivalents) at room temperature for a period of 2h. The solution was concentrated in vacuo and the residue taken up in a mixture of water and ether and the phases separated and the organic phase discarded. The aqueous phase was acidified with aqueous potassium hydrogen sulfate to pH=1.5 and then extracted three times with ether. The combined ethereal phase was washed with saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo to give 2.60 g, 97% of N-4-Methoxybenzyloxycarbonyl α -methyl β -alanine (N-Moz-AMBA) which was purified by recrystallization from a mixture of ethyl acetate and hexane to give 2.44g, 91% of pure product, mp 96-97°C, MH+=268. ¹H NMR (D₆-acetone/300 MHz) 1.16 (3H, d, J=7.2Hz), 2.70 (1H, m), 3.31 (2H, m), 3.31 (3H, s), 4.99 (2H, s), 6.92 (2H, 4, J=8.7 Hz), 7.13 (2H, d, J=8.7 Hz).


30

72




Example 8

Following generally the procedure of Example 7,
the β -amino acids set forth in Table 1 were prepared.

5




Table 2

10

	Entry	R ¹	R ^{1'}	R ^{1''}
	1	-CH ₃	H	H
15	2	-CH(CH ₃) ₂	H	H
	3	-C(CH ₃) ₃	H	H
	4	H	H	H
	5	H	-CH ₃	H
	6	H	-CH ₃	-CH ₃
20	7	H	H	-CO ₂ CH ₃
	8	H	H	-CONH ₂
	9	-CH ₂ CH ₃	H	H
	10	-CH ₂ CH(CH ₃) ₂	H	H
	11	-CH ₂ C ₆ H ₅	H	H
25	12	-CH ₂ - 	H	H
	13	-CH ₂ - 	H	H
	14	-CH ₂ COOH	H	H
	15	H	-CH(CH ₃) ₂	H
	16	H	-CH ₂ CH(CH ₃) ₂	H
30	17	H	-CH ₂ - 	H

73

Table 2 (Cont'd)


5	Entry	R ¹	R ^{1'}	R ^{1''}
	18	H	-CH ₂ CH ₂ - 	H
	19	H	-(CH ₂) ₃ - 	H
10	20	H	-(CH ₂) ₄ - 	H
	21	H	-(CH ₂) ₃ CH(C ₆ H ₅) ₂	H

15

Example 9


Utilizing generally the procedure set forth in Example 7, the following β -amino acid compounds were prepared.

20



25

74

Example 10A


5 Preparation of 4-Pyridinecarboxamide,
N-[2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-
methylpropyl)amino]-1S-(phenylmethyl)propyl]

To a solution of 231 mg (0.57 mmol) of 2R-
 10 hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]
 amino-1S-(phenylmethyl)propylamine in 3 mL of methylene
 chloride at 0 C, was added 288 mg (2.85 mmol) of
 triethylamine and then 112 mg (0.63 mmol) of isonicotinoyl
 15 chloride hydrochloride. After 19 hours at room
 temperature, the solvent was removed, ethyl acetate
 added, then washed with saturated sodium bicarbonate,
 brine, dried with magnesium sulfate, filtered and
 concentrated to afford 290 mg of crude product. This was
 20 chromatographed on silica gel using 3-5%
 isopropanol/methylene chloride as eluent to afford 190 mg
 of the desired compound; mass spectrum calc. for
 C₂₇H₃₄N₃O₅S (M + H) 512.2219; found 512.2280.

25

30

75


Example 10B5 Preparation of Benzamide.

N-[2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-
methylpropyl)amino]-1S-(phenylmethyl)propyl]-2,6-dimethyl

To a solution of 83 mg (0.55 mmol) of 2,6-
 10 dimethylbenzoic acid and 125 mg (0.82 mmol) of N-
 hydroxybenzotriazole in 3 mL of anhydrous DMF at 0 C was
 added 117 mg (0.61mmol) of 1-(3-dimethylaminopropyl)-3-
 ethylcarbodiimide hydrochloride. After 2 hours at 0 C,
 203 mg (0.50 mmol) of 2R-hydroxy-3-[(2-methylpropyl)(4-
 15 methoxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine
 was added. After 22 hours at room temperature, the
 solvent was removed in vacuo, ethyl acetate added, then
 washed with saturated sodium bicarbonate, brine, dried
 over magnesium sulfate, filtered and concentrated to
 20 afford 300 mg of crude product. Chromatography on silica
 gel using 20-50% ethyl acetate/hexane afforded 37 mg of
 the desired product; mass spectrum calcd for C₃₀H₃₈N₂O₅S
 (M+H) 539.2580; found 539.2632.

25

30

Example 11A

5 Preparation of N1-[2R-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide

Part A:

10 A solution of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1S-(phenylmethyl)-propyl]carbamate prepared as in Example 3 (100 mg) in methanol (10 mL) was hydrogenated over 10% palladium on carbon for 2 hours, filtered through diatomaceous earth
15 and concentrated to give the product as an oil.

Part B:

A solution of N-CBZ-L-asparagine (61 mg, 0.23 mmol) and N-hydroxybenzotriazole (33 mg, 0.22 mmol)
20 in DMF (2 mL) was cooled to 0° C with an ice bath and then EDC (42 mg, 0.22 mmol) was added. The solution was stirred for 30 minutes at 0° C and then the product of Part A (69 mg, 0.21 mmol) in DMF (2 mL) was added. After 30 minutes at 0° C the reaction was allowed to warm to
25 room temperature and stir for 16 hours. The reaction mixture was then poured into a 50% saturated aqueous solution of sodium bicarbonate (100 mL) and the resulting white precipitate collected by suction filtration, washed with water and dried in vacuo. The phenylmethyl
30 [3-amino-1S-[[2R-hydroxy-3-[(3-methylbutyl)

77

(methylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carbamate was obtained as a white solid Anal. Calcd. for C₂₈H₄₀N₄O₇S . 0.5 H₂O: C, 57.42; H, 7.06; N, 9.57. Found: C, 57.72; H, 7.21; N, 9.24.

5

Part C:


A solution of phenylmethyl [3-amino-1S-[[2R-hydroxy-3-[(3-methylbutyl) (methylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carbamate
10 (135 mg, 0.23) in methanol (15 mL) was hydrogenated over 10% palladium on carbon for 6 hours, filtered through diatomaceous earth and concentrated to give the product as an oil.

15 Part D:

To a solution of the product from Part C (101 mg, 0.23 mmol) in DMF (5 mL) was added 2-quinoline carboxylic acid N-hydroxysuccinimide ester (67 mg, 0.25 mmol). The reaction was stirred at room temperature for
20 16 hours, then poured into a 50% saturated solution of sodium bicarbonate (60 mL). The resulting solid was collected by suction filtration washed with water and dried in vacuo. The N1-[2R-hydroxy-3-[(3-methylbutyl) (methylsulfonyl)-amino]-1S-(phenylmethyl)propyl]-2S-[(2-
25 quinolinylcarbonyl)-amino]butanediamide was obtained as a white solid Anal. Calcd. for C₃₀H₃₉N₅O₆S . 0.1 H₂O: C, 58.52; H, 6.71; N, 11.37. Found: C, 58.34; H, 6.35; N, 11.13.

30

78

Example 11B

5 Preparation of N1-[2R-hydroxy-3-[(3-methylbutyl)
(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-
quinolinylcarbonyl)amino]butanediamide.

Part A:

10 The CBZ protected compound phenylmethyl [2R-
hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-
(phenylmethyl)propyl]carbamate (200 mg, 0.38 mmol) was
deprotected by hydrogenation over 10% palladium on carbon
and the resulting product obtained as an oil.

15

Part B:

The free amine from Part A was coupled with
N-CBZ-L-asparagine (109 mg, 0.41 mmol) in the presence of
N-hydroxybenzotriazole (63 mg, 0.41 mmol) and EDC (77 mg,
20 0.40 mmol) to give phenylmethyl [3-amino-1S-[[2R-hydroxy-
3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-
(phenylmethyl)amino]carbonyl]-3-oxopropyl]carbamate as a
white solid Anal. Calcd. for C₃₃H₄₂N₄O₇S: C, 62.05; H,
6.63; N, 8.77. Found: C, 61.86; H, 6.60; N, 8.64.

25

Part C:

The product of Part B (110 mg, 0.17) was
deprotected by hydrogenation over 10% palladium on carbon
to give the product as an oil.

30


79

Part D:

The resulting free amine was coupled with 2-quinoline carboxylic acid N-hydroxysuccinimide ester (45 mg, 0.17 mmol) to give N1- [2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylnylcarbonyl)amino]butanediamide as a white solid

Anal. Calcd .for C₃₅H₄₁N₅O₆S: C, 63.71; H, 6.26; N, 10.61. Found: C, 63.59; H, 6.42; N, 10.42.

10

Example 12A

15 Preparation of 2S-[[[(dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(methylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutanamide

Part A:

To a solution of N-CBZ-L-tert-leucine (100 mg, 0.38 mmol) and N-hydroxybenzotriazole (52 mg, 0.34 mmol) in DMF (3 mL) was added EDC (65 mg, 0.34 mmol). The solution was stirred for 60 minutes at room temperature and then the product of Example 10, Part A (105 mg, 0.32 mmol) in DMF (2 mL) was added. The reaction was stirred

25 for 16 hours at room temperature, then poured into a 50% saturated solution of sodium bicarbonate (50 mL). The aqueous mixture was extracted twice with ethyl acetate (25 mL). The combined ethyl acetate layers were washed with water (25 mL) and dried over magnesium sulfate.

30 Filtration and concentration produced an oil which was

80

chromatographed on silica gel (50 gm) eluting with 2.5 % methanol in dichloromethane. The phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl)-(methylsulfonyl)amino]-1S-(phenylmethyl)propyl]amino]-carbonyl]-2,2-dimethylpropyl]carbamate was obtained as a gummy solid
5 Anal. Calcd. for C₃₀H₄₅N₃O₆S \diamond 2.2 H₂O: C, 58.55; H, 8.09; N, 6.83. Found: C, 58.38; H, 7.77; N, 7.10.

Part B:


10 A solution of phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl) (methylsulfonyl)amino]-1S-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]carbamate (100 mg, 0.17 mmol) in methanol (10 mL) was hydrogenated over 10% palladium on carbon for
15 2 hours. The reaction was filtered through diatomaceous earth and concentrated to an oil.

Part C:

20 N,N-dimethylglycine (20 mg, 0.19 mmol), N-hydroxybenzotriazole (28 mg, 0.18 mmol) and EDC (35 mg, 0.18 mmol) were stirred in DMF (4 mL) at room temperature for 40 minutes. The product from Part B in DMF (4 mL) was added and the reaction mixture stirred for 16 hours,
25 then poured into a 50% saturated sodium bicarbonate solution (50 mL). The aqueous mixture was extracted three times with dichloromethane (30 mL) which in turn were washed with water (30 mL) and dried over magnesium sulfate. Filtration and concentration afforded an oil.
30 The oil was chromatographed on silica gel (50 gm) eluting initially with 2.5 % methanol in dichloromethane (400 mL) and then with 5% methanol in dichloromethane. The 2S-[[[(dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl) (methylsulfonyl)amino]-1S-(phenylmethyl)-
35 propyl]-3,3-dimethylbutanamide was obtained as a white

solid Anal. Calcd. for $C_{26}H_{46}N_4O_5S \cdot 0.5 CH_2Cl_2$: C, 56.04; H, 8.34; N, 9.87. Found: C, 56.06; H, 8.36; N, 9.70.

5

Example 12B

Preparation of 2S-[[[(dimethylamino)acetyl]amino]-N-[2R-
 10 hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-
(phenylmethyl)propyl]-3,3-dimethylbutaneamide

Part A:

15 To a solution of N-CBZ-L-tert-leucine (450 mg, 1.7 mmol) and N-hydroxybenzotriazole (260 mg, 1.7 mmol) in DMF (10 mL) was added EDC (307 mg, 1.6 mmol). The solution was stirred for 60 minutes at room temperature and then the product of Example 11, Part A (585 mg, 1.5 mmol) in DMF
 20 (2 mL) was added. The reaction was stirred for 16 hours at room temperature, then poured into a 50% saturated solution of sodium bicarbonate (200 mL). The aqueous mixture was extracted thrice with ethyl acetate (50 mL). The combined ethyl acetate layers were washed with water (50 mL) and
 25 saturated NaCl solution (50 mL), then dried over magnesium sulfate. Filtration and concentration produced an oil which was chromatographed on silica gel (50 gm) eluting with 20% ethyl acetate in hexane. The phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-
 30 (phenylmethyl)propyl]amino]carbonyl]-2,2-

dimethylpropyl]carbamate was obtained as a solid Anal. Calcd for C₃₅H₄₇N₃O₆S: C, 65.91; H, 7.43; N, 6.59. Found: C, 65.42; H, 7.24; N, 6.55.

5 Part B:

A solution of phenylmethyl [1S-[[[2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)- amino]-1S-(phenylmethyl)propyl]amino]carbonyl]-2,2-dimethylpropyl]carbamate (200 mg, 0.31 mmol) in methanol (15 mL) was hydrogenated over 10% palladium on carbon for 2 hours. The reaction was filtered through diatomaceous earth and concentrated to an oil.


15 Part C:

The resulting free amine from part B (150 mg, 0.3 mmol) was combined with diisopropylethylamine (114 uL, 0.33 mmol) in dichloromethane (5 mL). To this was added
20 bromoacetyl chloride (27 uL, 0.33 mmol) dropwise. The reaction was stirred for 30 minutes at room temperature, then diluted with dichloromethane (30 mL) and extracted with 1 N HCl, water, and then saturated NaCl solution (25 mL each). The organic solution was dried over MgSO₄ and
25 concentrated to a solid. The 2S-[[bromoacetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide was sufficiently pure for use in the next step. This material can also be prepared by substituting bromoacetic anhydride
30 for bromoacetyl chloride, or one can use chloroacetyl chloride or chloroacetic anhydride.

83

Part D:

The product from part C was dissolved in dichloromethane (5 mL) and diisopropylethylamine (114 uL, 0.66 mmol) and dimethylamine hydrochloride (53 mg, 0.66 mmol) were added. The reaction was stirred for 18 hours then concentrated under a stream of nitrogen to about 1 mL. The residue was chromatographed on silica gel (50 gm) using 2% methanol in dichloromethane. The 2S-[[[(dimethylamino)-acetyl] amino]-N-[2R-hydroxy-3-[(3methylbutyl)-(phenylsulfonyl)amino]-1S-(phenylmethyl) propyl]-3,3-dimethylbutaneamide was obtained as a solid. Anal. Calcd for C₃₁H₄₈N₄O₅S: C, 63.24; H, 8.22; N, 9.52. Found: C, 63.03; H, 8.01; N, 9.40.


Example 12C

Preparation of 2S-[[[(methylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide

2S-[[[bromoacetyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide (103 mg, 0.16 mmol) and 40% aqueous methylamine (42 uL, 0.49 mmol) were combined in ethanol (2 mL) and stirred at room temperature for 24 hours. The reaction mixture was concentrated to dryness and triturated

with ether. The solid material was removed by filtration and the filtrate concentrated to an oil. The oil was chromatographed on silica (50 gm) using 4% methanol in dichloromethane. The 2S-[[[(methylamino)acetyl]amino]-N-[2R-
5 hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide was obtained as a solid. Anal. Calcd for C₃₀H₄₆N₄O₅S: C, 62.69; H, 8.07; N, 9.75. Found: C, 62.38; H, 8.14; N, 9.60.

10

Example 12D

Preparation of Pentanamide, 2S-
15 [[[(Dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-
methylbutyl)(phenylsulfonyl)amino]-1S-
(phenylmethyl)propyl]-3,3-dimethyl-

Part A:

20 To a solution the amine product of Example 11, Part A; (2.79 g, 7.1 mmol) in 27 mL of dioxane was added (2.3 g, 7.1 mmol) of N-t-butylcarbonyl-L-isoleucine-N-hydroxysuccinamide ester, and the reaction was stirred under nitrogen atmosphere for 16 hours. The contents of the
25 reaction were concentrated in vacuo, and the residue dissolved in ethyl acetate, washed with potassium hydrogen sulfate (5% aqueous), saturated sodium bicarbonate, and saturated sodium chloride. The organic layer was dried over magnesium sulfate, filtered and concentrated to yield 4.3

grams of crude material which was chromatographed using 3:1 ethyl acetate: hexane to obtain 3.05g, 72% yield of Pentanamide, 2S-[[[(1,1-dimethylethoxy)carbonyl]amino]-N-[2R-hydroxy-3-[(3-methylbutyl)phenylsulfonyl]amino]-1S-(phenylmethyl)propyl]-3-methyl-.
5

Part B

(3.05g, 5.0 mmol) of the product from Part A; was dissolved in 20 mL of 4N HCl in dioxane and stirred under
10 nitrogen atmosphere for 1.5 hours. The contents were concentrated in vacuo, and chased with diethyl ether. The crude hydrochloride salt was pumped on at 1 mm Hg until dry to yield 2.54 g of product as its hydrochloride salt.

15 Part C:


(2.54 g, 5.0 mmol) of amine hydrochloride was dissolved in 50 mL of tetrahydrofuran and to this was added (1.01 g, 10 mmol) of 4-methyl-morpholine, at which time a precipitate forms. To this suspension was added
20 chloroacetic anhydride (0.865 g, 5.0 mmol) and stirred for 40 minutes. The contents were concentrated in vacuo, and the residue partitioned in ethyl acetate (200 mL) and 5% KHSO₄. The organic layer was washed with saturated sodium bicarbonate, and saturated sodium chloride, dried over
25 magnesium sulfate, filtered and concentrated to yield the crude product. Purification by silica gel chromatography using an eluant of 1:1 ethyl acetate; hexanes yielded 1.89 grams of pure chloroacetamide.

30 Part D:

To a solution of chloroacetamide (1.89 g, 3.2 mmol) from Part C, in 25 mL of tetrahydrofuran was added 4.0 mL of 50% aqueous dimethylamine and the solution was stirred for 1 hour. The solution was concentrated in vacuo and the
35 residue was dissolved in ethyl acetate and washed with

86

water. The organic layer was dried over magnesium sulfate, filtered and concentrated to yield the crude product which was purified by crystallization from ethyl acetate and isooctane to yield 1.80 g, (88% yield), mp. = 121-122 C,
 5 HRes. MS. calc. 589.3424, found 589.3405.

Example 12E

10


Preparation of Pentanamide, 2S-[[(Methylamino)acetylaminol]-
N-[2R-hydroxy-3-[(3-methylbutyl) (phenylsulfonyl)aminol]-1S-
(phenylmethyl)propyl]-3S-methyl-

15

To a solution of the chloroacetamide of Example 12D, Part C, (2.36 g, 4.0 mmol) in tetrahydrofuran (25 mL) was added 3 mL of aqueous methylamine 40 wt%, and the reaction stirred for 1 hour. The contents were concentrated
 20 and the residue was partitioned between ethyl acetate (100 mL) and water (100 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated to yield the crude product, which was purified by recrystallization from ethyl acetate heptane; (M+H) 575, HRes. found 575.3267.

25

87

Example 12F

5 Preparation of Pentanamide, 2S-[[[(Dimethylamino)acetyl]aminol-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenyl)sulfonyl]aminol]-1S-(phenylmethyl)propyl]-3S-methyl-

10 Part A:

To a solution of 2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenylsulfonyl)amino]1-S-propylamine (1.70 g, 4.18 mmol) in 40 mL of dichloromethane was added N-carbobenzyloxy-L-isoleucine-N-hydroxysuccinamide ester (1.51 g, 4.18 mmol) and the solution stirred under nitrogen atmosphere for 16 hours. The contents were concentrated in vacuo and the residue was redissolved in ethyl acetate. The ethyl acetate solution was washed with an aqueous solution of 5% KHSO₄, saturated sodium bicarbonate, and saturated sodium chloride, dried over magnesium sulfate, filtered, and concentrated to yield 2.47g of crude product. The product was purified by silica gel chromatography using 1 2:1 hexane:ethyl acetate eluant to yield 2.3 g. (84% yield) of Pentanamide, 2-[(carbobenzyloxy)amino]-N-[2-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1-(phenylmethyl)propyl]-3-methyl-, [4-(R*,S*,S*,)].

30 Part B:

(1.18 g, 1.8 mmol) of the product from Part A was dissolved in 50 mL of methanol, and to this was added 250 mg of 10% Palladium on Carbon while under a stream of nitrogen. The suspension was hydrogenated using 50 psig of hydrogen
5 for 20 hours. The contents were purged with nitrogen and filtered through celite, and concentrated in vacuo to yield 935 mg of Pentanamide, 2S-(amino)-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1-S-(phenylmethyl)propyl]-3S-methyl-, which was used without
10 further purification.

Part C:


(0.935 g, 1.8 mmol) of the amine from Part B was dissolved in 15 mL of dioxane and to this was added (190 mg,
15 1.85 mmol) of 4-methylmorpholine followed by (0.315 g, 1.8 mmol) of chloroacetic anhydride. The reaction mixture was stirred under nitrogen atmosphere for 3 hours, concentrated in vacuo, and redissolved in ethyl acetate. The ethyl acetate solution was washed with 50 mL of 5% aqueous KHSO₄,
20 saturated NaHCO₃, and saturated NaCl solution, dried over MgSO₄, filtered and concentrated to yield 613 mg, (68% yield) of Pentanamide, 2S-[(chloroacetyl)amino]-N-[2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3S-methyl-, after purification by
25 silica gel chromatography using 1:1 hexane:ethyl acetate.

Part D:

To a solution of the chloroacetamide from Part C; (673 mg, 1.10 mmol) in 20 mL of tetrahydrofuran was added 5
30 mL of 50 wt% aqueous dimethylamine and the solution was stirred for 1 hour. The reaction was concentrated and the residue was redissolved in 50 mL of ethyl acetate and washed with 25 mL of water. The ethyl acetate layer was dried over magnesium sulfate, filtered and concentrated to yield a
35 crude solid which was purified by silica gel column

chromatography using an eluant of 97:3
dichloromethane:methanol to provide 400 mg of Pentanamide,
2S-[[Dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-
methylpropyl)(4-methoxyphenylsulfonyl)amino]-1S-
5 (phenylmethyl)propyl]-3S-methyl-.

Example 13A



10

Preparation of Carbamic acid, [2R-hydroxy-3-[[[4-
dimethylaminophenyl)sulfonyl](2-methylpropyl)amino]-1S-
(phenylmethyl)propyl]-, phenylmethyl ester


15

To a solution of 100mg (0.19 mmol) of carbamic
acid, [2R-hydroxy-3-[[[4-fluorophenyl)sulfonyl](2-
methylpropyl)amino]-1S-(phenylmethyl)propyl]-,
phenylmethyl ester in 1 mL of pyridine was added 53 μ L of
triethylamine and 120 μ L (p.95 mmol) of 40% aqueous
20 dimethylamine. After heating for 24 hours at 100 C, the
solution was cooled, ethyl acetate added, then washed
with 5% citric acid, saturated sodium bicarbonate, dried
over magnesium sulfate, filtered and concentrated. The
resulting solid was recrystallized from ethyl

25

acetate/hexane to afford 10 mg of the desired product;
mass spectrum m/e = 540 (M+H).

90

Example 13B

- 5 Preparation of Carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)aminol-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester

Part A:

- 10 A solution of N-benzyloxycarbonyl-3S-amino-1,2-S-epoxy-4-phenylbutane (50g, 0.168 mol) and isobutylamine (246g, 3.24 mol) in 650 mL of isopropyl alcohol was refluxed for 1.25 hours. The solution was cooled to room temperature, concentrated in vacuo and then poured into
- 15 1L of stirring hexane whereupon the product crystallized from solution, was collected and air dried to give 57.6 g of N-[3S-benzyloxycarbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine, mp 108-109.5 C, mass spectrum m/e=371(M+H).

20

Part B:

- The amine from part A (1.11g, 3.0 mmol) and triethylamine (324mg, 3.20 mmol) in 20 mL of methylene chloride was treated with 715 mg(3.46 mmol) of 4-
- 25 methoxybenzenesulfonyl chloride. The solution was stirred at room temperature for 6 hours, concentrated, dissolved in ethyl acetate, then washed with 1N potassium hydrogen sulfate, saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered and concentrated
- 30 to afford a clear oil. This was recrystallized from

91

diethyl ether to afford 1.27 g of carbamic acid, [2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, phenylmethyl ester, mp 97-101 C, mass spectrum m/e=541 (M+H).

Part C:

A solution of 930mg (3.20 mmol) of the product of part B in 30 mL of methanol was hydrogenated in the presence of 70 mg of a 10% palladium on carbon catalyst under 40 psig for 17 hours, the catalyst was removed by filtration, and the solution concentrated to afford 704 mg of [2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propylamine, mass spectrum m/e = 407 (M+H), which was used directly in the next step without purification.

Part D:

To a solution of 2.5g (22.9 mmol) of 3-pyridylcarbinol in 100 mL of anhydrous acetonitrile was added 8.8 g (34.4 mmol) of N,N'-disuccinimidyl carbonate and 5.55 mL (68.7 mmol) of pyridine. The solution was stirred for 1 hour and then concentrated in vacuo. The residue was dissolved in ethyl acetate, then washed with saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered and concentrated to afford 5.3 g of N-Hydroxysuccinimide-3-pyridylmethyl carbonate, mass spectrum m/e = 251 (M+H), which was used directly in the next step without purification.

Part E:


To a solution of the amine from part C (2.87g, 7.0 mmol) and 1.38 mL of triethylamine in 24 mL of anhydrous methylene chloride was added a solution of 1.65g (6.6 mmol) of N-hydroxysuccinimide-3-pyridyl carbonate

92

from part D in 24 mL of methylene chloride. The solution was stirred for 1 hour, 100 mL of methylene chloride added, then washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered and

5 concentrated to afford 3.69 g of crude product. Chromatography on silica gel using 2% methanol/methylene chloride to afford 3.27 g of carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester, mass

10 spectrum m/e = 548 (M+Li).

Example 13C

15

Preparation of Carbamic acid, [2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester

20 Part A:

A solution of N-benzyloxycarbonyl-3S-amino-1,2-S-epoxy-4-phenylbutane (50g, 0.168 mol) and isobutylamine (246g, 3.24 mol) in 650 mL of isopropyl alcohol was refluxed for 1.25 hours. The solution was cooled to room

25 temperature, concentrated in vacuo and then poured into 1L of stirring hexane whereupon the product crystallized from solution, was collected and air dried to give 57.6 g of N-[3S-benzyloxycarbonylamino-2R-hydroxy-4-phenyl]-N-isobutylamine, mp 108-109.5 C, mass spectrum

30 m/e=371(M+H).

93

Part B:

The amine from part A (0.94g, 2.5 mmol) and triethylamine (288 mg, 2.85 mmol) in 20 mL of methylene chloride was treated with 461 mg (2.61 mmol) of benzenesulfonyl chloride. The solution was stirred at room temperature for 16 hours, concentrated, dissolved in ethyl acetate, then washed with 1N potassium hydrogen sulfate, saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered and concentrated to afford a clear oil. This was recrystallized from diethyl ether and hexane to afford 0.73 g of carbamic acid, [2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, phenylmethyl ester, mp 95-99 C, mass spectrum m/e=511 (M+H).

Part C:


A solution of 500mg of carbamic acid, [2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, phenylmethyl ester in 20 mL of methanol was hydrogenated in the presence of 250 mg of a 10% palladium on carbon catalyst under 40 psig for 3 hours, the catalyst was removed by filtration, and the solution concentrated to afford 352 mg of [2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propylamine, mass spectrum m/e = 377 (M+H), which was used directly in the next step without purification.

30 Part D:

To a solution of 1.24 mmol of 5-norbornene-2,3-dicarboximido carbonochloridate (Henklein, P., et. al., Synthesis 1987, 166-167) in 1 mL of anhydrous methylene chloride, was added a solution of 43 μ L (2.44 mmol) of 3-pyridylcarbinol and 129 μ L (1.6 mmol) of pyridine in 1 mL

94

of methylene chloride at 0°C under a nitrogen atmosphere. After 4 hours at room temperature, 150 mg (0.4 mmol) of [2R-hydroxy-3-[(phenylsulfonyl)](2-methylpropyl)amino]-1S-(phenylmethyl)propylamine from Part C above was added and 100 µL of pyridine. After stirring for 15 hours at room temperature, ethyl acetate was added, then washed with 1N hydrochloric acid, saturated sodium bicarbonate, brine, dried over magnesium sulfate, filtered and concentrated to afford 175 mg of crude product. Chromatography over silica gel using 1% methanol/methylene chloride to afford 69 mg of pure carbamic acid, [2R-hydroxy-3-[(phenylsulfonyl)](2-methylpropyl)amino]-1S-(phenylmethyl)propyl-, 3-pyridylmethyl ester, mass spectrum m/e = 512.2267 (M+H); calcd for C₂₇H₃₃N₃O₅S, 512.2219.

Example 13D

20

Preparation of Carbamic acid, [2R-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester, N-oxide

25

To a solution of 211mg (0.39 mmol) of carbamic acid, [2R-hydroxy-3-[[[(4-methoxyphenyl)sulfonyl]](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester in 5mL of methylene chloride at 0°C was added 500 mg of 50% 3-chloroperbenzoic acid. After stirring at room temperature for 1 hour, ethyl acetate

30

95


was added, the solution washed with saturated sodium bicarbonate, 0.2N ammonium hydroxide solution and brine, dried over magnesium sulfate, filtered and concentrated to afford 200 mg of crude product. This was

5 chromatographed on C18 reverse phase material using 20-40% acetonitrile/water, then 100% acetonitrile to afford 90mg of the desired product, which was then recrystallized from ethyl acetate/isooctane to yield 34mg of pure carbamic acid, [2R-hydroxy-3-[[[4-

10 methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester, N-oxide; mass spectrum m/e=564 (M+Li).

Example 13E

15



Preparation of Carbamic acid, [2R-hydroxy-3-[[[4-

hydroxyphenyl)sulfonyl](2-methylpropyl)aminol-1S-

20 (phenylmethyl)propyl]-, 3-pyridylmethyl ester

Part A:

A solution of 0.98 g (1.85 mmol) of carbamic acid, [2R-hydroxy-3-[[[4-fluorophenyl)sulfonyl](2-

25 methylpropyl)amino]-1S-(phenylmethyl)propyl]-phenylmethyl ester in 3.8 mL of anhydrous DMF was added to 22mg (7.4 mmol) of 80% sodium hydride in 2 mL of DMF. To this mixture was added 0.40g (3.7 mmol) of benzyl alcohol. After 2 hours, the solution was cooled to 0 C, water

30 added, and then ethyl acetate. The organic layer was

96

washed with 5% citric acid, saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to afford 0.90g of crude material. This was chromatographed on basic alumina using 3%

- 5 methanol/methylene chloride to afford 0.70g of 2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine, cyclic carbamate; mass spectrum $m/e=509$ (M+H).

10 Part B:

- To a solution of 0.65g (1.28 mmol) of the cyclic carbamate from part A in 15 mL of ethanol, was added 2.6 mL (6.4 mmol) of 2.5N sodium hydroxide solution. After 1 hour at reflux, 4 mL of water was
15 added and the solution refluxed for an additional eight hours. The volatiles were removed, ethyl acetate added, and washed with water, brine, dried over magnesium sulfate, filtered and concentrated to afford 550 mg of crude 2R-hydroxy-3-[(2-methylpropyl)(4-
20 hydroxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine.


Part C:

- A solution of crude 2R-hydroxy-3-[(2-
25 methylpropyl)(4-benzyloxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine in 10 mL of ethanol was hydrogenated in the presence of 500 mg of a 10% palladium on carbon catalyst under 50 psig of hydrogen for 2 hours. The catalyst was removed by filtration and the solvent
30 removed in vacuo to afford 330 mg of 2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine, mass spectrum $m/e = 393$ (M+H).

Part D:

97

To a solution of 320 mg (0.82 mmol) of the amine from part C in 6 mL of DMF, was added 192 mg (0.76 mmol) of N-hydroxysuccinimide-3-pyridylmethyl carbonate. After 15 hours at room temperature, the DMF was removed in vacuo, ethyl acetate added, washed with water, brine, dried with magnesium sulfate, filtered and concentrated to afford 390 mg of crude material. Chromatography on silica gel using 50-80% ethyl acetate/hexane afforded 180 mg of carbamic acid, [2R-hydroxy-3-[[4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester, mass spectrum $m/e = 528(M+H)$.


Example 13F

Preparation of Carbamic acid, [2R-hydroxy-3-[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 5-pyrimidylmethyl ester

To a solution of 9.5mg (0.09mmol) of 5-pyrimidylcarbinol in 1mL of anhydrous acetonitrile at room temperature, was added 24mg (0.09mmol) of N,N'-disuccinimidyl carbonate and 19.1 μ L (0.24mmol) of pyridine. After stirring for 5 hours, 32 mg (0.08mmol) of 2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine was added and the solution stirred for 48 hours. After concentration in vacuo, methylene chloride was added,

98


then washed with a 1:1 mixture of saturated sodium bicarbonate and brine, dried over magnesium sulfate, filtered and concentrated to give 27 mg of crude product. Chromatography on silica gel using 2% methanol/methylene chloride afforded 22 mg of the desired product, mass spectrum $m/e=543 (M+H)$.

Example 14

Preparation of phenylmethyl[3-amino-1S-[[2R-hydroxy-3-[(3-propyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carbamate

Phenylmethyl[2R-hydroxy-3-[(3-propyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-carbamate (200 mg, 0.40 mmol) was deprotected by hydrogenation over 10% palladium on carbon and the resulting free amine was coupled with N-CBZ-L-asparagine (157 mg, 0.42 mmol) in the presence of N-hydroxybenzotriazole (114 mg, 0.84 mmol) and EDC (130 mg, 0.67 mmol) to give phenylmethyl[3-amino-1S-[[2R-hydroxy-3-[(3-propyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)amino]carbonyl]-3-oxopropyl]carbamate as a solid. Anal. Calcd for $C_{31}H_{38}N_4O_7S \cdot 0.2H_2O$: C, 60.61; H, 6.30; N, 9.12. Found: C, 60.27; H, 6.16; N, 8.93.

99

Example 15A

5

Preparation of N1-[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediarnide

10 Part A:

N2-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-asparagine was prepared from Boc-L-aspartic acid alpha-benzyl ester (1.0 g, 3.09mmol), methylamine.HCl (209 mg, 3.09mmol), EDC (711 mg, 3.7 mmol), 1-hydroxybenzotriazole (627 mg, 4.63 mmol), and N-methylmorpholine (0.7 mL, 6.3 mmol), in DMF (20mL). After stirring overnight at r.t., the reaction mixture was diluted with ethyl acetate, washed with water, sat. sodium bicarbonate, 5% citric acid, brine, dried over magnesium sulfate and concentrated to an oil. The oil was taken up in 20 mL dry ethanol, and hydrogenated in the presence of 10% w/w of 10% Pd on C at atmospheric pressure and room temperature overnight. The mixture was filtered through Celite and concentrated to a white solid foam, 670 mg.

25

Part B:

A solution of phenylmethyl [2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)-

100

propyl]carbamate (310 mg, 0.59 mmol) in methanol (10mL) was hydrogenated over 10% palladium on carbon for 3 h., filtered through diatomaceous earth and concentrated to give the product as an oil (214 mg). This free amine
5 (208 mg, 0.53 mmol) was coupled with N2-[(1,1-dimethylethoxy)-carbonyl]-N-methyl-L-asparagine (137 mg, 0.56 mmol) in the presence of N-hydroxybenzotriazole (102 mg, 0.76mmol) and EDC (130 mg, 0.67mmol) to yield 290 mg of N1[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)-
10 amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(1,1-dimethylethoxy-carbonyl)amino]butane diamide.

Part C:


N1[2R-hydroxy-3-[(3-methylbutyl)(phenyl-
15 sulfonyl)amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(1,1-dimethylethoxycarbonyl)-amino]butane diamide (270 mg, 0.43 mmol) was stirred in 4N HCl in dioxane (5 mL) at r.t. for 0.5 h. Solvent and excess reagent were evaporated to dryness. The product was dried in vacuo.
20 This material (125 mg, 0.225 mmol) was then reacted with 2-quinoline carboxylic acid N-hydroxysuccimide ester (61 mg, 0.225 mmol), N-methylmorpholine (50 uL, 0.45 mmol) in methylene chloride (2 mL) for 3 h. The product N1[2R-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-N4-
25 methyl-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylylcarbonyl)-amino]butane diamide was purified by silica gel chromatography. Anal. Calcd for C₃₆H₄₃N₅O₆S.0.2H₂O: C, 63.83; H, 6.45; N, 10.34. Found: C, 63.64; H, 6.40; N, 10.34.

101

Example 15B

Following the procedures set forth above, the following compound was also prepared:

5



Preparation of Carbamic acid, [3-[[2-hydroxy-3-[(3-methylbutyl)(phenylsulfonyl)amino]-1-(phenylmethyl)propyl]amino]-2-methyl-3-oxopropyl]-, (4-methoxyphenyl)methyl ester, [1S-[1R*(S*),2S*]]-

Thus, 4.10g, (7.8 mmol), of Carbamic acid, [2R-hydroxy-3-[(3-methylbutyl)(phenylsulphonyl)amino]-1S-(phenylmethyl)propyl]-, phenylmethyl ester, [R-(R*,S*)]- was hydrogenated in a solution of methanol and ethanol using catalytic Pd/C. 10% at 50 psig hydrogen for 3 hours. The catalyst was filtered and the solvents removed in vacuo to yield 3.0 grams of free amine.

20

In a separate flask, 2.09g, (7.8 mmol), of N-Moz-AMBA was added to 10 mL of dimethylformamide and 1.58g, (1.5 equiv.), of N-hydroxybenzotriazole and the solution was cooled to 5 degrees C. To this solution was added 1.49g, (7.8 mmol), of EDC and the solution stirred for 30 min. To this was added the free amine in 10 mL of dimethylformamide, and the reaction was stirred for 20 hours. The solvent was removed by evaporation and the crude material was partitioned between ethyl acetate and

25

102

saturated aqueous sodium bicarbonate. The ethyl acetate layer was washed with 5% potassium hydrogen sulfate and brine, dried over magnesium sulfate, filtered and concentrated to yield 2.58 grams of pure product after
 5 recrystallization from ethyl acetate, ether, and hexanes. 52% yield.

Example 16


10 Following the procedures of Examples 1-15, the compounds shown in Table 3 were prepared.





TABLE 3

15









Entry No.	R	R1	R3	R4
1	Cbz	t-Butyl	i-Amyl	Methyl
20 2	N,N-Dimethylglycine	t-Butyl	i-Amyl	Methyl
3	Cbz	i-Propyl	i-Amyl	Phenyl
4	Cbz	sec-Butyl	i-Amyl	Phenyl
5	Cbz	CH ₂ C(O)NH ₂	n-Propyl	Phenyl
6	N-Methylglycine	t-Butyl	i-Amyl	Phenyl
25 7	Cbz	t-Butyl	i-Butyl	Phenyl
8	N,N-Dimethylglycine	t-Butyl	i-Amyl	Phenyl
9	N-Methylglycine	t-Butyl	i-Amyl	Phenyl
10 10	N,N-Dimethylglycine	t-Butyl	i-Butyl	(4-OCH ₃) Phenyl
11 11	N-Methylglycine	t-Butyl	i-Butyl	(4-OCH ₃) Phenyl

TABLE 4











Entry	No.	R	R ³	R ⁴
10	1	Cbza	CH ₃	n-Butyl
	2	Cbz	i-Butyl	CH ₃
	3	Cbz	i-Butyl	n-Butyl
	4	Q ^b	i-Butyl	n-Butyl
	5	Cbz	i-Propyl	n-Butyl
15	6	Q	i-Propyl	n-Butyl
	7	Cbz	C ₆ H ₅	n-Butyl
	8	Cbz	-CH ₂ - 	n-Butyl
	9	Cbz	-CH ₂ - 	n-Butyl
20	10	Q	-CH ₂ - 	n-Butyl
	11	Cbz		n-Butyl
	12	Cbz	i-Butyl	n-Propyl

104
TABLE 4 (Cont'd.)

	Entry	No. R	R ³	R ⁴
5	13	Cbz	i-Butyl	-CH ₂ CH(CH ₃) ₂
	14	Cbz	(R)-CH(CH ₃)- 	n-Butyl
	15	Cbz	CH ₂ - 	i-Propyl
	16	Cbz	-CH ₂ - 	-CH ₂ CH ₂ CH(CH ₃) ₂
10	17	Cbz	i-Butyl	-CH ₂ CH ₃
	18	Cbz	i-Butyl	-CH(CH ₃) ₂
	19	Cbz	i-Butyl	
	20	Q	-Butyl	
	21	Cbz	-CH ₂ - 	-(CH ₂) ₂ CH(CH ₃) ₂
15	22	Cbz	(CH ₂) ₂ CH(CH ₃) ₂	-CH(CH ₃) ₂
	23	Q	i-Butyl	-CH(CH ₃) ₂
	24	Cbz	i-Butyl	-C(CH ₃) ₃
	25	Q	i-Butyl	-C(CH ₃) ₃
	26	Cbz	-CH ₂ - 	-C(CH ₃) ₃
20	27	Q	-CH ₂ - 	-C(CH ₃) ₃
	28	Cbz	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃
	29	Q	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃
	30	Cbz	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃
	31	Q	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃
25	32	Cbz	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃
	33	Cbz	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃
	34	Cbz	n-Butyl	-C(CH ₃) ₃








125

TABLE 4 (Cont'd.)

	Entry No.	R	R ³	R ⁴
5				
	35	Cbz	n-Pentyl	-C(CH ₃) ₃
	36	Cbz	n-Hexyl	-C(CH ₃) ₃
	37	Cbz	-CH ₂ - 	-C(CH ₃) ₃
	38	Cbz	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃
10	39	Q	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃
	40	Cbz	-CH ₂ CH ₂ -N 	-C(CH ₃) ₃
	41	Cbz	-CH ₂ C ₆ H ₅ OCH ₃ (para)	-C(CH ₃) ₃
	42	Cbz	-CH ₂ - 	-C(CH ₃) ₃
	43	Cbz	-CH ₂ - 	-C(CH ₃) ₃
15	44	Cbz	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃
	45	Q	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃
	46	Cbz	-(CH ₂) ₄ OH	-C(CH ₃) ₃
	47	Q	-(CH ₂) ₄ OH	-C(CH ₃) ₃
	48	Q	-CH ₂ -  -F	-C(CH ₃) ₃
20	49	Q	-CH ₂ - 	-C(CH ₃) ₃
	50	Cbz	-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	51		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	52	(CH ₃) ₂ N- 	-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅







106

TABLE 4 (Cont'd.)

Entry No.	R	R ³	R ⁴
5			
53		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
54		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
55		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
56		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
10 57		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
58		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
59		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅









107

TABLE 4 (Cont'd.)











Entry No.		R	R ³	R ⁴
5	60		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	61		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	62		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	63		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	64		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
10	65		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅

108

TABLE 4 (Cont'd.)















Entry No.		R	R ³	R ⁴
5	66		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	67		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	68		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	69		-CH ₂ CH(CH ₃) ₂	-C ₆ H ₅
	70	Q	-CH ₂ Ph	-Ph
10	71	Q	-CH ₂ - 	-Ph
	72	Q	-CH ₂ - 	-Ph
	73	Q	-CH ₂ - 	-Ph
	74	Q	-CH ₂ - 	-Ph

109
TABLE 4 (Cont'd.)


	Entry No.	R	R ³	R ⁴
5	75	Q	$-\text{CH}_2-$ 	-Ph
	76	Q	$-\text{CH}_2\text{CH}=\text{CH}_2$	-Ph
	77	Q		-Ph
	78	Q		-Ph
10	79	Q	$-\text{CH}_2\text{CH}_2\text{Ph}$	-Ph
	80	Q	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$	-Ph
	81	Q	$-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$	-Ph
	82	Q	$-\text{CH}_2\text{CH}_2-\text{N}$ 	-Ph
	83	Q	$-\text{CH}_3$	-Ph
15	84	Q	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{SCH}_3$	-Ph
	85	Q	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{S}(\text{O})_2\text{CH}_3$	-Ph
	86	Q	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	
	87	Q	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	$-\text{CH}_2-$ 
	88	Q	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	$-\text{CH}_2\text{CH}_2\text{CH}_3$
20	89	Q	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	$-\text{CH}_3$
	90	Q	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	
	91	Q	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	
	92	Q	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	
	93	Q	$-\text{CH}_2\text{CH}_2\text{CH}(\text{CH}_3)_2$	


110

TABLE 4 (Cont'd.)

Entry No.	R	R ³	R ⁴
5			
94	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
95	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
96	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
97	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
10	98	Q	- 
99	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
100	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
101	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
102	Q	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
15	103	-CH ₂ CH(CH ₃) ₂	- 
104	Q	-CH ₂ CH(CH ₃) ₂	- 
105	Q	-CH ₂ CH(CH ₃) ₂	- 
106	Q	-CH ₂ CH ₂ CH ₃	- 
107	Q	-CH ₂ CH ₂ CH ₂ CH ₃	- 
20	a benzyloxycarbonyl		
	b 2-quinolinylcarbonyl		

///
TABLE 5



Entry	A	R ³	R ⁴
1	Cbz-Val	<i>i</i> -amyl	-C ₆ H ₅
2	Cbz-Leu	<i>i</i> -amyl	-C ₆ H ₅
3	Cbz-Ile	<i>i</i> -amyl	-C ₆ H ₅
4	Ac-D-homo-Phe	<i>i</i> -Bu	methyl
5	Qui-Orn(g-Cbz)	-CH ₂ - 	-C ₆ H ₅
6	Cbz-Asn	-CH ₂ CH=CH ₂	-C ₆ H ₅
7	Acetyl-t-BuGly	<i>i</i> -amyl	-C ₆ H ₅
8	Acetyl-Phe	<i>i</i> -amyl	-C ₆ H ₅
9	Acetyl-Ile	<i>i</i> -amyl	-C ₆ H ₅
10	Acetyl-Leu	<i>i</i> -amyl	-C ₆ H ₅
11	Acetyl-His	<i>i</i> -amyl	-C ₆ H ₅
12	Acetyl-Thr	<i>i</i> -amyl	-C ₆ H ₅
13	Acetyl-NHCH(C(CH ₃) ₂ (SCH ₃))C(O)-	<i>i</i> -amyl	-C ₆ H ₅
14	Cbz-Asn	<i>i</i> -amyl	-C ₆ H ₅
15	Cbz-Ala	<i>i</i> -amyl	-C ₆ H ₅
16	(N,N-dimethylglyciny1)Val	<i>i</i> -amyl	-C ₆ H ₅
17	(N-methylglyciny1)Val	<i>i</i> -amyl	-C ₆ H ₅
18	(N,N-dimethylglyciny1)Ile	<i>i</i> -amyl	-C ₆ H ₅
19	(N-methylglyciny1)Ile	<i>i</i> -amyl	-C ₆ H ₅


112

TABLE 5 (Cont'd)

Entry	A	R ³	R ⁴
20	Cbz-Ala	<i>i</i> -amyl	-C ₆ H ₅
21	Cbz-beta-cyanoAla	<i>i</i> -amyl	-C ₆ H ₅
22	Cbz-t-BuGly	<i>i</i> -amyl	-C ₆ H ₅
23	Q-t-BuGly	<i>i</i> -amyl	-C ₆ H ₅
24	Q-SCH ₃ Cys	<i>i</i> -amyl	-C ₆ H ₅
25	Cbz-SCH ₃ Cys	<i>i</i> -amyl	-C ₆ H ₅
26	Q-Asp	<i>i</i> -amyl	-C ₆ H ₅
27	Cbz-(NHCH(C(CH ₃) ₂ (SCH ₃))C(O)-	<i>i</i> -amyl	-C ₆ H ₅
28	Cbz-EtGly	<i>i</i> -amyl	-C ₆ H ₅
29	Cbz-PrGly	<i>i</i> -amyl	-C ₆ H ₅
30	Cbz-Thr	<i>i</i> -amyl	-C ₆ H ₅
31	Q-Phe	<i>i</i> -amyl	-C ₆ H ₅
32	Cbz-Phe	<i>i</i> -amyl	-C ₆ H ₅
33	CH ₂ =CHCH ₂ O)C=O)	<i>i</i> -Butyl	-C ₆ H ₅ (4-OCH ₃)

113
TABLE 5A

Entry




MASS MEASUREMENT

	R ³	R ⁴	R ⁷	MOL FORM	CALC M+H	FOUND
1				C ₂₇ H ₃₈ N ₂ O ₅ S	503.2661	503.2624
2				C ₂₈ H ₄₀ N ₂ O ₅ S	517.2736	517.2777
3				C ₂₉ H ₄₂ N ₂ O ₅ S	531.2893	531.2916
4				C ₃₂ H ₄₀ N ₂ O ₅ S	565.2736	565.2731
5				C ₃₀ H ₃₅ N ₃ O ₅ S	550.2376	550.2427

114
TABLE 5A (Cont'd)

Entry




Entry	R ³	R ⁴	R ⁷	MASS MEASUREMENT		
				MOL FORM	CALC	FOUND
6	CH ₂ -CH(CH ₃) ₂			C ₃₀ H ₃₈ N ₂ O ₅ S	539(M+H)	539
7				C ₂₉ H ₃₆ N ₂ O ₅ S	?	?
8				C ₃₀ H ₃₈ N ₂ O ₅ S	539.2580 (M+H)	539.2591

116

TABLE 5A (Cont'd)

Entry




MASS MEASUREMENT

	R ³	R ⁴	R ⁷	MOL FORM	CALC (M+H)	FOUND
9				C ₂₇ H ₃₃ N ₃ O ₅ S	512.2219	512.2271
10				C ₂₈ H ₃₅ N ₃ O ₅ S	526.2376	526.2388
11				C ₂₇ H ₃₃ N ₃ O ₅ S	512.2219	512.2287
12				C ₂₈ H ₃₃ N ₂ O ₅ ClS	545.1877	545.1887
13				C ₃₀ H ₃₈ N ₂ O ₅ S	539.2580	539.2592
14				C ₃₁ H ₄₀ N ₂ O ₅ S	553.2736	553.2714
15				C ₃₀ H ₃₈ N ₂ O ₅ S	539.2580	539.2632
16				C ₃₀ H ₃₈ N ₂ O ₅ S	539 (M+H)	539

116

TABLE 5A (Cont'd)

Entry




MASS MEASUREMENT

	R ³	R ⁴	R ⁷	MOL FORM	CALC	FOUND
17				C ₂₉ H ₃₆ N ₂ O ₇ S ₂	589.2042 (M+H)	589.2086
18				C ₂₉ H ₃₆ N ₂ O ₇ S ₂	595.2124 (M+Li)	595.2103
19				C ₂₉ H ₃₆ N ₂ O ₇ S ₂	595.2124 (M+Li)	595.2191
20				C ₃₀ H ₃₈ N ₂ O ₇ S ₂	609.2281 (M+Li)	609.2313
21				C ₃₀ H ₃₈ N ₂ O ₇ S ₂	603.2199 (M+H)	603.2247
22				C ₃₀ H ₃₈ N ₂ O ₇ S ₂	603.2199 (M+H)	603.2266

117

TABLE 5A (Cont'd)

Entry



EXACT MASS MEASUREMENT

	R ³	R ⁴	R ⁷	MOL FORM	CALC (M+H)	FOUND
23						
24				C ₂₇ H ₃₂ N ₂ O ₄ S	481.2161	481.2213
25				C ₂₈ H ₃₅ N ₂ O ₅ S	511.2267	511.2319
26				C ₂₉ H ₃₆ N ₂ O ₅ S	525.2423	525.2469
27				C ₂₉ H ₃₆ N ₂ O ₅ S	525.2428	525.2464
28				C ₂₉ H ₃₆ N ₂ O ₅ S	525.2423	525.2432
29				C ₂₉ H ₃₆ N ₂ O ₆ S	541.2372	541.2332
30				C ₂₉ H ₃₆ N ₂ O ₆ S	541.2372	541.2355
31				C ₂₉ H ₃₆ N ₂ O ₆ S	541.2372	541.2329

118

TABLE 5B

Table	Entry	IC ₅₀ (uM) or % inhibition
1A	3	0.02
5A	1	0.04
5A	3	0.02
5A	4	0.01
5A	5	0.026
5A	6	0.023
5A	7	0.007
5A	9	0.067
5A	11	0.018
5A	12	0.006
5A	13	0.0098
5A	14	0.049
5A	16	0.008
5A	17	59% @ 10μM
5A	18	0.13
5A	19	0.092
5A	20	85% @ 1μM
5A	22	63% @ 1μM
5A	24	0.047


119

TABLE 5B (cont'd)

Table	Entry	IC ₅₀ (uM) or % inhibition
5A	25	0.014
5A	26	0.005
5A	28	0.015
5A	29	0.19
5A	30	0.03
5A	31	0.02

120

TABLE 6




Entry

R¹

1	CH ₂ SO ₂ CH ₃
2	(R) -CH(OH)CH ₃
3	CH(CH ₃) ₂
4	(R, S)CH ₂ SOCH ₃
5	CH ₂ SO ₂ NH ₂
6	CH ₂ SCH ₃
7	CH ₂ CH(CH ₃) ₂
8	CH ₂ CH ₂ C(O)NH ₂
9	(S) -CH(OH)CH ₃
10	-CH ₂ C≡C-H

121

TABLE 7








Entry	R ²	A
1	n-Bu	Cbz-Asn
2	cyclohexylmethyl	Cbz-Asn
3	n-Bu	Boc
4	n-Bu	Cbz
5	C ₆ H ₅ CH ₂	Boc
6	P-F-C ₆ H ₅ CH ₂	Cbz
7	C ₆ H ₅ CH ₂	benzoyl
8	cyclohexylmethyl	Cbz
9	n-Bu	Q-Asn
10	cyclohexylmethyl	Q-Asn
11	C ₆ H ₅ CH ₂	Cbz-Ile
12	C ₆ H ₅ CH ₂	Q-Ile
13	P-F-C ₆ H ₅ CH ₂	Cbz-t-BuGly
14	C ₆ H ₅ CH ₂	Q-t-BuGly
15	C ₆ H ₅ CH ₂	Cbz-Val
16	C ₆ H ₅ CH ₂	Q-Val
17	2-naphthylmethyl	Cbz-Asn
18	2-naphthylmethyl	Q-Asn
19	2-naphthylmethyl	Cbz
20	n-Bu	Cbz-Val
21	n-Bu	Q-Val
22	n-Bu	Q-Ile
23	n-Bu	Cbz-t-BuGly


/22

TABLE 7 (Cont'd)

Entry	R ²	A
24	n-Bu	Q-t-BuGly
25	p-F (C ₆ H ₄) CH ₂	Q-Asn
26	p-F (C ₆ H ₄) CH ₂	Cbz
27	p-F (C ₆ H ₄) CH ₂	Cbz-Asn
28	C ₆ H ₅ CH ₂	Cbz-propargylglycine
29	C ₆ H ₅ CH ₂	Q-propargylglycine
30	C ₆ H ₅ CH ₂	
acetylpropargylglycine		

/ 28
TABLE 8

Entry	R ³	R ⁴
1	-CH ₂ CH(CH ₃) ₂	-C(CH ₃) ₂
2	-CH ₂ CH ₂ CH(CH ₃) ₂	
3	-CH ₂ CH ₂ CH(CH ₃) ₂	
4	-CH ₂ CH ₂ CH(CH ₃) ₂	
5	-CH ₂ CH ₂ CH(CH ₃) ₂	


124
TABLE 9

Entry


R

R¹


1

-CH₃


2

-CH₃


3

-CH(CH₃)₂


4

-CH(CH₃)₂


5

-C(CH₃)₃


6

-CH₃

7

-CH₃

125
Table 9 (Cont'd)


Entry	R	R ¹
8	$\text{HO}_2\text{CCH}_2\text{CH}_2\text{-C}(=\text{O})\text{-}$	-CH ₃
9		-CH ₃
10	$\text{CH}_3\text{NH-C}(=\text{O})\text{-}$	-CH ₃
11	$(\text{CH}_3)_2\text{CH-C}(=\text{O})\text{-}$	-CH ₃
12	$\text{CH}_3\text{OCH}_2\text{-C}(=\text{O})\text{-}$	-CH ₃
13	$(\text{CH}_3)_2\text{NCH}_2\text{-C}(=\text{O})\text{-}$	-CH ₃
14	$\text{CH}_3\text{CH}(\text{OH})\text{-C}(=\text{O})\text{-}$	-CH ₃

126


TABLE 9 (Cont'd)

Entry


15




16



127
TABLE 10




Entry	R ¹	R ^{1'}	R ^{1''}	R
1	H	H	H	
2	H	H	H	
3	H	CH ₃	H	
4	H	CH ₃	CH ₃	
5	H	H	CO ₂ CH ₃	
6	H	H	H	
7	H	H	H	
8	H	H	CONH ₂	Cbz
9	H	H	CONH ₂	2-quinolinylcarbonyl

¹²⁸
TABLE 11


Entry	R	R'	X
1	R=H	R'=H	X=H
2	R=Me	R'=Me	X=H
3	R=H	R'=Me	X=H
4	R=Me	R'=Me	X=F
5	R=H	R'=Me	X=F
6	R=Cbz	R'=Me	X=H
7	R=H	R'=Bz	X=H
8	R+R'=pyrrole		X=H

129
TABLE 12










Entry	Acyl Group (R)
1	benzyloxycarbonyl
2	<u>tert</u> -butoxycarbonyl
3	acetyl
4	2-quinoylcarbonyl
5	phenoxyacetyl
6	benzoyl
7	methyloxaloyl
8	pivaloyl
9	trifluoracetyl
10	bromoacetyl
11	hydroxyacetyl
12	morpholinylacetyl
13	N,N-dimethylaminoacetyl
14	N-benzylaminoacetyl
15	N-phenylaminoacetyl
16	N-benzyl-N-methylaminoacetyl
17	N-methyl-N-(2-hydroxyethyl)aminoacetyl
18	N-methylcarbamoyl
19	3-methylbutyryl
20	N-isobutylcarbamoyl
21	succinoyl (3-carboxypropionyl)
22	carbamoyl
23	N-(2-indanyl)aminoacetyl

130
TABLE 13














Entry	R ³	R ⁴
1	-CH ₃	-n-Butyl
2	-i-Butyl	-CH ₃
3	-i-Butyl	-n-Butyl
4	-i-Propyl	-n-Butyl
5	-C ₆ H ₅	-n-Butyl
6	-CH ₂ -	-n-Butyl
7	-CH ₂ -	-n-Butyl
8		-n-Butyl
9	-i-Butyl	-n-Propyl
10	-i-Butyl	-CH ₂ CH(CH ₃) ₂
11	-(R)-CH(CH ₃)-	-n-Butyl
12	-CH ₂ -	-i-Propyl
13	-CH ₂ -	-CH ₂ CH ₂ CH(CH ₃) ₂
14	i-Butyl	-CH ₂ CH ₃
15	i-Butyl	-CH(CH ₃) ₂
16	i-Butyl	













131
TABLE 13 (Cont'd)

Entry	R ³	R ⁴
17	-CH ₂ - 	-(CH ₂) ₂ CH(CH ₃) ₂
18	(CH ₂) ₂ CH(CH ₃) ₂	-CH(CH ₃) ₂
19	i-Butyl	-CH(CH ₃) ₂
20	i-Butyl	-C(CH ₃) ₃
21	-CH ₂ - 	-C(CH ₃) ₃
22	-(CH ₂) ₂ CH(CH ₃) ₂	-C(CH ₃) ₃
23	-CH ₂ C ₆ H ₅	-C(CH ₃) ₃
24	-(CH ₂) ₂ C ₆ H ₅	-C(CH ₃) ₃
25	n-Butyl	-C(CH ₃) ₃
26	n-Pentyl	-C(CH ₃) ₃
27	n-Hexyl	-C(CH ₃) ₃
28	-CH ₂ - 	-C(CH ₃) ₃
29	-CH ₂ C(CH ₃) ₃	-C(CH ₃) ₃
30	-CH ₂ CH ₂ -N 	-C(CH ₃) ₃
31	-CH ₂ C ₆ H ₅ OCH ₃ (para)	-C(CH ₃) ₃
32	-CH ₂ - 	-C(CH ₃) ₃
33	-CH ₂ - 	-C(CH ₃) ₃
34	-(CH ₂) ₂ C(CH ₃) ₃	-C(CH ₃) ₃
35	-(CH ₂) ₄ OH	-C(CH ₃) ₃
36	-CH ₂ - 	-C(CH ₃) ₃









132
TABLE 13 (Cont'd)

Entry	R ³	R ⁴
37	$-\text{CH}_2-$ 	$-\text{C}(\text{CH}_3)_3$
38	$-\text{CH}_2\text{CH}(\text{CH}_3)_2$	$-\text{C}_6\text{H}_5$
39	i-amyl	$-\text{CH}_2\text{C}(\text{CH}_3)_3$
40		$-\text{CH}_2\text{C}(\text{CH}_3)_3$
41	CH_3- 	$-\text{CH}_2\text{C}(\text{CH}_3)_3$
42	i-butyl	$-\text{CH}_2\text{C}(\text{CH}_3)_3$
43	$-\text{CH}_2\text{Ph}$	$-\text{Ph}$
44	$-\text{CH}_2-$ 	$-\text{Ph}$
45	$-\text{CH}_2-$ 	$-\text{Ph}$
46	$-\text{CH}_2-$ 	$-\text{Ph}$
47	$-\text{CH}_2-$ 	$-\text{Ph}$
48	$-\text{CH}_2-$ 	$-\text{Ph}$
49	$-\text{CH}_2\text{CH}=\text{CH}_2$	$-\text{Ph}$
50		$-\text{Ph}$
51		$-\text{Ph}$
52	$-\text{CH}_2\text{CH}_2\text{Ph}$	$-\text{Ph}$
53	$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$	$-\text{Ph}$
54	$-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$	$-\text{Ph}$
55	$-\text{CH}_2\text{CH}_2-\text{N}$ 	$-\text{Ph}$
56	$-\text{CH}_3$	$-\text{Ph}$

/ 23
TABLE 13 (Cont'd)

Entry	R ³	R ⁴
57	-CH ₂ CH ₂ CH ₂ SCH ₃	-Ph
58	-CH ₂ CH ₂ CH ₂ S(O) ₂ CH ₃	-Ph
59	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
60	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₂ - 
61	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₂ CH ₂ CH ₃
62	-CH ₂ CH ₂ CH(CH ₃) ₂	-CH ₃
63	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -F
64	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
65	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -NO ₂
66	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
67	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -OCH ₃
68	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
69	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
70	-CH ₂ CH ₂ CH(CH ₃) ₂	- 
71	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -NHAc
72	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -Cl


134
TABLE 13 (Cont'd.)


Entry	R ³	R ⁴
73	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -CH ₃
74	-CH ₂ CH ₂ CH(CH ₃) ₂	-  -CO ₂ CH ₃
75	-CH ₂ CH(CH ₃) ₂	- 
76	-CH ₂ CH(CH ₃) ₂	-  -F
77	-CH ₂ CH(CH ₃) ₂	-  -NHAc
78	-CH ₂ CH(CH ₃) ₂	-  -CH ₃
79	-CH ₂ CH ₂ CH ₃	-  -OCH ₃
80	-CH ₂ CH ₂ CH ₂ CH ₃	-  -OCH ₃

a benzyloxycarbonyl


b 2-quinolinylcarbonyl

135
Table 14



Entry	R ¹	R ³
1	C(CH ₃) ₃	CH ₂ CH ₂ CH(CH ₃) ₂
2	CH ₂ C≡CH	CH ₂ CH ₂ CH(CH ₃) ₂
3	C(CH ₃) ₂ (SCH ₃)	CH ₂ CH ₂ CH(CH ₃) ₂
4	C(CH ₃) ₂ (S[O]CH ₃)	CH ₂ CH ₂ CH(CH ₃) ₂
5	C(CH ₃) ₂ (S[O] ₂ CH ₃)	CH ₂ CH ₂ CH(CH ₃) ₂
6	C(CH ₃) ₃	CH ₂ CH(CH ₃) ₂
7	C(CH ₃) ₃	
8	CH(CH ₃) ₂	CH ₂ CH(CH ₃) ₂
9	CH(CH ₂ CH ₃)(CH ₃)	CH ₂ CH(CH ₃) ₂

Entry



Example 17

The compounds of the present invention are effective HIV protease inhibitors. Utilizing an enzyme assay as described below, the compounds set forth in the examples herein disclosed inhibited the HIV enzyme. The preferred compounds of the present invention and their calculated IC₅₀ (inhibiting concentration 50%, i.e., the concentration at which the inhibitor compound reduces enzyme activity by 50%) values are shown in Table 16. The enzyme method is described below. The substrate is 2-Ile-Nle-Phe(p-NO₂)-Gln-ArgNH₂. The positive control is MVT-101 (Miller, M. et al, Science, 246, 1149 (1989))

The assay conditions are as follows:

Assay buffer: 20 mM sodium phosphate, pH 6.4
20% glycerol
1 mM EDTA
1 mM DTT
0.1% CHAPS

The above described substrate is dissolved in DMSO, then diluted 10 fold in assay buffer. Final substrate concentration in the assay is 80 μM.

HIV protease is diluted in the assay buffer to a final enzyme concentration of 12.3 nanomolar, based on a molecular weight of 10,780.

The final concentration of DMSO is 14% and the final concentration of glycerol is 18%. The test compound is dissolved in DMSO and diluted in DMSO to 10x the test concentration; 10μl of the enzyme preparation is added, the materials mixed and then the mixture is incubated at ambient temperature for 15 minutes. The enzyme reaction is initiated by the addition of 40μl of substrate. The increase in fluorescence is monitored at 4 time points (0, 8, 16 and 24 minutes) at ambient

138


temperature. Each assay is carried out in duplicate wells.

The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.

10

TABLE 15A

Entry	Compound	IC ₅₀ (nanomolar)
-------	----------	------------------------------







20

139

TABLE 15A (Cont'd)

5	Entry	Compound	IC ₅₀ (nanomolar)
	4		27
	5		19
	6		10
10	7		3.6

140
TABLE 15A (Cont'd)

Entry	Compound	IC ₅₀ (nanomolar)
5		
8		4.2
9		3.5
10		100
11		81

141

TABLE 15A (Cont'd)

Entry	Compound	IC ₅₀ (nanomolar)
-------	----------	------------------------------




TABLE 15B

	Ex.	Table	Entry	IC ₅₀ (uM) or % inhib
10				
15	6	1a	1	0.011
	6	1a	2	0.010
20	6 uM	1a	3	38% @ 1 uM, 79% @ 10
	6	1a	4	0.016
25	6	1a	5	0.10
	6	1a	6	36% @ 10 uM
	6	1a	7	0.0096
30	6	1a	39	0.016
	6	1a	40	0.21
35	6 uM	1a	41	24% @ 1uM, 74% @ 10
	6 uM	1a	50	42% @ 1uM, 89% @ 10

142

	6 uM	1a	51	31% @ 1uM, 76% @ 10
5	6 uM	1a	52	39% @ 1 uM, 81% @ 10
	6	1a	53	0.049
	6	1a	54	0.0028
10	6	1a	55	0.10
	6	1a	56	0.0036
15	16	3	1	0.081
	16 1.0 uM	3	2	38% @ 0.1 uM, 90% @
20	16	3	4	0.0024
	16	3	6	0.0018
	16	3	8	0.003
25	16	3	10	0.0025
	16	3	12	0.0016
30	16	4	102	0.0015
	16	5	1	0.0014
	16	5	14	0.0022
35	16	5	22	0.0018
	16	5	33	0.0044
40	16	5	34	0.0020
	16	7	31	0.0028
45	16	7	32	0.0015

143

	16	11	1	0.13
	16	11	9	41% @ 0.1 μ M, 86% @ 1
5	μ M			
	16	12	10	0.0033
	16	14	3	0.0049
10	16	14	10	0.0032

Example 18

15

The effectiveness of the compounds listed in Table 15 were determined in the above-described enzyme assay and in a CEM cell assay.

20

The HIV inhibition assay method of acutely infected cells is an automated tetrazolium based colorimetric assay essentially that reported by Pauwles et al, J. Virol. Methods, 20, 309-321 (1988). Assays were performed in 96-well tissue culture plates. CEM

25 cells, a CD4⁺ cell line, were grown in RPMI-1640 medium (Gibco) supplemented with a 10% fetal calf serum and were then treated with polybrene (2 μ g/ml). An 80 μ l volume of medium containing 1×10^4 cells was dispensed into each well of the tissue culture plate. To each well was added

30 a 100 μ l volume of test compound dissolved in tissue culture medium (or medium without test compound as a control) to achieve the desired final concentration and the cells were incubated at 37°C for 1 hour. A frozen culture of HIV-1 was diluted in culture medium to a

35 concentration of 5×10^4 TCID₅₀ per ml (TCID₅₀ = the dose of virus that infects 50% of cells in tissue culture), and a 20 μ L volume of the virus sample (containing 1000 TCID₅₀ of virus) was added to wells containing test compound and to wells containing only medium (infected

40 control cells). Several wells received culture medium

144

without virus (uninfected control cells). Likewise, the intrinsic toxicity of the test compound was determined by adding medium without virus to several wells containing test compound. In summary, the tissue culture plates
5 contained the following experiments:

	Cells	Drug	Virus
10	1. +	-	-
	2. +	+	-
	3. +	-	+
	4. +	+	+

15 In experiments 2 and 4 the final concentrations of test compounds were 1, 10, 100 and 500 µg/ml. Either azidothymidine (AZT) or dideoxyinosine (ddI) was included as a positive drug control. Test compounds were dissolved in DMSO and diluted into tissue culture medium
20 so that the final DMSO concentration did not exceed 1.5% in any case. DMSO was added to all control wells at an appropriate concentration.

25 Following the addition of virus, cells were incubated at 37°C in a humidified, 5% CO₂ atmosphere for 7 days. Test compounds could be added on days 0, 2 and 5 if desired. On day 7, post-infection, the cells in each well were resuspended and a 100µl sample of each cell suspension was removed for assay. A 20µL volume of a 5
30 mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each 100µL cell suspension, and the cells were incubated for 4 hours at 27°C in a 5% CO₂ environment. During this incubation, MTT is metabolically reduced by living cells resulting in
35 the production in the cell of a colored formazan product. To each sample was added 100µl of 10% sodium dodecylsulfate in 0.01 N HCl to lyse the cells, and samples were incubated overnight. The absorbance at 590 nm was determined for each sample using a Molecular




145

Devices microplate reader. Absorbance values for each set of wells is compared to assess viral control infection, uninfected control cell response as well as test compound by cytotoxicity and antiviral efficacy.






5

TABLE 16

10





Entry	Compound	IC ₅₀ (nm)	EC ₅₀ (nm)	TD ₅₀ (nm)
1		16	55	27
2		1	5	203
3		1	11	780

146
TABLE 16 (Cont'd)

Entry	Compound	IC ₅₀	EC ₅₀	TD ₅₀
		(nM)	(nM)	(nM)
4		27	64	28
5		19	88	11
6		>100	380	425
7		3	25	39
8		85	1200	24





147

TABLE 16 (Cont'd)

Entry	Compound	IC ₅₀ (nm)	EC ₅₀ (nm)	TD ₅₀ (nm)
5				
9		53	398	15
10		45	700	12
11		3	11	54
10	12 	2	12	7.5






148

TABLE 16 (Cont'd)

Entry	Compound	IC ₅₀	EC ₅₀	TD ₅₀
		(nM)	(nM)	(nM)
13		3	<16	
14		4	15	55,000
15		5	38	
16		9	80	62,000

149

TABLE 16 (Cont'd)

Entry	Compound	IC50	EC50	TD50
		(nM)	(nM)	(nM)
17		4	5	59,000
18		4		
19		8		
20		4		
21		73		

150

TABLE 16 (Cont'd)






5	Entry	Compound	IC ₅₀ (nm)	EC ₅₀ (nm)	TD ₅₀ (nm)
	22		15	18	31,000
	23		2		
	24		3		
	25		60	120	167,000
10	26				

TABLE 16 (Cont'd)





Entry	Compound	IC ₅₀ (nm)	EC ₅₀ (nm)	TD ₅₀ (nm)
5				
27		5	177	300,000
28		14	76	213,000
29		5	105	196,000
30		6	154	154,000


TABLE 16 (Cont'd)

Entry	Compound	IC ₅₀ (nm)	EC ₅₀ (nm)	TD ₅₀ (nm)
31		10		
32		5	98	17,000
33		18	68	
34		67	188	

153
TABLE 16 (Cont'd)

Entry	Compound	IC ₅₀ (nm)	EC ₅₀ (nm)	TD ₅₀ (nm)
-------	----------	--------------------------	--------------------------	--------------------------

5



10 The compounds of the present invention are effective antiviral compounds and, in particular, are effective retroviral inhibitors as shown above. Thus, the subject compounds are effective HIV protease inhibitors. It is contemplated that the subject

15 compounds will also inhibit other retroviruses such as other lentiviruses in particular other strains of HIV, e.g. HIV-2, human T-cell leukemia virus, respiratory syncytial virus, simia immunodeficiency virus, feline leukemia virus, feline immuno-deficiency virus,

20 hepadnavirus, cytomegalovirus and picornavirus. Thus, the subject compounds are effective in the treatment and/or prophylaxis of retroviral infections.

25 Compounds of the present invention can possess one or more asymmetric carbon atoms and are thus capable of existing in the form of optical isomers as well as in the form of racemic or nonracemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, for

30 example by formation of diastereoisomeric salts by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric

154

and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of Formula I with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of Formula I can likewise be obtained by utilizing optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.

The compounds of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate, lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, palmoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, mesylate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates,

155

long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.

5

Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

15

Total daily dose administered to a host in single or divided doses may be in amounts, for example, from 0.001 to 10 mg/kg body weight daily and more usually 0.01 to 1 mg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.

20

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

25

The dosage regimen for treating a disease condition with the compounds and/or compositions of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex, diet and medical condition of the patient, the severity of the disease, the route of administration, pharmacological considerations such as the activity, efficacy, pharmacokinetic and toxicology profiles of the particular compound employed, whether a drug delivery system is utilized and whether the compound is administered as part of a drug combination. Thus, the dosage regimen actually employed may vary widely and therefore may deviate from

30

35

156

the preferred dosage regimen set forth above.

The compounds of the present invention may be administered orally, parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

157

Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose
5 lactose or starch. Such dosage forms may also comprise, as in normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering
10 agents. Tablets and pills can additionally be prepared with enteric coatings.

Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions,
15 suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

20

While the compounds of the invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more immunomodulators, antiviral agents or other antiinfective
25 agents. For example, the compounds of the invention can be administered in combination with AZT, DDI, DDC or with glucosidase inhibitors, such as N-butyl-1-deoxynojirimycin or prodrugs thereof, for the prophylaxis and/or treatment of AIDS. When administered as a
30 combination, the therapeutic agents can be formulated as separate compositions which are given at the same time or different times, or the therapeutic agents can be given as a single composition.

35 The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be


within the scope and nature of the invention which are defined in the appended claims.

From the foregoing description, one skilled in
5 the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

159

WHAT IS CLAIMED IS:

1. A compound represented by the formula:



or a pharmaceutically acceptable salt, prodrug or ester thereof wherein:

- 10 R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl,
- 15 heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl,
- 20 aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl,
- 25 heterocycloalkyl radicals, or wherein said aminocarbonyl and aminoalkanoyl radicals are disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
- 30 R' represents hydrogen and radicals as defined for R³ or R"SO₂- wherein R" represents radicals as defined for R³; or R and R' together with the nitrogen to which they are

160

attached represent heterocycloalkyl and heteroaryl radical;

5 R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃,
-CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),
-C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl,
alkenyl, alkynyl and cycloalkyl radicals, and amino acid
side chains selected from asparagine, S-methyl cysteine
and the sulfoxide (SO) and sulfone (SO₂) derivatives
10 thereof, isoleucine, allo-isoleucine, alanine, leucine,
tert-leucine, phenylalanine, ornithine, histidine,
norleucine, glutamine, threonine, glycine, allo-
threonine, serine, O-alkyl serine, aspartic acid, beta-
cyano alanine and valine side chains;

15 R^{1'} and R^{1''} independently represent hydrogen and radicals
as defined for R¹, or one of R^{1'} and R^{1''}, together with
R¹ and the carbon atoms to which R¹, R^{1'} and R^{1''} are
attached, represent a cycloalkyl radical;

20 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
and aralkyl radicals, which radicals are optionally
substituted with a group selected from alkyl and halogen
radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹

25 represents hydrogen and alkyl radicals;

R³ represents hydrogen, alkyl, haloalkyl, alkenyl,
alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl,
cycloalkylalkyl, heterocycloalkyl, heteroaryl,
30 heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl,
aminoalkyl and mono- and disubstituted aminoalkyl
radicals, wherein said substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl, and
35 heterocycloalkylalkyl radicals, or in the case of a
disubstituted aminoalkyl radical, said substituents along

/6/

with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical;

5 R^4 represents radicals as defined by R^3 except for hydrogen;


R^6 represents hydrogen and alkyl radicals;

10 x represents 0, 1, or 2;

t represents either 0 or 1; and

15 Y represents O, S and NR^{15} wherein R^{15} represents hydrogen and radicals as defined for R^3 .

2. Compound represented by the formula:



20 wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, 25 aralkanoyl, aroyl, aryloxy carbonyl, aryloxy carbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxy carbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy carbonyl, 30 heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from

162

alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents
5 along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;

R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are
10 attached represent heterocycloalkyl and heteroaryl radical;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),
15 -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine,
20 tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-threonine, serine, O-methyl serine, aspartic acid, beta-cyano alanine and valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen
radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹
represents hydrogen and alkyl radicals, and halogen
30 radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl,
35 aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl,

163

cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical;

R⁴ represents radicals as defined by R³.

10 3. Compound of Claim 2 wherein R represents aralkoxycarbonyl and heteroaroyl radicals.

 4. Compound of Claim 2 wherein R represents carbobenzoy, 2-benzofurancarbonyl and 2-quinolinylcarbonyl radicals.

 5. Compound of Claim 2 wherein R represents carbobenzoy.

20 6. Compound of Claim 2 wherein R represents 2-quinolinylcarbonyl and 2-benzofurancarbonyl radicals.

 7. Compound of Claim 2 wherein R¹ represents alkyl, alkynyl and alkenyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, threonine, allo-threonine, isoleucine, S-methyl cysteine and the sulfone and sulfoxide derivatives thereof, alanine, and allo-isoleucine.

30 8. Compound of Claim 2 wherein R¹ represents methyl, propargyl, t-butyl, isopropyl and sec-butyl radicals, and amino acid side chains selected from the group consisting of asparagine, valine, S-methyl cysteine, allo-iso-leucine, iso-leucine, threonine, serine, aspartic acid, beta-cyano alanine, and allo-threonine side chains.

164

9. Compound of Claim 2 wherein R¹ represents propargyl and t-butyl radicals.
10. Compound of Claim 2 wherein R¹ represents a t-butyl radical.
11. Compound of Claim 2 wherein R¹ represents amino acid side chains selected from asparagine, valine, alanine and isoleucine side chains.
12. Compound of Claim 2 wherein R¹ represents amino acid side chains selected from asparagine, iso-leucine and valine side chains.
13. Compound of Claim 2 wherein R¹ represents an asparagine side chain.
14. Compound of Claim 2 wherein R¹ represents a t-butyl radical and an asparagine side chain.
15. Compound of Claim 2 wherein R¹ represents a propargyl radical.
16. Compound of Claim 2 wherein R¹ represents an isoleucine side chain.
17. Compound of Claim 2 wherein R¹ represents a valine side chain.
18. Compound of Claim 2 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula -OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl radicals.
19. Compound of Claim 2 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals.

165

20. Compound of Claim 2 wherein R² represents aralkyl radicals.

21. Compound of Claim 2 wherein R² represents
5 CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

22. Compound of Claim 2 wherein R² represents
10 an n-butyl and iso-butyl radicals.

23. Compound of Claim 2 wherein R² represents benzyl, 4-fluorobenzyl and 2-naphthylmethyl radicals.

24. Compound of Claim 2 wherein R² represents
15 a cyclohexylmethyl radical.

25. Compound of Claim 2 wherein R³ and R⁴
independently represent alkyl, haloalkyl, alkenyl,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
20 heterocycloalkyl, heterocycloalkylalkyl, aryl, aralkyl
and heteroaralkyl radicals.

26. Compound of Claim 25 wherein R⁴ represents
25 phenyl.

27. Compound of Claim 25 wherein R³ and R⁴
independently represent alkyl and alkenyl radicals.

28. Compound of Claim 25 wherein R³ and R⁴
30 independently represent alkyl, alkenyl, haloalkyl,
alkoxyalkyl and hydroxyalkyl radicals.

29. Compound of Claim 25 wherein R³ and R⁴
independently represent alkyl, cycloalkyl and
35 cycloalkylalkyl radicals.

/ 66

30. Compound of Claim 25 wherein R³ and R⁴ independently represent alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

5 31. Compound of Claim 25 wherein R³ and R⁴ independently represent alkyl, aryl and aralkyl radicals.

32. Compound of Claim 25 wherein R⁴ represents phenyl and substituted phenyl radicals.

10

33. Compound of Claim 2 wherein R³ represents alkyl radicals having from about 2 to about 5 carbon atoms.

15 34. Compound of Claim 2 wherein R³ represents n-pentyl, n-hexyl, n-propyl, i-butyl, cyclohexyl, neo-pentyl, i-amyl, and n-butyl radicals.

20 35. Compound of Claim 2 wherein R³ and R⁴ independently represent alkyl radicals having from about 2 to about 5 carbon atoms, cycloalkylalkyl radicals, aralkyl radicals, heterocycloalkylalkyl radicals or heteroaralkyl radicals.

25 36. Compound of Claim 2 wherein R³ represents isobutyl, n-propyl, n-butyl, isoamyl, cyclohexyl, cyclohexylmethyl radicals and R⁴ represents phenyl and substituted phenyl radicals.

30 37. Compound of Claim 2 wherein R³ is cyclohexylmethyl and R⁴ is phenyl and substituted phenyl radicals.

35 38. Compound of Claim 2 wherein R³ is i-amyl or i-butyl and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, para-aminophenyl, and para-methoxyphenyl.

167

39. Compound of Claim 2 wherein R³ is i-butyl and R⁴ is phenyl.

5 40. Compound of Claim 2 wherein R³ is n-butyl and R⁴ is phenyl.

 41. Compound of Claim 2 wherein R³ is cyclohexyl and R⁴ is phenyl or substituted phenyl
10 selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, para-aminophenyl, and para-methoxyphenyl.

 42. Compound of Claim 2 wherein R⁴ represents alkyl and cycloalkyl radicals.
15

 43. Compound of Claim 2 wherein R⁴ represents aryl radicals.

 44. Compound of Claim 2 wherein R⁴ represents
20 heteroaryl radicals.

 45. Compound of Claim 2 wherein R³ represents heteroaralkyl radicals and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-
25 fluorophenyl, para-nitrophenyl, para-aminophenyl, and para-methoxyphenyl.

 46. Compound of Claim 2 wherein R³ is a p-fluorobenzyl radical and R⁴ is a phenyl radical or
30 substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, para-aminophenyl, and para-methoxyphenyl.

 47. Compound of Claim 2 wherein R³ is a
35 4-pyridylmethyl radical or its N-oxide and R⁴ is a phenyl radical or substituted phenyl selected from para-

168

chlorophenyl, para-fluorophenyl, para-nitrophenyl, para-aminophenyl, and para-methoxyphenyl.

48. Compound of Claim 2 wherein R⁴ represents
5 an alkyl radical having from 1 to about 6 carbon atoms.

49. Compound of Claim 2 wherein R⁴ represents
a 5 or 6-membered heterocyclyl radical, optionally
substituted with an alkyl radical having from 1 to about
10 3 carbon atoms.

50. Compound of Claim 1 wherein R^{1'} and R^{1''}
are both hydrogen and R¹ represents an alkyl radical
having from 1 to about 4 carbon atoms.

15
51. Compound of Claim 1 wherein R^{1'} and R^{1''}
are both hydrogen and R¹ represents -CH₂SO₂NH₂, CO₂NH₂,
CO₂CH₃, alkyl and cycloalkyl radicals and amino acid side
chains selected from asparagine, S-methyl cysteine and
20 the sulfone and sulfoxide derivatives thereof, histidine,
norleucine, glutamine, glycine, allo-isoleucine, alanine,
threonine, isoleucine, leucine, tert-leucine,
phenylalanine, ornithine, allo-threonine, serine,
aspartic acid, beta-cyano alanine and valine side chains.

25
52. Compound of Claim 2 where R¹ represents
the amino acid side chain of asparagine.

53. Compound of Claim 52 where R represents a
30 heteroaroyl radical.

54. Compound of Claim 52 where R represents a
2-quinolinylcarbonyl or 2-benzofurancarbonyl radical.

35
55. Compound of Claim 2 where R¹ represents a
t-butyl or a propargyl radical or an amino acid side
chain of valine or isoleucine.

169

56. Compound of Claim 55 where R represents an arylalkanoyl, aryloxy carbonyl, alkanoyl, aminocarbonyl, mono-substituted aminoalkanoyl, or disubstituted aminoalkanoyl, or mono-or dialkylaminocarbonyl radical.

57. Compound of Claim 55 where R represents an arylalkanoyl, aryloxy carbonyl or alkanoyl radical.

58. Compound of Claim 55 where R represents an aminocarbonyl radical, a monosubstituted aminoalkanoyl radical or disubstituted aminoalkanoyl radical.

59. Compound of Claim 55 where R represents acetyl, N,N-dimethylaminoacetyl, N-methylaminoacetyl or N-benzyl-N-methylaminoacetyl.

60. Compound of Claim 1 where R¹ is a methyl radical.

61. Compound of Claim 60 where R represents an alkanoyl, arylalkanoyl, aryloxyalkanoyl or arylalkyloxy carbonyl radical.

62. Compound of Claim 60 where R represents a phenoxyacetyl, 2-naphthyloxyacetyl, benzyloxy carbonyl or p-methoxybenzyloxy carbonyl radical.

63. Compound of Claim 60 wherein R represents an N,N-dialkylaminocarbonyl radical.

64. Compound of Claim 60 wherein R represents an aminocarbonyl or an alkylaminocarbonyl radical.

65. Compound of Claim 60 where R represents an N-methylaminocarbonyl radical.

170

66. A pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.

5 67. A pharmaceutical composition comprising a compound of Claim 2 and a pharmaceutically acceptable carrier.

10 68. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 66.

15 69. Method of Claim 68 wherein the retroviral protease is HIV protease.

70. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 66.

20 71. Method of Claim 70 wherein the retroviral infection is an HIV infection.

25 72. Method for treating AIDS comprising administering an effective amount of a composition of Claim 66.

30 73. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 67.

74. Method of Claim 73 wherein the retroviral protease is HIV protease.


35 75. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 67.

/ 7 /

76. Method of Claim 75 wherein the retroviral infection is an HIV infection.

77. Method for treating AIDS comprising
5 administering an effective amount of a composition of Claim 67.

78. Compound represented by the formula:



wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl,
15 alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy carbonyl, aryloxy carbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxy carbonyl, heterocyclylalkanoyl,
20 heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
25 aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals, or where said
30 aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;

172

R' represents hydrogen and radicals as defined for R³ or R and R' together with the nitrogen to which they are attached represent heterocycloalkyl and heteroaryl radical;

5

R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃, -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃), -C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl, alkenyl, alkynyl and cycloalkyl radicals, and amino acid side chains selected from asparagine, S-methyl cysteine and the sulfoxide (SO) and sulfone (SO₂) derivatives thereof, isoleucine, allo-isoleucine, alanine, leucine, tert-leucine, phenylalanine, ornithine, histidine, norleucine, glutamine, threonine, glycine, allo-
10 threonine, serine, aspartic acid, beta-cyano alanine and
15 valine side chains;

R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally
20 substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;

R³ represents alkyl, haloalkyl, alkenyl, alkynyl,
25 hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl,
30 cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl
35 radical; and

R⁴ represents radicals as defined by R³.

173

79. Compound of Claim 78 wherein R¹ represents a methyl radical.

5 80. Compound of Claim 78 wherein R¹ represents hydrogen, alkyl and alkenyl radicals.

81. Compound of Claim 78 wherein R¹ represents alkyl radicals having from 1 to about 4 carbon atoms and
10 alkynyl radicals having from 3 to 8 carbon atoms.

82. Compound of Claim 78 wherein R¹ represents methyl, ethyl, isopropyl, propargyl and t-butyl radicals.

15 83. Compound of Claim 78 wherein R' is hydrogen and R is $\text{NH}_2\text{C}(=\text{O})$ or $\text{CH}_3\text{NH}-\text{C}(=\text{O})-$ group.

84. Compound of Claim 78 wherein R' is hydrogen and R represents acetyl, phenoxyacetyl,
20 2-naphthyloxy-carbonyl, benzyloxycarbonyl, p-methoxybenzyloxycarbonyl.

85. Compound of Claim 78 wherein R' is hydrogen and R is an aralkoxycarbonyl radical.
25

86. Compound of Claim 78 wherein R' is hydrogen and R represents heteroaralkoxycarbonyl radical.

87. Compound of Claim 78 wherein R and R' are
30 independently selected from methyl and phenethyl radicals.

88. Compound of Claim 78 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which
35 radicals are optionally substituted with halogen radicals

174

and radicals represented by the formula $-OR^9$ and $-SR^9$ wherein R^9 represents hydrogen and alkyl radicals.

89. Compound of Claim 78 wherein R^2 represents
5 alkyl, cycloalkylalkyl and aralkyl radicals.

90. Compound of Claim 78 wherein R^2 represents
aralkyl radicals.

10 91. Compound of Claim 78 wherein R^2 represents
 $CH_3SCH_2CH_2-$, iso-butyl, n-butyl, benzyl, 4-fluorobenzyl,
2-naphthylmethyl and cyclohexylmethyl radicals.

15 92. Compound of Claim 78 wherein R^2 represents
an n-butyl and iso-butyl radicals.

93. Compound of Claim 78 wherein R^2 represents
benzyl, 4-fluorobenzyl, and 2-naphthylmethyl radicals.

20 94. Compound of Claim 78 wherein R^2 represents
a cyclohexylmethyl radical.

25 95. Compound of Claim 78 wherein R^3 and R^4
independently represent alkyl, haloalkyl, alkenyl,
alkoxyalkyl, cycloalkyl, cycloalkylalkyl,
heterocycloalkyl, heterocycloalkylalkyl, heteroaryl,
aryl, aralkyl and heteroaralkyl radicals.

30 96. Compound of Claim 95 wherein R^4 represents
methyl and phenyl.

97. Compound of Claim 95 wherein R^3 and R^4
independently represent alkyl and alkenyl radicals.

35 98. Compound of Claim 95 wherein R^3 and R^4
independently represent alkyl and hydroxyalkyl radicals.

175

99. Compound of Claim 95 wherein R³ and R⁴ independently represent alkyl, cycloalkyl and cycloalkylalkyl radicals.

5 100. Compound of Claim 95 wherein R³ and R⁴ independently represent alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

10 101. Compound of Claim 95 wherein R³ and R⁴ independently represent alkyl, heteroaryl, aryl and aralkyl radicals.

15 102. Compound of Claim 95 wherein R³ and R⁴ independently represent alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, aryl, aralkyl, and heteroaralkyl radicals.

20 103. Compound of Claim 78 wherein R³ represents alkyl radicals having from about 2 to about 5 carbon atoms.

25 104. Compound of Claim 103 wherein R⁴ represents methyl, phenyl and substituted phenyl radicals.

30 105. Compound of Claim 78 wherein R³ and R⁴ independently represent alkyl radicals having from about 2 to about 5 carbon atoms, cycloalkylalkyl radicals, aryl radicals, aralkyl radicals, heterocycloalkylalkyl radicals and heteroaralkyl radicals.

35 106. Compound of Claim 78 wherein R³ represents isobutyl, n-propyl, n-butyl, isoamyl, cyclohexylmethyl, cyclohexyl, benzyl, para-fluorobenzyl, para-methoxybenzyl, para-methylbenzyl and 2-naphthylmethyl radicals and R⁴ represents phenyl and substituted phenyl radicals wherein substituents of the

176

substituted phenyl radical are selected from chloro fluoro, nitro, methoxy and amino substituents.

107. Compound of Claim 78 wherein R³ is
5 cyclohexylmethyl and R⁴ phenyl.

108. Compound of Claim 78 wherein R³ is i-amyl
and R⁴ is phenyl.

109. Compound of Claim 78 wherein R³ is
10 i-butyl and R⁴ is phenyl.

110. Compound of Claim 78 wherein R³ is
n-butyl and R⁴ is phenyl.
15

111. Compound of Claim 78 wherein R³ is
cyclohexyl and R⁴ is phenyl.

112. Compound of Claim 78 wherein R⁴
20 represents alkyl and cycloalkyl radicals.

113. Compound of Claim 78 wherein R⁴
represents methyl and cyclohexyl radicals.

114. Compound of Claim 78 wherein R and R'
25 together with the nitrogen to which they are bonded
represent pyrrolidinyl, piperidinyl, morpholinyl, and
piperazinyl radicals.

115. Compound of Claim 78 wherein R³
30 represents heteroaralkyl radicals and R⁴ is methyl or
phenyl.

116. Compound of Claim 78 wherein R³ is a
35 p-fluorobenzyl radical and R⁴ is a methyl or phenyl
radical.

/29

117. A pharmaceutical composition comprising a compound of Claim 78 and a pharmaceutically acceptable carrier.

5 118. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 117.


10 119. Method of Claim 118 wherein the retroviral protease is HIV protease.

120. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 117.

15 121. Method of Claim 120 wherein the retroviral infection is an HIV infection.

20 122. Method for treating AIDS comprising administering an effective amount of a composition of Claim 117.

123. Compound represented by the formula:



wherein:

R represents hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl,

30

heteroaralkoxycarbonyl, heteroaryloxy-carbonyl,
heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl,
aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl,
aminocarbonyl, aminoalkanoyl, and mono- and disubstituted
5 aminocarbonyl and mono- and disubstituted aminoalkanoyl
radicals wherein the substituents are selected from
alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl,
heteroaryl, heteroaralkyl, heterocycloalkyl,
heterocycloalkylalkyl radicals, or where said
10 aminoalkanoyl radical is disubstituted, said substituents
along with the nitrogen atom to which they are attached
form a heterocycloalkyl or heteroaryl radical;

R' represents hydrogen and radicals as defined for R³ or
15 R and R' together with the nitrogen to which they are
attached represent heterocycloalkyl and heteroaryl
radical;

R¹ represents hydrogen, -CH₂SO₂NH₂, -CH₂CO₂CH₃, -CO₂CH₃,
20 -CONH₂, -CH₂C(O)NHCH₃, -C(CH₃)₂(SH), -C(CH₃)₂(SCH₃),
-C(CH₃)₂(S[O]CH₃), -C(CH₃)₂(S[O]₂CH₃), alkyl, haloalkyl,
alkenyl, alkynyl and cycloalkyl radicals, and amino acid
side chains selected from asparagine, S-methyl cysteine
and the sulfoxide (SO) and sulfone (SO₂) derivatives
25 thereof, isoleucine, allo-isoleucine, alanine, leucine,
tert-leucine, phenylalanine, ornithine, histidine,
norleucine, glutamine, threonine, glycine, allo-
threonine, serine, aspartic acid, beta-cyano alanine and
valine side chains;

30 R^{1'} and R^{1''} independently represent hydrogen and radicals
as defined for R¹, or one of R^{1'} and R^{1''}, together with
R¹ and the carbon atoms to which R¹, R^{1'} and R^{1''} are
attached, represent a cycloalkyl radical;

35 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl
and aralkyl radicals, which radicals are optionally

179

substituted with a group selected from alkyl and halogen radicals, $-\text{NO}_2$, $-\text{C}\equiv\text{N}$, CF_3 , $-\text{OR}^9$, $-\text{SR}^9$, wherein R^9 represents hydrogen and alkyl radicals;

- 5 R^3 represents alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said
- 10 substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they
- 15 are attached, form a heterocycloalkyl or a heteroaryl radical; and

R^4 represents radicals as defined by R^3 .

- 20 124. Compound of Claim 123 wherein R' represents hydrogen and R represents aralkoxycarbonyl and heteroaroyl radicals.

- 25 125. Compound of Claim 123 wherein R' is hydrogen and R represents carbobenzoyl, 2-benzofurancarbonyl, and 2-quinolinylcarbonyl radicals.

- 30 126. Compound of Claim 123 wherein R' is hydrogen and R is 2-quinolinylcarbonyl.

127. Compound of Claim 123 wherein R^1 , $\text{R}^{1'}$ and $\text{R}^{1''}$ independently represent hydrogen and alkyl radicals having from 1 to about 4 carbon atoms, alkenyl, alkynyl, aralkyl radicals and radicals selected from $-\text{CH}_2\text{SO}_2\text{NH}_2$, $-\text{CO}_2\text{CH}_3$, $-\text{CONHCH}_3$, $-\text{CON}(\text{CH}_3)_2$, $-\text{CH}_2\text{C}(\text{O})\text{NHCH}_3$, $-\text{CH}_2\text{C}(\text{O})\text{N}(\text{CH}_3)_2$, $-\text{CONH}_2$, $-\text{C}(\text{CH}_3)_2(\text{SCH}_3)$, $-\text{C}(\text{CH}_3)_2(\text{S}[\text{O}]\text{CH}_3)$ and $-\text{C}(\text{CH}_3)_2(\text{S}[\text{O}]\text{CH}_3)$.
- 35

180

128. Compound of Claim 123 wherein R¹, R^{1'} and R^{1''} independently represent hydrogen, methyl, ethyl, benzyl, phenylpropyl, propargyl, hydroxyl and radicals selected from -C(O)OCH₃, -C(O)NH₂, -C(O)OH.

129. Compound of Claim 123 wherein R¹ and R^{1'} are both hydrogen and R^{1''} is C(O)NH₂.

130. Compound of Claim 123 wherein R represents aralkoxycarbonyl and heteroaroyl radicals.

131. Compound of Claim 123 wherein R¹ and R^{1'} are both hydrogen and R^{1''} is methyl.

132. Compound of Claim 123 wherein R^{1'} is hydrogen and R¹ and R^{1''} together with the carbon atoms to which they are attached form a three to six-membered cycloalkyl radical.

133. Compound of Claim 129 wherein R is carbobenzoxy, 2-quinolinylcarbonyl and 2-benzofuran carbonyl radicals.

134. Compound of Claim 123 wherein R¹ and R^{1'} are both hydrogen and R^{1''} is propargyl.

135. Compound of Claim 123 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with halogen radicals and radicals represented by the formula -OR⁹ and -SR⁹ wherein R⁹ represents hydrogen and alkyl radicals.

136. Compound of Claim 123 wherein R² represents alkyl, cycloalkylalkyl and aralkyl radicals.

/ 8 /

137. Compound of Claim 123 wherein R² represents aralkyl radicals.

138. Compound of Claim 123 wherein R²
5 represents CH₃SCH₂CH₂-, iso-butyl, n-butyl, benzyl, 2-naphthylmethyl and cyclohexylmethyl radicals.

139. Compound of Claim 123 wherein R² represents an n-butyl and iso-butyl radicals.

10

140. Compound of Claim 123 wherein R² represents benzyl, 4-fluorobenzyl, and 2-naphthylmethyl radicals.

15

141. Compound of Claim 123 wherein R² represents a cyclohexylmethyl radical.

142. Compound of Claim 123 wherein R³ and R⁴ independently represent alkyl, haloalkyl, alkenyl,
20 alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, aryl, aralkyl and heteroaralkyl radicals.

143. Compound of Claim 123 wherein R³
25 represents alkyl and alkenyl radicals and R⁴ represents aryl radicals.

144. Compound of Claim 142 wherein R³ and R⁴ independently represent alkyl and alkenyl radicals.

30

145. Compound of Claim 123 wherein R³ and R⁴ independently represent alkyl and alkoxyalkyl radicals.

146. Compound of Claim 123 wherein R³ and R⁴
35 independently represent alkyl, cycloalkyl and cycloalkylalkyl radicals.

182

147. Compound of Claim 123 wherein R³ and R⁴ independently represent alkyl, heterocycloalkyl and heterocycloalkylalkyl radicals.

5 148. Compound of Claim 123 wherein R³ and R⁴ independently represent alkyl, aryl and aralkyl radicals.

10 149. Compound of Claim 123 wherein R³ and R⁴ independently represent alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, aryl, aralkyl, and heteroaralkyl radicals.

15 150. Compound of Claim 123 wherein R³ represents alkyl radicals having from about 2 to about 5 carbon atoms.

20 151. Compound of Claim 123 wherein R³ independently represent n-propyl, i-butyl, cyclohexyl, cyclohexylmethyl, i-amyl, and n-butyl radicals and R⁴ represents phenyl and substituted phenyl radicals.

25 152. Compound of Claim 123 wherein R³ and R⁴ independently represent alkyl radicals having from about 2 to about 5 carbon atoms, cycloalkylalkyl radicals, aryl radicals, heteroaryl radicals, aralkyl radicals, heterocycloalkylalkyl radicals and heteroaralkyl radicals.

30 153. Compound of Claim 123 wherein R³ represents benzyl, para-fluorobenzyl, para-methoxybenzyl, para-methylbenzyl, and 2-naphthylmethyl radicals and R⁴ represents phenyl and substituted phenyl radicals wherein substituents of the substituted phenyl radical are selected from chloro fluoro, nitro, methoxy and amino
35 substituents.

183

154. Compound of Claim 123 wherein R³ is cyclohexylmethyl and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

5

155. Compound of Claim 123 wherein R³ is i-amyl or n-butyl and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

10

156. Compound of Claim 123 wherein R³ is i-butyl or n-propyl and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

15

157. Compound of Claim 123 wherein R³ is benzyl or p-fluorobenzyl and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

20

158. Compound of Claim 123 wherein R³ is cyclohexyl and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

25

159. Compound of Claim 123 wherein R⁴ represents alkyl and aryl radicals.

30

160. Compound of Claim 123 wherein R⁴ represents phenyl, para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

35

161. Compound of Claim 123 wherein R⁴ represents aryl radicals.

184

162. Compound of Claim 123 wherein R³ represents heteroaralkyl radicals and R⁴ is aryl.

5 163. Compound of Claim 123 wherein R³ is a p-fluorobenzyl radical and R⁴ is phenyl or substituted phenyl selected from para-chlorophenyl, para-fluorophenyl, para-nitrophenyl, p-methoxyphenyl and para-aminophenyl.

10 164. A pharmaceutical composition comprising a compound of Claim 123 and a pharmaceutically acceptable carrier.

15 165. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 164.

20 166. Method of Claim 165 wherein the retroviral protease is HIV protease.

167. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 164.

25 168. Method of Claim 167 wherein the retroviral infection is an HIV infection.

30 169. Method for treating AIDS comprising administering an effective amount of a composition of Claim 164.

170. A compound of Claim 1 which is:

35 Phenylmethyl[2R-hydroxy-3-[(3-methyl-butyl)(methanesulfonyl)amino]-1S-(phenyl-methyl)propyl]carbamate;

185

Phenylmethyl[2R-hydroxy-3-[(3-methylbutyl)(phenyl-sulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate;

5 N1-[2R-hydroxy-3-[(3-methylbutyl)(methyl-sulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide;

10 N1-[2R-hydroxy-3-[(3-methylbutyl)(methyl-sulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(phenylmethyloxycarbonyl)amino]butanediamide;

15 N1-[2R-hydroxy-3[(3-methylbutyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)-amino]butanediamide;

N1-[2R-hydroxy-3[(3-methylbutyl)(phenylsulfonyl)-amino]-1S-(phenylmethyl)propyl]-2S-[(phenylmethyloxycarbonyl)amino]butanediamide;


20 2S-[[(dimethylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methyl- butyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide;

25 2S-[[(methylamino)acetyl]amino]-N-[2R-hydroxy-3-[(3-methyl- butyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]-3,3-dimethylbutaneamide; or

30 N1-[2R-hydroxy-3-[(3-methylbutyl)(phenyl-sulfonyl)amino]-N4-methyl-1S-(phenylmethyl)propyl]-2S-[(2-quinolinylcarbonyl)amino]butanediamide; or

35 [3-[[2-hydroxy-3-[(3-methylbutyl)(phenylsufonyl)amino]-1-(phenylmethyl)propyl]amino]-2-methyl-3-oxopropyl]-, (4-methoxyphenyl)methyl ester, [1S-[1R*(S*),2S*]]-.

171. A compound represented by the formula:



wherein:

- 5 P¹ and P² independently represent hydrogen, alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxy-
- 10 carbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxy-
- 15 carbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radicals wherein the substituents are selected from
- 20 alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkylalkyl radicals, or where said aminoalkanoyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical;
- 25 R² represents alkyl, aryl, cycloalkyl, cycloalkylalkyl and aralkyl radicals, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, -NO₂, -C≡N, CF₃, -OR⁹, -SR⁹, wherein R⁹ represents hydrogen and alkyl radicals;
- 30 R³ represents hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl,

/87

- aminoalkyl and mono- and disubstituted aminoalkyl radicals, wherein said substituents are selected from alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and
- 5 heterocycloalkylalkyl radicals, or in the case of a disubstituted aminoalkyl radical, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; and
- 10 R⁴ represents radicals as defined by R³ except for hydrogen.

172. Compound of Claim 171 wherein P¹ and P² independently represent hydrogen, alkoxycarbonyl,
- 15 aralkyloxycarbonyl, heteroaralkoxycarbonyl, aroyl, heteroaroyl, alkanoyl, cycloalkanoyl, 3-pyridylmethyloxycarbonyl, 3-pyridylmethyloxycarbonyl N-oxide, 4-pyridylmethyloxycarbonyl, 4-pyridylmethyloxycarbonyl N-oxide, 5-
- 20 pyrimidylmethyloxycarbonyl, tert-butyloxycarbonyl, allyloxycarbonyl, 2-propyloxycarbonyl, benzyloxycarbonyl, cycloheptylcarbonyl, cyclohexylcarbonyl, cyclopentylcarbonyl, benzoyl, 2-substituted benzoyl, 4-pyridylcarbonyl, 2-methylbenzoyl, 3-methylbenzoyl, 4-
- 25 methylbenzoyl, 2-chlorobenzoyl, 2-ethylbenzoyl, 2,6-dimethylbenzoyl, 2,3-dimethylbenzoyl, 2,4-dimethylbenzoyl, 2,5-dimethylbenzoyl;

- R² represents cycloalkylalkyl, aralkyl, alkyl, benzyl,
- 30 cyclohexylmethyl, 2-naphthylmethyl, para-fluorobenzyl, para-methoxybenzyl, isobutyl, n-butyl;

- R³ represents alkyl, cycloalkyl, cycloalkylalkyl, isobutyl, isoamyl, cyclohexyl, cyclohexylmethyl, n-butyl,
- 35 n-propyl; and

188

R⁴ represents aryl, alkyl and heteroaryl, aryl, para-substituted aryl, heteroaryl, phenyl, para-methoxyphenyl, para-cyanophenyl, para-chlorophenyl, para-hydroxyphenyl, para-nitrophenyl, para-fluorophenyl, 2-naphthyl, 3-pyridyl, 3-pyridyl N-oxide, 4-pyridyl, 4-pyridyl N-oxide.

173. A pharmaceutical composition comprising a compound of Claim 171 and a pharmaceutically acceptable carrier.

174. Method of inhibiting a retroviral protease comprising administering a protease inhibiting amount of a composition of Claim 173.

175. Method of Claim 174 wherein the retroviral protease is HIV protease.

176. Method of treating a retroviral infection comprising administering an effective amount of a composition of Claim 173.

177. Method of Claim 176 wherein the retroviral infection is an HIV infection.

178. Method for treating AIDS comprising administering an effective amount of a composition of Claim 173.

179. A compound of Claim 171 which is:

Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(phenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate;

Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenylsulfonyl)amino]-1S-(phenylmethyl)propyl]carbamate;

189

- Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-fluorophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 5 Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-nitrophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 10 Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-chlorophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 15 Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-acetamidophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 20 Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-aminophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 25 Phenylmethyl[2R-hydroxy-3-[(3-methylbutyl)(4-methoxyphenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 30 Phenylmethyl[2R-hydroxy-3-[(3-methylbutyl)(4-fluorophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 35 Phenylmethyl[2R-hydroxy-3-[(3-methylbutyl)(4-nitrophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;
- 40 Phenylmethyl[2R-hydroxy-3-[(3-methylbutyl)(4-chlorophenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;

190

Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-methoxyphenylsulfonyl) amino]-1S-(4-fluorophenylmethyl)propyl]carbamate;

- 5 Phenylmethyl[2R-hydroxy-3-[(2-methylpropyl)(4-fluorophenylsulfonyl) amino]-1S-(4-fluorophenylmethyl)propyl]carbamate;

- 10 Phenylmethyl[2R-hydroxy-3-[(butyl)(phenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;

- 15 Phenylmethyl[2R-hydroxy-3-[(cyclohexylmethyl)(phenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;

- Phenylmethyl[2R-hydroxy-3-[(cyclohexyl)(phenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;

- 20 Phenylmethyl[2R-hydroxy-3-[(propyl)(phenylsulfonyl) amino]-1S-(phenylmethyl)propyl]carbamate;

- 25 Pentanamide, 2S-[[[(dimethylamino)acetyl] amino]-N-2R-hydroxy-3-[(3-methylpropyl)(4-methoxyphenylsulfonyl) amino]-1S-(phenylmethyl)propyl]-3S-methyl;

- 30 Pentanamide, 2S-[[[(methylamino)acetyl] amino]-N-2R-hydroxy-3-[(4-methylbutyl)(phenylsulfonyl) amino]-1S-(phenylmethyl)propyl]-3S-methyl;

- 35 Pentanamide, 2S-[[[(dimethylamino)acetyl] amino]-N-2R-hydroxy-3-[(4-methylbutyl)(phenylsulfonyl) amino]-1S-(phenylmethyl)propyl]-3S-methyl;
- [2R-hydroxy-3-[[[(4-methoxyphenyl) sulfonyl] (2-methylpropyl) amino]-1S-(phenylmethyl)propyl]amine;

2R-hydroxy-3-[(2-methylpropyl)(4-hydroxyphenyl)sulfonyl]amino-1S-(phenylmethyl)propylamine;

5 [2R-hydroxy-3-[(phenylsulfonyl)(3-methylbutyl)amino]-1S-(phenylmethyl)propylamine;

[2R-hydroxy-3-[(phenylsulfonyl)(2-methylpropyl)amino]-1S-(phenylmethyl)propylamine;

10

[2R-hydroxy-3-[(phenylsulfonyl)(cyclohexylmethyl)amino]-1S-(phenylmethyl)propylamine;

15 [2R-hydroxy-3-[(phenylsulfonyl)(cyclohexyl)amino]-1S-(phenylmethyl)propylamine;

4-Pyridinecarboxamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl];

20

Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2,6-dimethyl;

25 Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2-methyl;

Benzamide,
30 N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2-ethyl;

Benzamide,
N-[2R-hydroxy-3-[[(4-methoxyphenyl)sulfonyl] (2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-2-chloro;

35

192

Carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester;

- 5 Carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester, N-oxide;

- 10 Carbamic acid, [2R-hydroxy-3-[[phenylsulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester;

- 15 Carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 4-pyridylmethyl ester;

- 20 Carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 4-pyridylmethyl ester, N-oxide;

Carbamic acid, [2R-hydroxy-3-[[[4-chlorophenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester;

- 25 Carbamic acid, [2R-hydroxy-3-[[[4-nitrophenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester;

- 30 Carbamic acid, [2R-hydroxy-3-[[[4-fluorophenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester;

- 35 Carbamic acid, [2R-hydroxy-3-[[[4-hydroxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 3-pyridylmethyl ester; or

193

Carbamic acid, [2R-hydroxy-3-[[[4-methoxyphenyl)sulfonyl](2-methylpropyl)amino]-1S-(phenylmethyl)propyl]-, 5-pyrimidylmethyl ester.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/07814

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07C311/29 C07D213/30 C07K5/06 C07C317/44 C07C311/05
C07C311/18 C07D213/89 C07D215/48 C07C317/14 C07D239/26
C07D213/81 C07D213/82 C07C323/67 C07C311/41 C07D209/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07C C07D C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 264 795 (MERCK PATENT GMBH) 27 April 1988 cited in the application see column 1 - 2; column 28, lines 5-6 ---	1-67, 171-173
X	EP,A,0 468 641 (SHIONOGI) 29 January 1992 see table 6 ---	171,172
A	WO,A,92 08699 (MONSANTO) 29 May 1992 see page 3 - page 5 -----	1-179

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 January 1994

Date of mailing of the international search report

- 4. 02. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

ENGLISH, R

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K31/18 A61K37/02 A61K31/44 A61K31/27

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

17 January 1994

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

ENGLISH, R

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/07814

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 68-77, 118-122, 165-169, 173-178 are directed to a method of treatment of the human or animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/07814

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0264795	27-04-88	DE-A- 3635907	28-04-88
		AU-A- 7982387	28-04-88
		JP-A- 63112548	17-05-88
		ZA-A- 8707950	26-04-88
EP-A-0468641	29-01-92	AU-B- 4489093	25-11-93
		AU-B- 643036	04-11-93
		AU-A- 7930491	02-01-92
		CA-A- 2045008	29-12-91
		JP-A- 5009162	19-01-93
		US-A- 5194608	16-03-93
		US-A- 5272268	21-12-93
		US-A- 5223615	29-06-93
WO-A-9208699	29-05-92	AU-A- 9053191	11-06-92
		AU-A- 9085191	11-06-92
		AU-A- 9092591	11-06-92
		AU-A- 9125191	11-06-92
		AU-A- 9133291	11-06-92
		CA-A- 2096407	20-05-92
		CA-A- 2096409	20-05-92
		CA-A- 2096525	20-05-92
		CA-A- 2096528	20-05-92
		EP-A- 0558603	08-09-93
		EP-A- 0554400	11-08-93
		EP-A- 0558630	08-09-93
		EP-A- 0558657	08-09-93
		EP-A- 0558673	08-09-93
		WO-A- 9208698	29-05-92
		WO-A- 9208700	29-05-92
		WO-A- 9208701	29-05-92
		WO-A- 9208688	29-05-92